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Abstract 
Title - Randomised controlled trial (RCT) to identify if cognitive behavioural therapy (CBT) with 
respiratory nurses reduces anxiety in patients with chronic obstructive pulmonary disease 
(COPD).  (Trial Registration - ISCRCTN55206395). 
 
Introduction  
Anxiety and depression are common comorbidities in COPD.  The aim of this research is to iden-
tify if CBT delivered by respiratory nurses reduces anxiety in a large COPD population. 
Methods 
Study Design – Prospective RCT. 
Sample Size - 112 for each arm were required.   
Approach – 1,518 patients were approached: 279 were recruited.  
Randomisation –Electronic randomisation was used.  
Intervention – CBT with a respiratory nurse plus self-help leaflets. 
Comparison – Self- help leaflets.  
Main Outcomes -Primary outcome was symptoms of anxiety. Secondary outcomes were depres-
sion and quality of life.  
Data collection – was undertaken by nurses blinded to treatment allocation. 
Results  
The groups were well matched at baseline.  The CBT intervention achieved clinical and statisti-
cally significant change for all outcomes: HADS-Anxiety group mean change of 3.4 (SD 4.20) 
p=<0.001 CI 2.62- 4.17; HADS-Depression 2.20 (SD 3.62) p=<001, CI 1.53 – 2.87; CAT 2.7 (SD 6.36) 
p=< 0.001, CI 1.49 – 3.88 and EQ-5D utility group mean change of 0.08 (SD 0.31) p=0.007, CI -
0.14 - -0.02 at 3 months.   The leaflet group achieved a clinical and significant reduction in group 
mean change of 1.9 (SD 3.80) p= <0.001, CI 1.19 - 2.55 in HADS-Anxiety and CAT 2.06 (SD 5.34) 
p=<0.001, CI 1.09 – 3.04. The HADS-Depression group mean change was only statistically signifi-
cant 1.07 (SD 3.55) p=0.001, CI 0.44 – 1.71. The EQ-5D utility scores group mean change of -
0.003 (SD 0.31) p= 0.09 CI -0.06 – 0.05 which did not reach statistical or clinical significance. 
Conclusion 
Overall the CBT intervention was superior to the leaflet intervention. 
Funded by: National Institute for Health Research (NIHR). 
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Thesis Overview 
This thesis describes research undertaken to address symptoms of anxiety and depression in 
patients with COPD.  The first chapter provides an introduction to COPD to set the scene. 
The impact of COPD is considerable.  Not only does COPD lead to debilitating physical symp-
toms, but it also has a significant impact on psychological well-being and symptoms of anxi-
ety and depression are common.   Chapter two explores the important psychological impact 
of this progressive disease.  A literature review was completed on the psychological treat-
ment of anxiety and depression in COPD and is shown in chapter three.  Conclusions of pre-
vious research clearly suggests  there is a need for a well powered randomised controlled 
trial (RCT) to evaluate the effectiveness and acceptability of CBT among patients with COPD.  
The aim of this research is to address the gap in the literature by conducting an appropri-
ately designed RCT.  In chapter four I have described the development of a novel CBT based 
intervention used in this study to address symptoms of anxiety. The development of the CBT 
model was underpinned with theoretical and clinical insight into the psychological impact of 
COPD and experience using CBT with COPD patients. The CBT model used was developed 
and refined over many years before funding from the National Institute for Health Research 
was awarded to embark on this research.   
Chapter five describes the research methods used to conduct this study and is followed by 
the results and discussion.  This research is unique in that respiratory nurses have been 
trained to deliver the CBT intervention rather than mental health practitioners. Respiratory 
nurses have expertise in COPD from a physical perspective.  Combining additional skills in 
psychological care may be a better model of care for patients with complex physical health 
needs.   As with most non-drug interventions the CBT intervention is inherently complex.  
CBT has a number of components, the intensity of the intervention will vary depending on 
patient needs, a number of nurses’ deliver the CBT and importantly it is commonly difficult 
to identify which interventions are the most effective.  The final chapter proposes implica-
tions for practice and future recommendations for further research.   A number of 
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dices are located at the back of the thesis and will be referred to in the text.  Appendix 11 in-
cludes a summary of publications, presentations and webinar’s   completed since commenc-
ing this PhD. 
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Chapter 1 - COPD 
1.1 Introduction 
In the United Kingdom (UK) life expectancy is increasing and continues to improve (1).  How-
ever, as people are living longer the prevalence of health problems is growing.   Already 30% 
of the population with long term conditions accounts for 70% of National Health Service 
(NHS) spending (2). A term used to describe ill-health or disease burden is ‘disability adjusted 
life years’ (DALYs).  DALYs reflect the number of years lost due to ill health, disability or early 
death (3).  The UK has poor rankings in terms of DALYs in five out of 30 disease areas as-
sessed including heart disease, breast cancer, lung cancer, respiratory infections and COPD 
(1).  COPD is a very common long term respiratory condition and a major public health issue 
causing significant disability and mortality worldwide (4).  Poor physical health increases the 
risk of mental illness (5).   Increasing evidence indicates that there is a close relationship with 
obstructive lung diseases such as asthma, chronic bronchitis and emphysema with mental 
health problems (6).  One large Canadian  study suggests that adults from a general popula-
tion with COPD have an increased risk of major anxiety and depression disorders compared 
to those without COPD with odds ranging from 1.9 to 3.8 (7).   The risk may well be higher in 
the North East due to a high prevalence of smoking which is a major cause of COPD. 
For many years there has been poor integration of physical and mental health which it is ar-
gued merely reinforces stigma, constrains physical health outcomes, and impairs broader 
economic performance (5).   There is increasing evidence that integrating mental and physi-
cal care for people with long-term conditions can improve both physical and mental health 
and reduce costs (5).  The aim of this research is to identify if an intervention delivered by 
respiratory nurses can help reduce symptoms of anxiety and depression in a large COPD 
population. 
1.2 Definition of COPD 
COPD is a preventable disease characterised by persistent airflow limitation and is associ-
ated with chronic inflammatory changes (8).    Chronic bronchitis results from inflammation 
which causes structural changes and narrowing of the large airways.  Emphysema involves 
destruction of lung tissue causing alveoli to lose their elasticity.  This reduces the support of 
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the airways and results in obstruction. Physiologically, emphysema is characterised by a re-
duction in the transfer of carbon monoxide and oxygen within the lungs (8). These pathologi-
cal changes lead to air trapping and progressive airflow problems resulting in breathlessness 
and other characteristic symptoms of COPD (8).  With chronic bronchitis and emphysema 
the work of breathing is increased and ventilatory capacity is reduced (9). 
Airflow limitation is best measured by spirometry, as this is the most widely available repro-
ducible test of lung function (8).  Spirometry measures how much air can be exhaled in one 
second (forced expiratory volume in one second or FEV1) and how much air can be exhaled 
fully in one breath (forced vital capacity or FVC).  Airway obstruction has to be established by 
measuring the FEV1/FVC ratio (8).  A FEV1/FVC ratio of <70% is indicative of COPD (8).  Unfor-
tunately, significant airflow obstruction is often present before the patient is aware of it (10). 
1.3 Classification of COPD 
There are a variety of classification systems for COPD; many are based on lung function crite-
ria.  At the onset of this study one of the best known scoring systems for COPD in the UK was 
the National Institute of Clinical Excellence (NICE) COPD Guidelines which were updated in 
2010 (10).  The NICE criteria for severity of COPD is presented in table 1. 
Table 1 NICE Spirometric Classification of COPD (10). 
COPD Classification FEV1 FEV1/FVC Ratio 
Mild > 80% predicted <0.70 
Moderate >50 - <80 predicted <0.70 
Severe 30 - <50% predicted <0.70 
Very Severe <30  or >50% predicted with chronic respiratory failure                 <0.70 
 
A major drawback of using spirometric classifications is that FEV1 is a poor descriptor of dis-
ease status (8).  More recently classifications have encompassed spirometric and clinical 
phenotypes. Newer classification systems are recommended by The Global Initiative For 
Chronic Obstructive Lung Disease (GOLD) which include symptom burden, exacerbation fre-
quency, activity limitation, future risk of disease progression and a combined assessment (8).  
The GOLD classification system can be found in table 2 (8). 
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Table 2 – GOLD Classification system of COPD (8). 
Pa-
tient 
Characteristics Spirometric Classifica-
tion 
Exacerbations 
a year 
Medical Research 
Council  Breathless-
ness Score 
CAT 
Score 
A Low risk.  
Less symptoms FEV1 ≥ 80% predicted ≤ 1 0-1 <10 
B Low risk.   
More symptoms FEV1 ≥ 50 - <80% ≤ 1 ≥ 2 ≥10 
C High risk.  
Less symptoms FEV1 ≥ 30 - <50% ≥ 2 0-1 <10 
D High risk.   
High symptoms FEV1 < 30% ≥ 2 ≥ 2 ≥10 
 
1.4 Causes of COPD 
The main cause of COPD is smoking  (10).  In 1974, just under 50% of adults in the UK 
smoked (1).  Thankfully the prevalence has decreased over the years.  The change in smoking 
habits is presented in figure 1 from data from the Office for National Statistics (11). 
Figure 1 - Change in cigarette smoking habits from 1974 – 2013  from Office of National Statistics (11). 
In the North East the prevalence of smoking has reduced to 22.3% but it remains higher than 
the national average of 19.5% (12).  Data from the office for National Statistics highlights the 
smoking rates by region can be seen in figure 2 (11). 
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Figure 2 - North East prevalence of adult cigarette smokers (11). 
Source: Office of National Statistics (11) 
In routine and manual workers in the North East, the prevalence of smoking is as high as 31% 
which is the second highest in the country (13).   Stopping smoking can prevent further dete-
rioration of lung function but it cannot repair the damage that has already occurred (14).  As 
a result it is imperative to help patients to stop smoking (15).  In clinical practice smoking is 
often recorded in terms of ‘pack years’.  One pack year is equivalent to smoking twenty ciga-
rettes a day for one year.  So for example,  if a patient smoked 20 cigarettes a day for one 
year this is documented as one pack year  (16).  If a patient smokes 20 cigarettes for 20 years 
that is documented as 20 pack years.   
There are other causes of COPD including exposure to biomass fuels, workplace exposure to 
dust and fumes, history of repeated lower respiratory-tract infections during childhood, 
chronic asthma, and history of pulmonary tuberculosis, intrauterine growth problems, and 
poor nutrition. Whilst the mining industry is no longer in existence in the North East, occupa-
tional dust such as coal dust (17) and pollution are said to be particularly relevant causes of 
COPD in the North East region (13). In a minority of patients deficiency of anti-protease en-
zymes can also cause the development of COPD (18).   
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1.5 Socioeconomic status and COPD 
There is strong evidence that the risk of developing COPD is inversely related to socioeco-
nomic status (19).  This may be due to more smokers coming from lower socioeconomic and 
disadvantaged  groups  (20).     When reviewing the literature there are several definitions of 
socioeconomic status.  In general, the term socioeconomic status encompasses several ele-
ments including income, education, occupation (including employment status), location of 
residence, housing (including home amenities), an individual’s social standing and may also 
include participation in social organisations (21).  Whilst socioeconomic status is often asso-
ciated with poverty it is closely linked to health as it is an important determinant of health 
and premature death (21).   There are a number of studies that have demonstrated a posi-
tive relationship between socioeconomic status and pulmonary function.   Both spirometry 
measures (FEV1 and FVC) and measurements of other lung function tests such as transfer 
factor are reduced with low socioeconomic status (21, 22).   
Smoking contributes to the adverse effects of poverty but other factors may contribute (21).   
What is not clear is whether the risk of COPD reflects exposure to pollutants, crowding, poor 
nutrition, infections or other factors that are related to low socioeconomic status (8).  In re-
ality, the link between socioeconomic status and COPD  is complex  (23),  likely to be multi-
factorial and includes several factors including smoking,   prenatal exposures, more frequent 
lower respiratory tract illness in childhood, housing conditions, air pollution, environmental 
tobacco smoke, diet, genetic factors and occupation (19).   
COPD is closely associated with deprivation and higher rates are seen in deprived urban 
communities (24).  In a large cross-sectional study involving 422 general practices in England, 
COPD was found in the most deprived people (31.1 per 1000 patients; 95% CI=28.4 to 30.1) 
and those living in the North East of England had the highest prevalence (25). Locally the 
health of people in Newcastle upon Tyne is varied compared to the England average and 
deprivation is higher than the national average (26).  Younger patients with COPD tend to 
live in the most deprived areas (24).   
 
A large national audit of COPD admissions across England calculated deprivation using the 
Index of Multiple Deprivation (IMD).  The results showed that COPD patients admitted to 
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hospital were notably deprived in respect to income, employment, health deprivation/disa-
bility, education, skills and training (24).  Prescott and Vestbo (1999) highlight that the risk of 
admission to hospital for COPD was threefold higher for people of the lowest socioeconomic 
group compared to the highest even when adjusted for smoking  (19). 
1.6 Symptoms of COPD 
Many people are unaware they have COPD as they may not experience symptoms in the 
early stages of the disease.  Chronic cough and sputum production may precede the devel-
opment of airflow limitation by many years. The chronic cough may be intermittent and may 
be unproductive (8).  Conversely, significant airflow limitation may develop without chronic 
cough and sputum production (8).  However, as the disease progresses the cardinal symp-
toms of COPD are cough, sputum production, and breathlessness (8). These symptoms are 
progressive in nature.  Breathlessness is an important feature of cardio-respiratory disease. 
(27). Breathlessness is not simply an automatic physiological function but a complex interac-
tion between physiological, psychological, social and environmental factors (28).  The mind 
has the power to alter breathing patterns temporarily and dysfunctional breathing patterns 
can develop (9).   If patients focus on their breathing this can make matters worse.  Breath-
lessness has much in common with pain; both are highly subjective sensations (29). Typical 
COPD patients describe their breathlessness as a sense of increased effort to breathe, heavi-
ness, air hunger or gasping (30).  Breathlessness is a major cause of disability and anxiety (8) 
and managing breathlessness is a fundamental goal of treatment in COPD (28).   
Assessing breathlessness can be challenging.   One method of assessing breathlessness is to 
use the Medical Research Council (MRC) Breathlessness scale (presented in table 3) origi-
nally developed by Fletcher in 1952 (31). The MRC breathlessness scale is a self-reported 
scale that quantifies the disability associated with breathlessness rather than the severity of 
breathlessness (27).   The scale has been used for many years and is recommended by the 
National Institute of Clinical Excellence in the Quality Standards for COPD (32). The scale 
does not quantify breathlessness, instead it provides a range of respiratory disability from 
none (grade 1) to almost complete incapacity (grade 5) (27). The scale is also not sensitive to 
changes in breathlessness (33).   However, a recent report has found that the MRC score is 
only being recorded in 60% of patients admitted to hospital  (24). 
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Table 3– MRC Breathlessness Scale (31) 
Grade Degree of breathlessness related to activities 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying on the level or walking up a slight hill 
3 
Walks slower than most people on the level, stops after a mile or so or stops after 15 minutes at 
own pace 
4 Stops for breath after walking about 100 yards or a few minutes on level ground 
5 Too breathless to leave the house, or breathless when undressing 
 
In addition to breathlessness, systemic effects can occur.  COPD is a multi-system condition 
and other symptoms include fatigue, effort intolerance (10), skeletal muscle weakness and 
weight loss (34).  COPD may also initiate or worsen comorbidities such as ischaemic heart 
disease, osteoporosis, normocytic anaemia, diabetes, metabolic syndrome and depression 
(8).  Patients are also prone to respiratory failure, often resulting in admission to hospital 
(35).   
1.7 Diagnosis of COPD 
There is no single diagnostic test for COPD.  The diagnosis is made on the basis of symptoms, 
clinical history, risk factors and lung function tests (8, 10, 36).   Spirometry is required to 
make the diagnosis (8).  The presence of a post-bronchodilator FEV1/FVC ratio less than 70% 
confirms the presence of persistent airflow limitation found in COPD.  This criterion has been 
used in numerous clinical trials   and is routinely accepted in clinical practice.  However, the 
use of airflow limitation will result in more frequent diagnosis of COPD in the elderly and less 
frequent diagnosis in adults younger than 45 years of age (37). Although COPD is defined on 
the basis of airflow limitation, in practice the decision to seek medical help is usually deter-
mined by the impact of a symptom on a patient’s life.  A person may seek attention because 
of a chronic symptom or because of a first exacerbation or worsening of COPD (8).  An exam-
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ple of spirometry from a patient with COPD can be seen in figure 3 (8).  According to the De-
partment of Health, one in eight people over 35 has COPD that has not yet been identified or 
diagnosed, and over 15% are only diagnosed when they present to hospital as an emergency 
(38). Notably there are some variants of emphysema where there is significant lung destruc-
tion but little or no airflow limitation. Such patients would not be deemed as having COPD 
within all COPD classification systems. 
Figure 3– Example of obstructive spirometry from Global Initiative for Chronic Obstructive Lung 
Disease (8) 
 
Source: Global Initiative for Obstructive Lung Disease (8). 
1.8 Prevalence 
It is well established that smoking is the single most important cause of COPD.  Whilst the 
incidence of smoking is well documented, surprisingly little is known about the true preva-
lence of COPD (39) although more studies are emerging.  It is estimated that approximately 
64 million people are affected by COPD globally (3).  There is a linear increase in the preva-
lence of COPD with age, irrespective of smoking status (26).  As a result of the aging popula-
tion, the prevalence and mortality rates will increase in the coming decades (3).  Prevalence 
rates in men have reached a plateau but are increasing in women (40).  Approximately 
974,999 patients were recorded on General Practitioner (GP) COPD registers for 2008 (41).  
It is estimated that approximately 2,000,000 people remain undiagnosed (42).  This is equiv-
alent to 13% of the population of England aged 35 and over (39).  The figures on prevalence 
in the UK need to be interpreted with caution as the accuracy of data depends on clinical 
  
 
30 
case finding and recording by general practices which is often poor (42). This is certainly the 
experience locally.  Under diagnosis may be due to a number of factors such as: 
x People not recognising the symptoms which may have developed gradually over a 
long period of time (42). This is particularly likely for patients with mild COPD, who 
may not realise their cough or breathlessness is a sign of something more serious 
(43). 
x People consider symptoms are due to smoking and think nothing can be done to help 
(37). 
x Health care professionals treat symptoms but fail to diagnose an underlying lung dis-
ease (37).  It has been suggested that some patients may attend their general prac-
tice but not receive a diagnosis due to the testing and clinical interpretation required 
(43). 
x Primary care may lack resources to undertake opportunistic case finding which can 
be cost effective (44). 
The North of England has the highest prevalence of COPD in England with a prevalence rate 
of 4.6% (43).   Recorded prevalence by local authorities in the North East can be found in fig-
ure 4.   One contributing factor will undoubtedly be the low socioeconomic status of the 
area. 
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Figure 4- Recorded COPD prevalence in 2010 based on (Quality Outcome Framework (QOF) data 
from 2009/2010) compared with estimated prevalence (Health Survey of England, 2001) for 16 + 
populations in Local Authorities in the North East of England from North East Public Observatory 
(43). 
Source: North East Public Observatory (43). 
1.9 Mortality 
There is increasing evidence suggesting that COPD increases the risk of mortality (45).  Data 
from the World health Organisation (WHO) suggests that death rates from respiratory dis-
ease in the UK are almost double the European Union (EU) average (3).    For the first time 
there were over half a million deaths registered in England and Wales in 2013 (41).  In 2013 
there were 27,000 deaths in England and Wales attributable to COPD (11).   Mortality from 
COPD is expected to be the third leading cause of death by the year 2030 (3).  Premature 
death from respiratory disease is a problem in the North East Region with the main cause of 
mortality reflecting its industrial legacy of mining and ship-building and high smoking rates  
(12).    In the North East life expectancy for  men is 77.5 and women is 81.4, both of which 
are  lower than the average in England which is 79.2 for men and 83 for women (26).  
With very severe disease five year survival is 30% in men and 24% in women (10).   If you are 
admitted to hospital with an exacerbation of COPD your mortality can be affected.  Of those 
patients who are admitted, 15% will die within three months (42), 25% will die within one 
year (10) and following an exacerbation the five-year mortality is approximately 50% (46).  
The place of death is also important.  Research indicates that patients with COPD are less 
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likely to engage in end of life care planning (47).  In addition, it has been suggested that peo-
ple dying from respiratory diseases were much more likely to die in hospital than at home or 
in a hospice (48). 
1.10 Management of COPD 
Once COPD has been diagnosed, effective management should be based on an individualised 
assessment of their symptoms and future risks (8).  COPD is treatable but not curable.  The 
management of COPD has improved over the last twenty years. COPD treatment has tradi-
tionally focused on lung function but it is now recognised that  FEV1 alone is a poor de-
scriptor of disease status (8).  The Outcomes Strategy for COPD and Asthma set out bold ob-
jectives to improve the quality and outcomes for people with COPD and Asthma (38).  In the 
strategy a key objective is to enhance quality of life  (QOL) for people with COPD by provid-
ing early identification, diagnosis, treatment with proactive care and management of all 
stages of the disease (38).  Achieving this objective may be very difficult given the limited re-
sources in the NHS.  The goals of effective management of patients with COPD have recently 
been revised in the GOLD Strategy (8).  Two fundamental objectives of treatment have been 
identified.  The first objective is relieving and reducing the short term impact of symptoms.  
The second is reducing the long-term impact of COPD such as exacerbations (8).  
1.10.1 Pharmacological treatment 
Pharmacological therapy in COPD is used to reduce symptoms, reduce the frequency and se-
verity of exacerbations, and improve health status and QOL (8).  Recommendations for suita-
ble models for pharmacological management have been produced by a number of organisa-
tions including the NICE (10) and the recently updated GOLD Strategy (8). Nowadays there 
are significantly more pharmacological and non-pharmacological treatments available.  A 
step-wise approach is generally used.  Bronchodilators are recommended and include beta-
agonists and anti-cholinergic therapies which may be long or short-acting depending on the 
patient’s symptoms (8).  Based on efficacy and side effects, inhaled treatments are preferred 
over oral preparations (8).  Long term treatment with inhaled corticosteroids is recom-
mended for patients with severe and very severe airflow limitation and for patients with fre-
quent exacerbations (or worsening of COPD) that are not adequately controlled by long-act-
ing bronchodilators (8).  Pharmacological treatments commonly used to treat exacerbations 
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of COPD are short-acting bronchodilators, oral corticosteroids and antibiotics.  Depending on 
the clinical condition of the patient respiratory support may be required including oxygen 
therapy, ventilator support may be provided using either noninvasive ventilation (with a na-
sal or facial mask) or invasive ventilation (by oro-tracheal tube or tracheostomy) (8).  In addi-
tion, appropriate fluid balance with attention to the use of diuretics, anticoagulants, nutri-
tion and the treatment of comorbidities is also recommended (8). 
1.10.2 Pulmonary rehabilitation  
A vast amount of research has been undertaken into pulmonary rehabilitation over the years 
with the bulk of evidence based on patients with COPD (49).  Pulmonary rehabilitation is an 
evidence based treatment recommended as a key management strategy for patients with 
COPD (8, 10, 42).  One of the main aims of rehabilitation is to  improve patient symptoms 
(49).   Patients who are most likely to benefit  from pulmonary rehabilitation are those who 
are limited by breathlessness or muscle fatigue (49).  Pulmonary rehabilitation programmes 
include individualised exercise and disease-related educational sessions (49).  A key compo-
nent of pulmonary rehabilitation is physical activity.  Physical activity is extremely important 
as inactivity has been linked with reduced survival, poorer QOL and increased healthcare uti-
lisation (50).  However, there are also psychosocial benefits of pulmonary rehabilitation (49).  
Given the complex nature of pulmonary rehabilitation, numerous outcome measures are 
used to capture changes in exercise capacity, QOL, symptoms and more recently levels of 
anxiety and depression (49).  These outcome measures are important to monitor patients’ 
progress before and after pulmonary rehabilitation.   
Unfortunately many patients decline to attend pulmonary rehabilitation.  This may be for a 
number of reasons including transport or acute illness.  However, some patients have diffi-
culty understanding the rationale or benefits behind the referral for pulmonary rehabilita-
tion.  Others may have strong beliefs about their ability to exercise given their physical prob-
lems or lack the motivation to attend (49).   Anxiety and depression co-morbidity in patients 
with COPD predicts poor adherence to pulmonary rehabilitation (51).  In 2011 the results of 
a large study demonstrated that anxiety and depression were related to worse outcomes 
not only at the start of pulmonary rehabilitation, but also at the end (52).    It has been sug-
gested that CBT may improve uptake and completion of this important treatment (49) and a
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large Health Technology Assessment multi-center randomised controlled trial is planned to 
start 2015/2016, of which I am co-applicant.   
1.11 Exacerbations and Hospital Admissions 
An exacerbation of COPD is defined as an acute event characterised by a worsening of the 
patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a 
change in medication (8).   Exacerbations are common, particularly those with severe disease 
(38).  Exacerbations become more frequent (two or more) and more severe as the severity 
of COPD increases (53) resulting in reduced physical activity (54), poorer QOL (55) and in-
creased risk of death (56).   Unfortunately exacerbations contribute to further deterioration 
of lung function.  The more frequent the exacerbations the greater the decline (57).   The 
best predictor of having frequent exacerbations is a history of previous treated exacerba-
tions and the risk also increases as airflow limitation worsens (8). There appears to be an in-
dependent COPD phenotype of patients who exacerbate frequently and this has significant 
implications for targeting exacerbation prevention strategies (53). 
Exacerbations are a common cause of hospital admissions.   COPD is responsible for approxi-
mately 10% of all medical admissions (38), the second most common cause of emergency 
admissions to hospital and one of the most costly inpatient conditions to be treated by the 
NHS (38).  Reducing emergency admissions is a national and local priority as resources within 
the NHS are very limited (42).  Over the last few years there has been an increasing number 
of community services tasked to prevent hospital admissions.  Despite these services COPD 
admissions continue to increase.  It is estimated that COPD admissions have increased 13% 
between 2008 and 2014  (24). Whilst the number of hospital admissions in Newcastle upon 
Tyne NHS Hospitals Foundation Trust is decreasing, there were 263.4 admissions per 
100,000 of the population (58).  A proactive Community Chest Outreach Team in Newcastle 
may account for the fall.  However, it is entirely appropriate for some patients with COPD to 
be admitted, for example, with severe exacerbations, pneumonia or other complications. Pa-
tients are also prone to respiratory failure, requiring admission to hospital (35). The percent-
age of females admitted with COPD exacerbations has risen slowly since 2003 with 51% of 
admitted cases in an audit completed in 2014 (24). 
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Long term conditions such as COPD are amongst the most common reasons for readmissions 
in the North East Region  (12). In 2011/2012 the 30 day emergency readmission rate for pa-
tients in the North East region was higher than that of any other health region in the country 
(12).   Readmissions may be clinically appropriate but some admissions are considered to re-
flect ineffective patient management (12).  A variety of factors may contribute to avoidable 
readmissions including inappropriate discharge and lack of care within the community.  
However, a study in 2003 identified that a low FEV1, low levels of physical activity and pas-
sive smoking (or indeed actual smoking) were risk factors of readmission (59).     
However, there are some admissions where the main cause of admission is anxiety and 
panic. It has been suggested that there may be a relationship between anxiety and depres-
sion and exacerbations of COPD (60, 61).   Whilst the literature was not conclusive, a recent 
systematic review in 2014, suggested that anxiety and depression increased the likelihood of 
hospitalisation, prolonged the length of stay and resulted in a greater risk of mortality post 
discharge (57).  A vicious cycle can develop (figure 5). 
 
Figure 5 – Diagrammatic representation of the theoretical relationship between anxiety and de-
pression and acute exacerbations of COPD that result in hospital admissions or readmission (57). 
 
                          
                                               
It is important to remember that many patients have transitory mood symptoms during ex-
acerbations that improve spontaneously as their physical state improves (57).  The challenge 
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is to identify those who have more permanent and sustained anxiety and depression; to de-
velop ways of screening and implementing effective management strategies to alleviate the 
impact of these comorbidities; and enable patients to cope better with their COPD (57). 
1.12 Impact on QOL 
As COPD cannot be cured, treatment has focused on managing symptoms and improving 
QOL (8).    QOL is a term used to describe ‘the standard of health, comfort, and happiness ex-
perienced by an individual’ (62).  The term ‘health related QOL’ (HRQOL)  or health status as 
it is often referred to,  is also used and is more specific to health (63).  As improving HRQOL 
is an important goal in COPD management assessing health status is now established to as-
sess therapy for patients with chronic lung disease (64).   More recently patient-reported 
outcome measures (PROMS) have been used to determine outcome for healthcare.  PROMS 
are intended to reflect outcomes relevant to patients and are increasingly being used for 
healthcare quality improvement.  Essentially, PROMS are health questionnaires asking pa-
tients to report on their symptoms and QOL (65). 
In COPD, QOL and health status are determined by factors including gender, disease severity, 
lung function, body mass index, smoking, symptoms, comorbidity, anxiety, depression and 
exacerbations (63).  Two of the most common and least treated comorbidities of COPD are 
anxiety and depression (66).  The impact of pulmonary disease on activities of daily life is ad-
versely affected by anxiety and depression even after controlling for the effects of breath-
lessness (67).   Anxiety and depression has a significant impact on QOL and affects outcomes 
such as pain, physical function and general health (68).  Disease specific outcomes such as 
mastery of their illness and symptoms of breathlessness are also affected (68).  As a result of 
physical symptoms of COPD patients become less active.  For some patients activity levels 
can reduce but often patients actually avoid activities that induce breathlessness resulting in   
physically deconditioned and a vicious cycle develops.       
Symptoms of COPD lead to a gradual progression of disability over many years that may be 
accelerated in a stepwise fashion after exacerbations or hospitalisation.  As a consequence 
day to day functioning is affected and QOL is reduced. Patients focus on feeling unwell and 
their inability to perform activities of daily living.  Feelings of frustration, anxiety and depres-
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sion can follow.  It is clear that patients cope with COPD in many ways.  Some people per-
ceive that their lives are almost untouched by COPD, yet others are significantly disabled 
(63).   
1.13 Compliance with medication and self-management 
Each year millions of pounds are spent on drug treatment for COPD.  Untreated anxiety and 
depression has been shown to have major implications for compliance with medical treat-
ment, due to the effects on cognitive functioning and the decreased effectiveness of self-
management activities   (69, 70).  An increasing number of people with COPD living with sig-
nificant disability have to ‘self- manage’ their conditions on a daily basis.  It has been sug-
gested that helping people to care for themselves more effectively can improve their physi-
cal and mental well-being (2).  There appears to be  evidence that supporting self-manage-
ment can have a positive impact on people’s clinical symptoms, attitudes, behaviours, QOL 
and patterns of healthcare resource use (2).  In COPD, ‘self-management’ often refers to the 
use of rescue packs to manage exacerbations of the disease.  However, this is a simplistic 
view of self-management which encompasses much more than that. 
A recent review and meta-analysis on the effectiveness of self-management interventions on 
QOL  and healthcare utilisation in people with COPD identified 22 RCTs included in  five sys-
tematic reviews categorised as ‘self-management and education’ for COPD from the 
Cochrane Library.  The results suggest that self-management interventions can improve 
HRQOL and reduce the number of emergency department visits but there is wide variation in 
effect (71).  Furthermore, interventions that tackle mental health and promote physical ac-
tivity are more effective than those aimed directly at respiratory health (71).   However, this 
is a simplistic view of self-management.  Recommendations for future interventions should 
focus on tackling mental health and promoting physical activity not just taking rescue packs 
for exacerbations (71). It was also suggested that brief, simple self-management interven-
tions may be as effective as more complex interventions (71).  This is an important finding 
for clinical practice as brief interventions are easier to deliver and potentially of lower cost 
(71).   
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There are a number of ways to support self-management including providing information 
leaflets, peer support, one to one counselling, group education, telemedicine and psycholog-
ical behaviour change interventions (2).  In COPD the use of self-management plans is less 
well characterised compared with other long term conditions (72). Self-management sup-
port is not a new concept and has been around for many years.  Whilst research is growing 
in the area of self-management more research is needed.  De Silva (2011) suggests that 
more ways of  developing the effectiveness of  behavioural change are  necessary (2).  For 
some long term conditions there has been a focus on ‘giving information’ in a structured way 
to facilitate self- management e.g. diabetic patients may receive technical information about 
diet, medication, exercise, eye and foot care.   It is argued that the focus of care for anxiety 
and depression should be on cognitive and behavioural interventions (2). 
1.14 Economic Burden of COPD 
COPD is a very costly condition and is associated with significant economic burden (8).  The 
total annual cost of COPD to the NHS is estimated to be over £800 million for direct 
healthcare costs, which equates to £1.3 million per 100,000 (73).   COPD exacerbations ac-
count for the greatest proportion of the total COPD burden on the health care system (8).  In 
this country, COPD causes 115,000 emergency admissions per year (74) with an estimated 
cost of around £2,000 each (73).   
However, any estimates of the cost of COPD are likely to under-represent the economic 
value of home care provided by family members (8).  It is argued that COPD may force indi-
viduals to leave the workplace as a result of their illness or perhaps care for a family member 
who has the disease.  The Department of Health (2011) suggest that 40% of people with lung 
diseases are below retirement age and are unable to work as a result of their illness (42).  It 
has been suggested that the indirect costs of COPD may represent a serious threat to na-
tional economies (8).   
1.15 Summary 
COPD is one of the most important chronic diseases of both developing and developed coun-
tries.   In the UK millions of people are believed to have the disease – many of whom will not 
yet be diagnosed.  The principal features of COPD are airflow obstruction with associated 
cough, sputum production and breathlessness.   It is a progressive incurable illness with 
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worsening symptoms such breathlessness and gradual disability.  Whilst smoking is the main 
cause of COPD in the majority of cases there are other causes of the disease. Exacerbations 
are common, particularly for those with severe disease.  Comprehensive guidelines for the 
management of COPD exist, using pharmacological and non-pharmacological treatments 
such as pulmonary rehabilitation to manage symptoms.   
COPD has a significant impact on morbidity and mortality and for those who survive the ill-
ness their QOL can be severely affected.  As COPD cannot be cured the focus of care is on 
improving the patient’s QOL.  The following chapter will explore the emotional conse-
quences of COPD and the role of anxiety and depression in this debilitating disease. 
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Chapter 2 - Psychological Comorbidity in COPD 
2.1 Introduction 
Physical health and mental health are inextricably linked (75).  It is estimated that around 
30% of people with a long term physical health problem also have a mental health problem 
(76).  Not surprisingly there has been an increasing awareness of the psychological morbidity 
of medical problems for a number of years.  Figure 6 below illustrates the overlap between 
long term conditions and mental health problems (77).   The mechanisms underlying the re-
lationship between mental and physical health are complex (77).   Evidence suggests a com-
bination of biological, psychosocial, environmental and behavioural factors may all be in-
volved (78). 
Figure 6 – The overlap between long-term conditions and mental health problems  (77). 
 
 
Source: Kings Fund Report (77). 
It is difficult to determine whether the chronic medical problem causes anxiety and depres-
sion or the psychological disorder increases the risk of developing physical health problems 
(79). People who are anxious or depressed are more likely to smoke and it is estimated that  
approximately three million smokers in the UK have a mental health disorder (80). Smoking 
is around twice as common among people with mental disorders, and more so with severe 
mental health problems (80).   Whilst smoking is a well-known cause of COPD it is also asso-
ciated with an increased risk of onset of anxiety disorders and depression (80).   On the 
other hand, high levels of anxiety have been identified as a risk factor for starting smoking in 
the first instance (81).  Whatever the direction of causality, it is clear that mental health 
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problems have a major impact on symptoms and outcomes for people with COPD (77).  Inde-
pendent of COPD severity, comorbid mental health problems are associated with worse 
health status and breathlessness (82) which are both important factors for treatment of 
COPD. 
The prevalence of anxiety in COPD is generally considered to be high (83).  Prevalence fig-
ures are difficult to interpret as reviews of studies suggest prevalence ranges from 2- 96% 
(83).   A systematic review and meta-analysis reported the prevalence of clinically significant 
symptoms of anxiety as 36%, and 40% for depression in patients with COPD.  Screening for 
symptoms of anxiety and depression are recommended by strategies such as GOLD Strategy  
(8) and the NICE COPD Guidelines (10).  However, in clinical practice this is rarely undertaken 
despite the fact that these psychological conditions are potentially treatable.      
For patients who have recently recovered from an acute exacerbation of COPD, the preva-
lence of depression and anxiety is reported to be as high as 50% for depression and 58% for 
anxiety (66).  For some patients symptoms may be transient and improve spontaneously as 
the patients physical condition improves but for others the symptoms may persist (66).   A 
number of variables have been associated with anxiety and depression in patients with 
COPD (66).  These variables are listed in table 4. 
Table 4 – Variables associated with anxiety and depression in patients with COPD (66) 
Physical disability 
Severe disability 
Presence of co-morbidity 
Percentage of predicted FEV1 <50% 
Low body mass index 
Poor QOL 
Living alone 
Female gender 
Current smoking 
Low socioeconomic status 
Long term oxygen therapy 
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The implications for people with COPD and comorbid anxiety and depression are serious.  
Patients have poorer clinical outcomes, lower QOL, reduced ability to manage physical symp-
toms effectively, increased risk of hospitalisation and re-hospitalisation and furthermore an 
increased risk of mortality (66, 84) .  It is apparent that one of the most important interven-
tions to prevent COPD, or to stop further deterioration of the disease is smoking cessation. 
Patients who may be anxious or depressed are more likely to be associated with unhealthy 
behaviours such as smoking (77, 80, 85).  It has been claimed that patients with mental ill-
ness are less likely to be successful quitting (86). However,   in contrast, it has been argued 
that whilst people with mental health problems are twice as likely to smoke, they have sub-
stantially greater quit rates (87).  
The economic impact of COPD has attracted much attention over the last few years. It is only 
recently that the additional costs of mental health problems and physical illness have been 
highlighted.  By interacting with and exacerbating physical illness, co-morbid mental health 
problems raise total health care costs by at least 45 per cent (77).    Melek and Norris (2008)  
suggest that patients with chronic medical conditions and comorbid anxiety and depression 
incur  considerably higher healthcare costs than those without psychological problems (79).  
Data from Melek and Norris’s research was presented in a recent report by the King’s Fund 
highlighting the important issue of mental health for patients with COPD and other medical 
conditions (figure 7) (77).  In 2007, the estimated cost of anxiety was £8.94 billion and £7.5 
billion for depression.  The projected costs for 2026 are £14.2 billion for anxiety and £12.2 
billion for depression (88). 
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Figure 7 – Costs associated with anxiety and depression and chronic conditions -data cited from 
Melek and Norris (2008) (77). 
                
Source: Kings Fund Report (77). 
Our physical, social and economic environments all have important effects on our physical 
and mental health (1).  Certain psychosocial factors have been investigated in COPD patients.  
As early as 1999, Prescott et al found that socioeconomic inequalities in education and in-
come are also associated with a threefold increase in hospital admission (19).  Coventry et al 
(2011) also found that patients who owned and occupied their own homes had fewer read-
missions to hospital compared with patients who did not (61).  In the same study, the au-
thors state that depression was found to be a significant predictor for initial hospital read-
missions (61).  Anxiety is a significant predictor of the frequency of hospital admissions and 
re-admissions for acute exacerbations of COPD (61). 
2.2 Anxiety 
Anxiety is an unpleasant emotional feeling associated with a state of ‘threat’ or not being 
able to cope.  Anxiety has been defined as a future orientated emotion, characterised by 
perceptions of frightening and uncontrollable events or situations (89).  Excessive levels of 
anxiety and stress have been shown to negatively impact on the functioning of many sys-
tems.  The brain is the key organ of the stress response as it determines what is threatening 
and therefore controls the behavioural and physiological responses (90). Many of the symp-
toms of anxiety are physiological in nature reflecting activation of the sympathetic and para-
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sympathetic nervous system (89).   Common symptoms of anxiety can be seen in table 5 
(89). 
Table 5- Common symptoms of anxiety (89). 
Physical Behavioural Cognitive/affective symptoms 
Shortness of breath/rapid 
breathing 
Choking sensation 
Sweating 
Increased heart rate/palpitations 
Chest pain/pressure 
Muscle tension 
Dizziness/lightheaded/headaches 
Increased BP 
Tingling in arms/legs 
Dry mouth 
Nausea/diarrhea 
Trembling/shaking 
Avoidance 
Escape (flight response) 
Hyperventilation 
Pursuit of safety or reassurance 
Difficulty speaking 
Freezing 
Restlessness 
Insomnia 
Frightening thoughts/images or 
memories 
Fear of losing control or being una-
ble to cope 
Catastrophising 
Worry 
Poor concentration 
Apprehension 
Difficulty in reasoning 
Poor memory 
Narrowing of attention 
 
Symptoms triggered by anxiety clearly overlap with the symptoms of COPD (91) and as a re-
sult can be more complex to identify and manage.  It has been hypothesised that a patient’s 
fear  leads to misinterpretation of bodily experiences such as breathlessness and hyperventi-
lation and  this can lead to intense feelings of panic  (92). Greater levels of anxiety have been 
associated with poor satisfaction with marital relationships in COPD patients (93), are more 
common in women than men and in current smokers compared to ex-smokers (70).   It is un-
clear whether the prevalence or magnitude of anxiety-related symptoms differ according to 
the severity of obstruction; with some studies but not all reporting no relationship between 
these (83).   Not surprisingly, anxiety has been shown to lead to impaired health status, 
poorer treatment outcomes and reduced survival (84).  In male patients, low levels of per-
ceived self-efficacy in symptom management, poorly adapted coping strategies and low lev-
els of social  support have been associated with higher levels of anxiety (85). 
 It is understandable that patients experiencing extreme breathlessness find it difficult to at-
tribute the symptoms correctly to anxiety and panic when they have a genuine respiratory 
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problem.     Indeed, sometimes health care professionals do not recognise the impact of anx-
iety on breathlessness and may well initiate treatment for an infective exacerbation of 
COPD.  However, a link between COPD and anxiety is highly plausible.  In extreme cases, anx-
iety may develop into panic attacks. 
2.3 Panic 
 The term ‘panic’ is derived from the name of the Greek God Pan (94).  According to Greek 
mythology, Pan would frighten people and the acute terror felt came to be called ‘panic’ 
(94).  A ‘panic’ is now defined as an episode of intense fear of sudden onset and is accompa-
nied by a surge of strong unpleasant physiological symptoms (hyper arousal) (95).   When 
danger is perceived, the automatic fear response occurs faster than conscious thought.    
Surges of adrenaline are released which subside quickly once the perceived or actual threat 
has passed (96).  During panic attacks there is an intense feeling of ‘air hunger’ (97) and of-
ten a fear of suffocation.  Some panic attacks are very sudden and unexpected.  For some 
people, however,  the panic attack may be provoked by exposure to an identified trigger and 
can be anticipated (94).    Attacks usually peak within a few minutes (98). Panic is also associ-
ated with difficulty reasoning, and a feeling of imminent catastrophe (98).  Therefore, the ex-
perience of panic can be so distressing that many people develop a strong apprehension 
about having another attack.  Individuals will often avoid situations that may trigger the 
panic (95).  
A leading theoretical model for panic is Clark’s cognitive model (99).  In Clark’s model a panic 
attack results when ambiguous bodily sensations are interpreted as imminently catastrophic, 
increasing arousal and so creating a vicious cycle (Figure 8) (92).  Of interest, within the 
COPD population with similar disease severity, catastrophic over-interpretation of the imme-
diate danger of breathlessness occurs in some individuals but not all  (99).  Indeed, it  has 
been proposed that elevated anxiety sensitivity, a trait variable, may increase symptoms in 
vulnerable people exposed to the stressful life events associated with living with COPD (99). 
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Figure 8 – Clark’s Model of Panic (92). 
                                           
 Critical features of panic attacks can be seen in table 6.  It is noticeable that many of the fea-
tures described in table six are similar to the physiology of COPD.  What may be different is 
the disproportionate responses that can occur during panic attacks.  The prevalence of panic 
disorder in patients with COPD is 10 times greater than the overall population (100).  There 
is evidence that untreated panic attacks in COPD do not resolve but may instead increase the 
risk of panic disorder developing (101). 
 
Table 6 – Critical features of panic attacks in COPD - Adapted from Clark and Beck (95) 
Situations which trigger symptoms e.g. exertion 
An abrupt onset of physiological arousal including breathlessness and fast heart rate 
Heightened self-focus  
Hypervigilance of bodily sensations e.g. increased focus on breathing 
Perceived physical, mental or behavioural catastrophe (I can’t breathe and I am going to die) 
Apprehension and fear of future panic attacks (I will have another attack and die) 
Extensive safety seeking behaviours (such as avoidance of activities or exertion; calling 999 for an 
ambulance for reassurance or having numerous admissions to hospital where it is perceived to 
be safe) 
Perceived lack of control (patients feel that they cannot do anything themselves) 
Is distinct from anxiety (it is an intense form of anxiety) 
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In contrast to Clark’s model of panic is the notion that psychological processes underlying 
pathological anxiety are mainly automatic (102).   Anxiety and panic are part of our ‘natural 
wiring’.  It could be argued that panic should not be seen as an extreme form of anxiety but 
rather it is a natural ‘fight or flight’ response to perceived imminent danger.  This natural re-
sponse can be helpful when we need to respond quickly to danger but becomes unhelpful if 
it is persistent, and can be very distressing.  
A link has been found with mental health problems such as panic, generalised anxiety and 
low FEV1/FVC ratio in numerous studies (6).  Spitzer et al (2011) suggest a  possible explana-
tion for the association between mental health and lung function  is that  airflow limitation 
may induce panic, or conversely, that panic may decrease airflow, but not to a clinical and 
diagnostic threshold (6).   A number of theories have been proposed to explain the links be-
tween anxiety and obstructive lung disease.  From a pathophysiological perspective it has 
been argued that hypercapnia and acid-base disturbances accompanying obstructive lung 
disease may induce anxiety (103).   A psychological explanation would suggest illness percep-
tions, beliefs and misinterpretations of respiratory symptoms (e.g. breathlessness) have a 
role to play (6).  It  has also been suggested that patients with prominent respiratory symp-
toms show greater fluctuations in end-tidal CO2 and brain lactate (97). 
Whether COPD  or anxiety causes breathlessness or indeed whether it is a combination of 
the two, there is no doubt that breathlessness can be a distressing and frightening symptom 
which can lead to catastrophic interpretation of what is happening (e.g. a patient may think 
that they cannot breathe and death is imminent).  A key feature of panic episodes is the ten-
dency to interpret the certain bodily sensations in terms of an impending biological disaster 
(95).  In individuals who have normal lung function physical symptoms such as increased res-
piratory rate and heart rate can be alarming.  However, for patients with respiratory prob-
lems an increase in respiratory rate can be terrifying.   Patients become anxious about be-
coming breathless and avoid exertion which may trigger unpleasant symptoms occurring, 
leading to physical deconditioning which then exacerbates the panic cycle.   Panic symptoms 
are most prevalent in people with low perceived control over symptoms and the disease; pa-
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tients having negative beliefs about the life-limiting consequences of unpredictable breath-
lessness attacks and by people using emotional coping strategies such as denial and avoid-
ance (104). 
Patients with COPD who experience panic attacks solely in relation to their COPD symptoms 
would not be diagnosed with panic disorder (105).  Panic disorder consists of recurring, un-
foreseen panic attacks which are unrelated to COPD.  Which, as discussed, is followed by 
persistent worry and distress about having further attacks (105).   Patients often begin to 
avoid situations they associate with an increase in unpleasant physiological sensations, such 
as physical exercise.  Behavioural avoidance is seen in approximately one-third of individuals 
with co-morbid COPD and panic disorder (106).   
A newer model has emerged proposing a diathesis (vulnerability)-stress explanation.  Diathe-
sis-stress models of panic suggest that specific psychological disorders develop as the result 
of an interaction between vulnerability factors and stressful events (99).  Examples of stress-
ors include physical activity leading to breathlessness.  Research into the relationships be-
tween cognitive diathesis for the development of panic-spectrum pathology is growing (99).   
Genetic factors, personality, behavioural characteristics, stressful life events (such as medical 
illness) may have a role in moderating or mediating the influence of life events on the devel-
opment of panic disorder (107).  In addition, socio-demographic variables and functional im-
pairment may also have a role to play in panic in biologically vulnerable individuals support-
ing a possibly gene-environment interaction (107).    It is thought that genetic make-up sets 
the biological vulnerability to anxiety.  A hypothetical model of genetic factors, life events 
and moderating/mediating factors in the etiology of panic can be seen in figure 9 (107).   
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Figure 9 – A modified hypothetical model of genetic factors, life events and moderating/mediating 
factors in the etiology of panic (107). 
                                
Whatever the mechanism responsible for the development of anxiety and panic, the impact 
on patients’ lives is considerable.  The literature suggests the negative effects of anxiety lead 
to poor functional status (108), increased in the likelihood of  admission and readmission to 
hospital  (109),  longer length of stay,  greater risk of mortality post discharge (57), impaired 
HRQOL and risk for suicide attempts (110).  Patients who have COPD and panic disorder of-
ten admit to ‘feeling safe’ when ambulance services are called, when they are admitted to 
hospital and often refuse to go home following an admission.  This increased reliance on the 
safety of health services can further exacerbate the panic cycle.  Inappropriate escalation of 
medical treatment can undermine patient confidence and have limited use on preventing 
admissions as a result of panic attacks.  Another important consideration is that patients 
with panic have a higher level of depressive symptoms further compounding their distress 
(99).  Given the impact of psychological symptoms outlined above, it seems reasonable to 
argue that the treatment of anxiety and panic among patients with COPD is imperative to 
improve patients QOL given there is no cure for their condition. 
2.4 Depression 
Depression refers to a wide range of mental health problems characterised by a loss of inter-
est and enjoyment in ordinary things and experiences (sometimes referred to as a loss of 
positive affect) (111).  A number of symptoms of depression are reported.  Physical, behav-
ioural and cognitive symptoms of depression are presented in table 7 (111).   
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Table 7– Common physical, behavioural and cognitive symptoms of depression (111). 
Physical Behavioural  Cognitive 
Insomnia Reduced activity Anxious thoughts 
Increased symptoms e.g. pain Social withdrawal Loss of interest/enjoyment 
Muscle tension Irritability Low self-esteem 
Altered appetite Tearfulness Poor concentration 
Possible weight loss Agitation Feelings of guilt/helplessness 
Fatigue Self-harm/suicide attempts Mental slowing 
Lack of libido  Negative thinking 
  Loss of confidence 
  Rumination 
  Unmotivated 
  Suicidal ideation 
 
Symptoms of depression must be present for at least two weeks and be associated with 
marked impairment of daily functioning (111).  Whilst individuals will vary in their experi-
ence of depression usually a diagnosis requires assessment of  the  severity, duration and 
course of the symptoms (111).  Four severity groups are provided in national guidelines 
(111): 
x Subthreshold depressive symptoms (fewer than five) with minor functional impair-
ment. 
x Mild depression with at least five symptoms or functional impairment. 
x Moderate depression with symptoms and functional impairment. 
x Severe depression with most symptoms and significant functional impairment. 
Increasingly, it is recognised that subthreshold or minor symptoms of depression can cause 
significant morbidity (111).   Ideally, early intervention to treat mild symptoms would be the 
goal of treatment to prevent the progression to severe depression, which is more difficult to 
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treat. Unfortunately there does not seem to be a distinctive ‘cut-off’ between ‘clinically sig-
nificant’ degrees of depression (111).  When patients have chronic physical health problems 
there is an added complexity distinguishing the somatic symptoms of the physical health 
problem from those associated with depression (111).   
People with depression vary in the pattern of symptoms they experience, due to a number 
of factors including gender, personality, family history, premorbid difficulties (e.g. trauma 
such as sexual abuse), social circumstances and psychological mindedness (111).  COPD can 
cause and exacerbate depression (111).  As a result of breathlessness patients may not be 
able to participate in normal activities of daily living.  This reduced activity leads to feelings 
of hopelessness, impacts on fatigue and perceived energy levels which ultimately affects 
mood (see figure 10) (111).  It is thought that depression is a time-limiting condition lasting 
up to six months before complete recovery (111).  Contradicting this view is data from  the 
World Health Organisation which found that depression was present at 12 months (112).  
However, in my clinical experience patients commonly report symptoms of depression last-
ing years.  
Depression is two to three times more common in patients with chronic physical health con-
ditions such as COPD (111).   Chronic physical health problems can both cause and exacer-
bate depression, but the reverse can also occur. Depression is associated with risk factors 
such as smoking, sedentary lifestyle and obesity, which are also risk factors for physical 
health problems (113).  Patients with COPD may have a spectrum of symptom severity rang-
ing from short term depression symptoms, to dysthymia (longer term low mood that is not 
yet disabling) to clinical depression (66).    
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Figure 10 – Vicious cycle of depression 
                                          
Depression can exacerbate distress and physical symptoms such as pain  and there may be a 
dose-response relationship between illness severity and the extent of disability (111).   How-
ever, this has not been the experience in respiratory clinics in Newcastle where anecdotal 
evidence suggests that patients with mild COPD can have at least as many if not more symp-
toms of depression than patients with very severe COPD.  What is clear is that symptoms of 
depression have a negative impact on a number of important patient outcomes.   
In a large prospective cohort study, Ng et al (2007) found that comorbid depressive symp-
toms in patients with COPD are associated with poorer survival, longer hospitalisation stay, 
persistent smoking, increased symptom burden, and poorer physical functioning (84).  The 
authors found that patients commonly feel hopeless and helpless about changing their life 
circumstances; lack the drive and motivation to seek help and may succumb to early death 
instead (84). Clearly this is something which must be addressed.   A recent systematic review 
found that symptoms of depression also led to  increased likelihood of being admitted to 
hospital, longer hospital stays and increased risk of death post discharge (4).  Worryingly, the 
systematic review also found that only about one third of COPD patients with depression 
were being treated for it (4). 
2.5 Screening for Anxiety and Depression 
Detecting symptoms of anxiety and depression is the first step in providing effective support 
for patients (77).  In research, symptoms of anxiety and depression are usually detected us-
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activity
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Low mood
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ing one of three types of measures: self-report questionnaires, checklist based structured in-
terviews and clinical assessment by a psychiatrist (114).  A number of validated measures 
could be employed to assess COPD patients’ symptoms of psychological distress. The most 
common measures used in previous COPD studies are the Beck Anxiety Inventory (BAI) 
(115), the Beck Depression Inventory (BDI) (116) and the Hospital Anxiety and Depression 
Scale (HADS) (117). The Beck Anxiety Inventory can over-estimate symptoms of anxiety in 
patients who have respiratory problems as it includes a question about breathlessness.  The 
HADS scale has fewer items to complete compared to the Beck Questionnaires and this is an 
important consideration for elderly patients.  The HADS scale is a brief self-reported ques-
tionnaire comprising of two scales with seven questions each.  One scale is for anxiety and 
another for depression (See Appendix 1).  Each item on the scale is rated on a four point Lik-
ert scale (zero to four).  Scores range from 0 -21 for each subscale.   A higher score indicates 
worse symptoms and is indicative of clinically significant emotional distress (61). The ques-
tionnaire assesses emotional symptoms over the preceding seven days (118) and takes a few 
minutes to complete (119).   
The classification of patients as being anxious or depressed according to HADS is controver-
sial (118). In a large cross-sectional study of stable COPD patients, the authors concluded 
that the HADS questionnaire had a low diagnostic accuracy of depression but was an appro-
priate scale to evaluate psychological distress.  This is in keeping with other recommenda-
tions that the HADS is used as both a screening tool and to monitor changes over time (61).  
The HADS has been found to be reliable and validated for hospital medical out-patient set-
ting (117). Nowak et al have suggested that a range of cut-offs have been used, for example, 
HADS-Depression >4 in coronary heart disease, HADS-Depression >7 in cancer and HADS-De-
pression >11 in end-stage renal disease   (118).    An updated analysis of the HADS in 2002 
found similar results in general medical, psychosomatic and psychiatric patients with an opti-
mal cut-off of ≥8 for both subscales to define patients with probable diagnosis of depression 
or anxiety (118).   With the above cut off, the HADS is reported to have high sensitivity (80%) 
and specificity (90%) (84).  Dowson et al found that more severe COPD (FEV1 predicted) cor-
related with higher HADS-Anxiety (r=0.39, p=0.001) and depression (r=0.34, p=0.005) scores 
(120). In a Dutch population the HADS has the advantage of being insensitive to age (121).    
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When using measurement scales it is useful to understand what the ‘minimal clinical im-
portant difference’ (MCID) to assess improvements in clinical settings. The MCID is con-
cerned with methods of estimating the threshold of clinical significance of a measurement 
such as HRQOL or symptoms e.g. HADS scores (64).   The MCID for the HADS Questionnaire 
in COPD has been reported to be  a reduction of 1.5 or a change of 20% on either sub-scale 
or the total score (122). However, there has been no agreed definition of what ‘the clinically 
significant threshold’ is (123).   
2.6 Treatment of anxiety and depression in COPD 
Once symptoms of anxiety and depression are identified, appropriate treatment should be 
given (10).  However, in clinical practice screening and management  of psychological symp-
toms in COPD patients remains extremely poor and is not done to a consistently high level 
(77).  A number of reasons may include the fact that health care professionals focus on phys-
ical symptoms (124). Very little attention is generally given to the patient’s psychological 
well-being, in spite of its impact in predicting disability and other outcomes. It may also be 
more difficult to identify the cause of symptoms such as breathlessness or fatigue which of-
ten overlap with COPD and psychological problems such as anxiety and depression.   
In addition, health care professionals working in the physical health setting have varying lev-
els of training in psychological well-being and may feel ill-equipped to deal with emotional 
difficulties. It has frequently been suggested that professionals feel that they will ‘open a can 
of worms’ by discussing psychological issues with patients.  More worryingly, there remains 
stigma relating to psychological problems and the use of psychiatric or psychological ser-
vices. Patients may interpret the suggestion of referral as a lack of understanding regarding 
the validity of their symptoms. Guidelines for the management of anxiety and depression  
recommend psychological treatment, pharmacological treatment or both in combination 
(111, 125) . Psychological interventions include CBT, counselling and self-help approaches.  
2.7 CBT 
CBT is a psychological therapy that represents a combination of behavioural and cognitive 
theories of  behavior (126).   In CBT, the term ‘cognitive’ relates to people’s thoughts (words 
or images), emotions, feelings, ideas, beliefs and values.  The term ‘behaviour’ relates to 
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what a person does or chooses not to do.  The core idea of therapy is that a person’s emo-
tional reactions are influenced by what they ‘think’ (cognitions) or indeed what they ‘do’ (be-
haviour).  A diagram of the model can be found in figure 11.   Part of the inheritance from 
behavioural therapy is the notion that our behaviour is crucial in maintaining or changing 
psychological states (127).  CBT is a treatment that focuses on understanding how experi-
ences are developed, interpreted and explores the interaction between physical symptoms, 
thoughts, mood, behaviour and environment which are intricately linked.   A core compo-
nent of CBT is that it is not the event that is important but what an individual makes of that 
event.  Patients may all experience the same physical illness but interpret the experience in 
different ways.  One patient may feel anxious and depressed about their situation and feel 
they have no control in managing their symptoms, others may feel the opposite.  
Figure 11 – The CBT Model (127) 
                                                                Situation/Trigger 
 
 
A fundamental part of cognitive therapy is the role of our cognitions or thoughts.  Negative 
automatic thoughts are particularly important in CBT.   Negative automatic thoughts are 
negative appraisals or interpretation of life events.  These thoughts pop into our minds, are 
usually unchallenged and impact on our mood and behaviour.  The CBT model helps thera-
pists try to identify unhelpful thoughts and behaviour.  Central to the CBT model is the use of 
a ‘formulation’ sometimes referred to as a ‘case conceptualisation’ or ‘the hot cross bun’ 
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(128).  The formulation is a summary of the patient’s problems, helps the patient and thera-
pist make sense of the current difficulties, can help identify factors that may be maintaining 
the problem and acts as a bridge to identify potential areas for change or interventions that 
may be useful.  A core skill for any cognitive therapist is to be able to understand the pa-
tient’s problems and collaboratively identify ways of tackling or adapting to the difficulties.  
By making sense of the problem new skills can be developed to change or reconsider unhelp-
ful thoughts and behavior leading to improved emotional health.   
The focus of treatment is on the ‘here and now’ rather than exploring difficulties from the 
past.  The rationale for dealing with the present is to tackle current problems and what is 
maintaining them.  However, it may be necessary to work at a deeper level if the patient’s 
problems affecting the present are rooted in past events or experiences.  In such cases expe-
riences, beliefs, values and precipitating events would be explored and addressed. 
Treatment is generally described as brief therapy, typically involving up to six sessions (brief 
intervention).  However, longer therapy sessions may be needed and up to 20 sessions may 
be provided (high intensity intervention).  CBT is structured and collaborative.  Patents are 
experts in what they are experiencing and therapists can help guide the patient to identify 
their problems and CBT techniques that might be helpful to them.  A cornerstone of cogni-
tive therapy is a technique called ‘socratic’ questioning.  Socratic questioning encourages pa-
tients to build on their problems, strengths, identify important goals for them and develop 
their own ideas or solutions to their problems.  This technique is different to the traditional 
questioning style used by many healthcare professionals who engage in ‘advice giving’.  A 
gifted therapist can make this look deceptively easy but it is a great skill. Therapists tend to 
develop their own repertoire of questions that have been beneficial in clinical practice.    
Whilst CBT will certainly not cure an individual’s medical condition, it may well be a means of 
helping manage comorbidities such as anxiety and depression.  Importantly, it may also in-
fluence physical symptoms such as breathlessness  (128).  Patients may be reluctant to 
change their behaviour to avoid the unpleasant feeling they experience when they become 
breathless.  In such circumstances,   the patient may lack confidence because they fear the 
consequences (what if I get breathless), they have had previous experience of failure (I al-
ways get breathless when I do anything), or because their emotional state (i.e. depressed, 
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anxious or stressed)   Techniques that can improve patients’ knowledge or skills (mastery) to 
be able to cope may help them take small steps to overcome obstacles to behavioural 
change (129) and support the potential role of cognitive and behavioural approaches.   
Measuring progress is an important aspect of CBT therapy.  A number of methods are used 
ranging from psychometric questionnaires, Likert scales and diaries.  The ultimate aim of 
therapy is to enable patients to learn useful skills to manage their own difficulties.  There are 
numerous cognitive and behavioural techniques.    These techniques will be discussed in 
Chapter 4 when the CBT model for COPD patients is discussed. 
2.8 Psychological Therapy in the physical health setting 
It is argued that people with long term physical health conditions and mental health needs 
often receive fragmented care.  Health and social care services are not currently organised 
to provide an integrated response to dual physical and mental health needs (77).  Naylor 
suggests that the institutional and professional separation of care leads to missed opportuni-
ties to improve the quality and efficiency of care (77).  Increasing specialisation and the de-
cline of generalism in hospital settings can create a lack of co-ordination and oversight of pa-
tients’ multiple needs (130).  The government’s mental health strategy ‘No Health Without 
Mental Health’ places considerable emphasis on the connections between mental and physi-
cal health (77).  The King’s Fund has previously argued that developing more integrated 
forms of care for people with co-morbid mental and physical health problems should be one 
of the top ten priorities for clinical commissioning groups  (131).   
Over the last ten to fifteen years the delivery of psychological care in the physical health set-
ting has changed considerably.  In particular, cancer services have made significant steps to 
improve psychological care for cancer patients.  In 2004 the National Institute for Clinical Ex-
cellence published excellent guidance for Cancer Services to improve supportive and pallia-
tive care for adults with cancer (132).  A four-level model of professional psychological as-
sessment and intervention was recommended (see table 8).    Psychological support at levels 
one and two are provided by health professionals directly responsible for the care of people 
with cancer.  More severe psychological distress (levels three and four) should be managed 
by a variety of specialists included counsellors, nurses, psychologists, psychotherapists and 
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liaison psychiatrists (132).  It was recommended that staff providing psychological care were 
adequately trained and supervised.   
Table 8– Recommended model of professional psychological assessment and support from NICE.  
Improving supportive and palliative care for adults with cancer (132). 
 
Level  Group Assessment Intervention 
1 All health and social care 
professionals. 
Recognition of psychological 
needs.   
Effective information giving, compas-
sionate communication and general 
psychological support. 
2 Health and social care pro-
fessionals with additional 
expertise. 
Screening for psychological 
distress. 
Psychological techniques such as prob-
lem solving. 
3 Trained and accredited 
professionals. 
Assess for psychological dis-
tress and diagnosis of some 
psychopathology. 
Counselling and specific psychological 
interventions such as anxiety manage-
ment and solution-focused therapy, 
delivered according to explicit theoret-
ical framework. 
4 Mental health specialists. Diagnosis of psychopathol-
ogy. 
Specialist psychological and psychiatric 
interventions such as CBT. 
 
In 2007 The Improving Access to Psychological Therapy (IAPT) programme was launched in 
the UK.  This programme was a large scale initiative which focuses on delivering psychologi-
cal therapy for adults with a particular emphasis on depression and anxiety disorders within 
the English NHS (133).   The overall purpose of IAPT is to implement NICE Guidance for the 
treatment of anxiety and depression.  The evidence in NICE Guidance prioritised CBT as it is 
the therapy with the widest application for anxiety and depression and the most evidence 
supporting its effectiveness (134). NICE systematically reviewed the evidence for the effec-
tiveness of a variety of interventions for depression and anxiety disorders which led to the 
publication of a series of clinical guidelines (133).  Other therapies (interpersonal psycho-
therapy, behavioural couple’s therapy, counselling and brief dynamic therapy) is recom-
mended for depression but not anxiety (133). 
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The IAPT model of care for the delivery of CBT interventions is ‘stepped care’ in line with 
Nice Guidelines (134).  Stepped care means assisted self-help or signposting being the focus 
at step two and face to face therapy at step three (133).  Patients may be offered the least 
intrusive, most effective intervention first such as low intensity therapy. For some patients 
low intensity interventions such as guided self-help delivered through books and leaflets, 
structured exercise, computerised forms of CBT or brief face to face interventions can help 
patients retain a sense of self-worth when working with a professional trained in CBT skills 
(134).  For patients with long standing or severe symptoms face to face high intensity inter-
ventions delivered by a specialist practitioner may be more appropriate.  Practitioners 
providing  step two treatment are typically NHS band four to five staff and band six or seven 
for staff providing high intensity therapy (135). However, even with the introduction of IAPT 
it has been recommended that ways of embracing the use of psychological therapies should 
be developed for physical health conditions than its current medical and diagnostically based 
approach (135).   
2.9 Summary 
It is well known that COPD is a serious illness with physical and psychological effects. Whilst 
guidelines on COPD recognise the psychological impact of COPD, there has been little re-
search beyond prevalence studies.  It is now widely accepted that anxiety and depression are 
common comorbidities experienced by patients with COPD.   Unfortunately, many patients 
will not benefit from the treatments recommended in the guidelines suggested above as 
their symptoms may not even be identified in the first place (79).  There is a significant op-
portunity to explore the use of cognitive and behavior strategies to address anxiety and de-
pression and new ways to deliver CBT within the National Health Service.  Complex psycho-
logical interventions such as CBT may well be effective in treating debilitating comorbidities 
such as anxiety and depression.   
Identifying symptoms of anxiety and depression is a key step to providing appropriate sup-
port and treatment.  CBT is a psychological intervention which is recommended for the 
treatment of many mental health problems including anxiety and depression (111).  Firstly, 
CBT is a treatment that helps develop an understanding of the patient’s current problems 
and explore the patient’s thoughts and behaviour to deal with the difficulties.  Secondly, 
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having a clearer understanding of problems can then lead to identifying ways to overcome 
these difficulties and identify strategies that can help improve the patient’s QOL.   Thirdly, 
many cognitive and behavioural techniques could potentially enhance medical care to man-
age difficult symptoms such as breathlessness e.g. behavioural techniques such as planning 
and pacing activities can help breathlessness alongside inhaled therapy.  CBT is evidence 
based psychological ‘talking’ treatment, which explores the links between situations 
thoughts, feelings, physical symptoms and behaviour.  By developing new skills, patients can 
then become their own therapist and use the techniques they have learnt in similar situa-
tions. This empowers patients and is thus a good fit with the move towards greater inclusion 
of patients in their care and supporting self-management.   
With the increasing awareness of psychological issues in long term conditions and the scale 
of the problem facing COPD patients it is becoming increasingly difficult to ignore the fact 
that CBT is a potentially useful treatment for COPD patients in improving symptoms of anxi-
ety, depression and improving self-management of the condition.  New ways of addressing 
physical and mental health needs are needed as current  health and social services in Eng-
land are not currently organised in a way which supports an integral response to the physical 
and mental health needs of patients (77).   The next chapter presents a literature review un-
dertaken to identify the effectiveness of psychological interventions in COPD. 
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Chapter 3 - Literature Review 
A comprehensive literature review was undertaken to identify previous research on the use 
of psychological based therapy in the management of anxiety and depression in the COPD 
population.  The initial search in 2011 has been updated in preparation for this thesis and all 
relevant papers are discussed in this chapter.  The chapter begins with details on the litera-
ture search strategy.  A critique of the literature from the 1980’s to the current date follows 
and important recommendations for future research are identified in section 3.3.  The chap-
ter concludes with a final summary. 
3.1 Literature Search Strategy 
At the start of this PhD I attended seminars on conducting robust literature searches before 
developing my research strategy.  An initial search of health and psychology databases iden-
tified a prior systematic review and meta-analysis of the efficacy of psychologically based in-
terventions to improve anxiety, depression and QOL (136).  The review analysed published 
research from 1983 to September 2009. The authors were contacted to gain permission to 
use the terms to extend their literature review from 2009. I then used these search terms to 
undertake the initial literature search.    I also consulted with a senior librarian to check the 
search strategy for robustness and no amendments to the search terms were deemed nec-
essary.   
3.1.1 Literature review Search terms 
A wide range of free-text terms for each of the concepts were selected in order to be as 
comprehensive as possible.  Synonyms were identified.  Truncation was used for variations 
of words e.g. Anxi* which would capture anxiety or anxious.  Controlled vocabulary terms, 
text words, synonyms and related terms for each concept at a time were joined  together  
with the Boolean ‘OR’ operator.  Search terms were formulated using population, interven-
tion, and comparison and outcome format (Table 9). 
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Table 9 – Literature review search terms. 
Population Intervention Comparison Outcome 
COPD 
COAD 
Chronic obstructive pulmonary 
disease 
Chronic obstructive airways 
disease 
Chronic bronchitis 
Emphysema 
Respiratory disease 
Depress* 
Anxi* 
Panic 
Cognitive behavioural therapy 
Cognitive behave* therapy 
CBT 
Psychotherapy 
Stress management 
Relax* 
Psychological intervention 
Education 
Usual Care 
Anxiety 
Depression 
Health related quality 
of life (HRQOL) 
Quality of Life (QOL) 
 
For the purpose of this review the working definition of ‘psychological intervention’ was 
studies which aimed to address and modify cognitions, behaviour and mood in order to re-
duce symptoms of anxiety and depression. 
3.1.2 Language  
The search was limited to English language. 
3.1.3 Databases 
Databases can be searched using standardised subject terms assigned by indexers. Standard-
ised subject terms (as part of a controlled vocabulary or thesaurus) are useful because they 
provide a way of retrieving articles that may use different words to describe the same con-
cept.  Each database was searched separately depending on the terms used within thesau-
rus/sub headings or mesh.  Databases searched can be found in table 10.   
Table 10 – Databases used for literature search. 
Medline (medical studies) 
Psychinfo (psychological studies) 
Web of Science 
Cinahl and BNI (nursing studies) 
Cochrane Central Register of Controlled Trials (CENTRAL) 
Google Scholar 
AMED 
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3.1.4 Search Results 
The results of the Medline search has been included in this thesis as an example of the 
search strategy results. 
 
The abstracts from the papers identified from database searches were reviewed to identify 
pertinent papers.  From all of the studies identified from electronic and hand searches 16 pa-
pers were included in this review and a number of methodological factors were assessed for 
quality.   
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3.1.5 Alerts 
The search strategy was saved and an alerts system was set up to capture newly published 
papers.  This strategy proved to be successful as one paper was found from a google scholar 
alert.  Alerts also identify abstracts from conferences and can highlight important develop-
ments in the field early. 
3.1.6 Reference lists 
Once relevant articles were identified reference lists were checked for additional papers. 
3.1.7 Author contact 
Authors of published research in the field were contacted and asked if they had any other 
current research that could be included in the review.  No further unpublished research was 
identified. 
3.1.8 Literature searches 
A search was undertaken from September 2009 to February 2012 to capture any studies 
published after the systematic review by Baraniak and Sheffield (136).  Dr. De Soyza and I in-
dependently reviewed the abstracts and met to confirm agreement of the inclusion or exclu-
sion of abstracts.  Papers were obtained if it was not clear from the abstract if the paper 
should be included. Five new papers were identified which had been published after 2009. 
To ensure the literature search was as up to date as possible, a further search was repeated 
in September 2015.  A  systematic review was conducted by Coventry et al on the effect of 
complex psychological or lifestyle interventions for depression and anxiety in COPD had 
been published (137).   The authors concluded that complex interventions that include an 
exercise component significantly improve symptoms of depression and anxiety in people 
with COPD and highlighted the importance of promotion physical activity in this population  
(137).  However the effect of physical activity was less for anxiety than depression (137).   
The last systematic review to date was published  in 2014 (4) and two papers had been pub-
lished (138, 139). Table 11 shows the studies identified in each systematic review.    In total 
16 papers including psychological interventions were identified. 
In addition, Dr De Soyza and I were invited to assist in a Cochrane Review of psychological 
interventions for the treatment of anxiety in COPD.  The protocol for the review has since 
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been published (140).  For the Cochrane review I screened over 500 abstracts and  no studies 
were identified that had not been included in this systematic review confirming that the lit-
erature search  strategy used for this PhD was robust.  A summary of the papers included in 
the five systematic reviews can be found in table 11. 
Table 11 – Summary of papers included in five systematic reviews on psychological interventions 
for anxiety and depression in COPD. 
Study Rose et 
al,2002 
(129) 
Coventry 
and Gel-
latly,2008 
(141) 
Baraniak 
and Shef-
field, 2011 
(136) 
Coventry 
et al, 2013 
(137) 
Smith et 
al, 2014 
(4) 
Heslop-
Marshall, 
2015 
Howard & Dupont, 2014 
(139) 
     √ 
Jiang & He, 2012 (138)     √ √ 
Hynninen, 2010 (142)    √ √ √ 
Cully, 2010 (143)      √ 
Lamers, 2010 (144)    √ √ √ 
Howard, 2010 (145)      √ 
Livermore, 2010 (101)    √ √ √ 
Heslop, 2009 (146)   √   √ 
De Godoy, 2003 (147)  √ √ √ √ √ 
Kunik, 2008 (148)   √ √ √ √ 
Kunik, 2001 (149)  √ √ √ √ √ 
Emery, 1998 (150) √ √ √ √  √ 
Eiser,1997 (151)  √ √   √ 
Lisansky and Clough, 1996 
(152) 
  √   √ 
Gift et al, 1992  (153) √  √ √  √ 
Rosser, 1983 (154) √  √   √ 
 
3.1.8 Data Extraction 
Data was extracted from the papers using standardised data extraction sheets from The 
Cochrane Collaboration. 
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3.2 Critique of Literature 
Over the past 35 years there has been a slow and steady development of psychological re-
search in patients with COPD (155).  Previously, psychoanalysis was the dominant psycholog-
ical approach (155).  Psychological factors were viewed as the primary causes of physical 
symptomatology in diseases such as asthma.  COPD tended to be an exception, most notably 
because smoking was clearly seen as a non-psychological determinant of the disease (155). 
The psychoanalytical approach aimed to help professionals understand and help their pa-
tients in managing their illness (155).  However, over time the psychoanalytic approach was 
criticised for being over reliant on subjective clinical judgment and speculation (155). Re-
searchers also sought to establish whether COPD could be linked to psychological personal-
ity states and traits rather than deep psychic conflicts (155).  Traits such as hypersensitivity, 
marked passivity and emotional immaturity were identified (156).   In 1977, other research-
ers explored the psychosocial consequences of COPD and found ‘disturbingly high preva-
lence of anxiety, depression, alcoholism, sexual dysfunction, and various psychiatric psycho-
pathologies (e.g. paranoid states)’ (157).   
In the 1980’s there were several developments in psychological research.   Psychologists spe-
cialising in neuropsychology collaborated with respiratory physicians and psychiatrists to in-
vestigate whether the chronic and progressive airway obstruction seen in COPD causes hy-
poxaemia and affects cognitive function (155).  Researchers established how COPD could 
lead to neuropsychological impairments (158).  It is argued that cognitive impairment may 
compromise patients’ capacity to engage with medical advice so this may be an important 
consideration (155).  Clinicians also began to recognise that there was a disparity between 
objective measurements of treatment effects and subjective measures reported by patients 
so began to focus on QOL (155).  Standardised questionnaires such as the Chronic Respira-
tory Disease Questionnaire (CRQ) (159) and St Georges’s Respiratory Questionnaire (SGRQ) 
were developed to assess QOL (160).  This was an important change as  ‘QOL’  was seen as a 
‘soft’, ‘subjective’ secondary outcome measure (155).  
Researchers also began to focus on illness behaviour and experiences.  The Bronchitis and 
Emphysema Symptom Checklist was developed and used to assess symptoms, attitudes, per-
sonality factors and clinical characteristics (161).  The investigation of such variables has led  
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researchers to consider how psychological and behavioural factors maintain and increase 
both perceived severity and medical intractability of the illness once it has already devel-
oped (155).  Kaptein suggests that interventions designed to modify illness behaviour may 
exert an impact on outcome variables (155).   Researchers also explored the role of patient 
education as a potential intervention that could help modify behaviour.  The results sug-
gested that patient education has a minor effect on health perception (i.e. locus of control) 
but no significant gains in terms of physical function, mental health or social function (162). 
3.2.1 Research in the 1980’s 
The first serious discussions and analysis of psychological treatment for COPD were pub-
lished in the early eighties (154).  The first study was undertaken in the UK and investigated 
the use of psychotherapy for psychiatric comorbidity in COPD patients who were disabled by 
breathlessness.  The authors rightly identified that breathlessness is a common, distressing 
and frequently untreated symptom from a psychological perspective (154).   This is certainly 
still the case thirty years later.   Details of the study characteristics can be found in table 12.   
Table 12 – Main characteristics of the study published in the 1980’s. 
Author/ 
Country 
Study Design and 
sampling 
Number of  
patients 
Intervention Compara-
tor 
Characteristics of  
participants and follow 
–up 
Psychological  
outcomes and 
measures 
Rosser 
et al, 
1983 
(154) 
UK 
Randomised Trial 
 
Recruited from 
patients attend-
ing clinic 
 
Blinding not re-
ported 
65 total: 
 
16 -analytic 
or support-
ive psycho-
therapy 
 
16- Nurse 
support  
 
16- Control 
(weekly lab 
tests) 
8 sessions 
Weekly 
45 minute  
For analytic or 
supportive psy-
chotherapy or 
 
Nurse adminis-
tered sessions 
(practicalities 
of living with 
COPD) 
Weekly 
lab tests 
Mean age 66 
68% male 
Mild-severe COPD 
Mean FEV1 0.9 
Anxiety (GHQ and 
VAS) 
Depression (GHQ 
and VAS) 
 
HSRS 
Abbreviations: General Health Questionnaire (GHQ), Health sickness rating scale (HSRS), Visual Analogue Scale (VAS). 
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As with many studies of complex interventions, it is unclear from the paper exactly what the 
therapy entailed.    It states that three types of psychotherapy were used and only two 
groups of psychotherapy could be identified (supportive psychotherapy and analytic psycho-
therapy).  One group was seen by a nurse ‘without any psychotherapy training’ and sessions 
included management of ‘practical realities in patients’ lives.  It is unclear that this would be 
classified as psychotherapy.  Furthermore, it would certainly be difficult to replicate this 
study from the details provided in the paper.  The results are also confusing and no firm con-
clusions can be made.  However, one useful point identified in the paper is that the authors 
did suggest that ‘nurse therapists would have an advantage of being cheap’.  The authors 
also commented that patients had not sought psychological help so this was a limitation of 
their study. Indeed, in clinical practice most patients with COPD do not actively seek help for 
symptoms of anxiety and depression. 
3.2.2 Research in the 1990’s 
Research into the efficacy of psychological interventions into anxiety and depression in 
COPD patients continued to grow in the 1990’s.  Four studies were published.  The main 
characteristics of the studies can be found in table 13.   Three studies involved CBT and one 
used progressive muscle relaxation (often used by CBT therapists to aid relaxation). Two 
studies were RCT’s (150, 153).  Gift et al (1992) conducted a small RCT on the effectiveness 
of progressive muscle relaxation (153).  The results reported that the use of relaxation tech-
niques decreased anxiety, dyspnoea and ‘airway obstruction’ (153).  The authors concluded 
that relaxation techniques needed to be tested on a larger sample of COPD patients (153).   
In 1997, Eiser et al conducted a small pilot study consisting of a six week course of group 
CBT.  The authors suggest the intervention produced a modest improvement in exercise tol-
erance in anxious and breathless patients with moderate to severe COPD, without alleviating 
their anxiety or improving their QOL (151).  However, there was a high risk of bias in this 
study (see Table 15).  
In 1996, Lisansky and Clough investigated the effectiveness of an eight week self-help educa-
tional program for patients in a very small study (152).  The authors suggest a positive treat-
ment response but acknowledged that additional studies were warranted for more intensive 
evaluations.  The findings of this study need to be viewed with caution as there was a high 
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risk of bias when assessed. The final study published in 1998 was Emery’s study which was 
the largest with 75 patients in total (150).  Exercise, education and stress management were 
the interventions assessed in this study.  The authors found that the education and stress 
management group experienced decreased symptomatology as a result of social support 
and better knowledge of the disease process (150).  Interestingly, the authors state that 
greater knowledge may have been associated with increased distress in the education and 
stress management group.  The results indicate that minimum psychological changes were 
observed among patients in the exercise only group.  This study also has a high risk of bias 
(see Table 15).   
A major limitation of studies into psychological interventions in COPD is the fact that there 
was a lack of high quality research up to the end of the 1990’s.  Trials were small and none of 
the studies had a power calculation.   
Table 13– Main characteristics of studies published in the 1990’s. 
Author/ 
Country 
Study Design 
and 
Sampling 
Number of  
patients 
Intervention Compara-
tor 
Characteristics of  
participants and fol-
low –up 
Psychological  
outcomes and 
measures 
Emery 
et al, 
1998 
(150) 
 
USA 
RCT 
Recruited from 
local better 
breathing clubs, 
advertising (TV 
and papers), 
work of mouth 
and physician re-
ferral 
79 total: 
3 groups:- 
 
29 -  exer-
cise, educa-
tion and 
stress man-
agement 
(EXESM) 
 
25 - Educa-
tion and 
stress man-
agement 
(ESM) 
 
25 - Control 
1 week course 
of 16 educa-
tion sessions & 
and 10 stress 
management 
classes over 10 
week course. 
 
One group re-
ceived 37 ses-
sions of exer-
cise in addition 
to above. 
Waiting list 
controls 
Mean age 66.6 
53% female 
FEV1/FVC <70% 
Clinical symptoms of 
COPD >6 months 
Anxiety (STAI; SCL 
subscale) 
Depression (CES-D 
affect-balance 
scale; SCL-90 de-
pression subscale) 
QOL (SIP) 
Eiser et 
al, 1997 
(154) 
 
UK 
Controlled Trial 
Recruited from 
hospital outpa-
tients 
18 total: 
 
12 Group 
CBT * 
  
8 Matched 
controls 
6 x 90 minute 
sessions of 
Group CBT 
 
Delivered by 
psychiatrist 
Control 
group re-
ceived no 
treatment 
Mean age 72 
55% female 
Moderate –severe 
COPD 
Anxiety (HADS) 
QOL (MRCQ) 
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*(2 patients 
dropped 
out) 
(replaced after 
3 sessions) 
Pre-trial HADS score 
higher in CBT group 
than controls. 
Lisansky 
& 
Clough, 
1996 
(152) 
USA 
Quasi-experi-
mental Study 
Pre-post test 
 
No information 
on patient re-
cruitment 
8 total: CBT 
 
13 initially 
(5 dropped 
out) 
 
8 weekly 90 
minute ses-
sions of 45 
minutes edu-
cation, 15 min 
break followed 
by group CBT.  
 
Not specified 
who delivered 
treatment 
No  
comparator 
Mean age 69.5 
Mean FEV1/FVC ra-
tio only (0.68) 
62.5% female 
20% Hispanic 
80% Anglo 
Moderate – severe 
COPD 
Anxiety (KSQ) 
Disability (SIP) 
Cognitions (COPD-
CEQ) 
Gift et 
al, 1992 
(153) 
USA 
RCT 
 
Recruited from 
patient list of 3 
private physi-
cians 
26 Total: 
 
13 PMR 
13 Controls 
4 weekly ses-
sions of pro-
gressive mus-
cle relaxation. 
 
Delivered by  
Venue: physi-
cian’s office 
Control – 
sat quietly 
in room for 
same time 
Venue: 
physician’s 
office 
Mean age 67 
69.2% female 
100% Caucasian 
Confirmed COPD by 
spirometry  
Anxiety (STAI) 
Abbreviations: Centre for Epidemiologic Studies -Depression (CES-D), COPD- Cognitive Error Scale (COPD-CEQ), Hospital 
Anxiety and Depression Scale (HADS), Kellner’s Symptoms Questionnaire (KSQ), Medical Research Council Questionnaire 
(MRCQ), Symptom Check List (SCL), Sickness Impact Profile (SIP), State Trait Anxiety Inventory (STAI). 
3.2.3 Research in the 2000’s 
Research grew at a significant pace in the 2000’s with the publication of 11 studies.  The ma-
jority of the studies were RCTs or controlled trials (CTs).  CBT was used in all 11 studies.  
Characteristics of the studies can be found in table 14.  From all of the studies published so 
far the format varied between individual treatment (101, 144, 146, 153) group therapy (142, 
145, 148, 149, 150-152) and in the most recent trials CBT self-help manuals have been used 
(with booster sessions organised by telephone) (138, 139). It is not clear from two papers if 
the intervention was individual or group therapy (147, 154). 
The first study published in 2001 investigated the effect of a two hour single session of CBT 
on anxiety, depression, QOL and satisfaction with treatment (149).  The results demon-
strated that anxiety and depression decreased with the brief intervention but there was no 
change in physical functioning of the patients (149).    De Godoy et al then published a study 
of pulmonary rehabilitation with 10 psychotherapy sessions (147).  The paper contained an 
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extremely vague description of ‘CBT and logotherapy’ to the extent it is unclear what the in-
tervention entailed.  This will be discussed in further detail in section 3.3.  In addition, the 
sample size was small and the control group improved more than the treatment group.  This 
is not surprising as it appeared that the control group did in fact receive information on ‘cop-
ing with illness’ which appeared to include CBT techniques which may have affected the out-
come of the study.  Finally, the study was also assessed as high risk of bias (see Table 15). 
In 2008, Kunik et al completed a further study involving group CBT and COPD education 
(148).  The results suggested improvements in QOL for COPD patients.  However, the study 
was deemed high risk of bias (see Table 15).  In 2009, a small case series was published in-
volving 10 patients with CBT (146). This study was the first to use respiratory nurses to de-
liver the CBT intervention which showed potential.   The study has a high risk of bias (see Ta-
ble 15).  The author concluded that further evaluation of CBT delivered by respiratory nurses 
was needed (146).  As part of a PhD, Lamer’s (2010) investigated the use of a CBT minimal 
psychological intervention for elderly patients with COPD (144).  The main focus for the 
study was depression, but data on anxiety was collected.  The study was of higher quality 
than previous studies and the results suggest the brief nurse led intervention in the patients’ 
home, reduced depressive symptoms and anxiety in elderly patients with minor to moderate 
depression.  It was concluded that adding the minimal psychological intervention to stand-
ard care is likely to improve the care for elderly COPD patients (144). 
An Australian study used another brief CBT intervention specifically to treat panic attacks 
and prevent the development of panic spectrum psychopathology and anxiety symptoms 
(101).  As with many studies, anxiety was not an entry criteria for the study.   The authors 
found a decrease in hospital admissions following the intervention but suggested that larger 
scale trials were needed to supplement the findings of their study. Another small study of 
group CBT was published in 2010 (142).   The authors investigated an intervention consisting 
of seven weekly sessions lasting two hours.  The paper was very well presented and evalu-
ated well when assessed for bias.  There was a significant reduction in symptoms of anxiety 
and depression and the authors concluded that the results underline the need for integrat-
ing mental healthcare into the overall medical regime for COPD (142).   
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A further paper from the USA was published in 2010 (143).  The study was a very small ‘open 
trial’ of poor quality.  There was no comparison group in the study.  The findings were that 
further research is needed and suggested that highly trained CBT therapists may not be re-
quired to improve patient outcomes.  In 2010, an interventional controlled study of group 
CBT  was published (145).  The results suggested that the intervention had potential and a 
future RCT was planned.  The definitive RCT followed in 2014 using a CBT self-help manual.  
The trial was the largest study to be undertaken to date and suggested that the manual im-
proved self-management and reduced costs to the NHS.  The authors concluded the treat-
ment should be considered as an option for the majority of patients as a preventative meas-
ure and develop coping strategies (139).   
The first study from China was published in 2012.  This study used CBT to address uncer-
tainty, anxiety, depression and QOL.  As with many of the other studies the paper was as-
sessed as high risk of bias (see Table 15).  The study suggests that uncertainty management 
can improve emotional status but further studies were needed.   Despite the fact the inter-
vention lasted 10 months the authors suggested a longer intervention may be beneficial. A 
summary of the main characteristics of studies published in the 2000’s can be found in table 
14. 
Table 14 – Main characteristics of the studies published in the 2000’s. 
Author/ 
Country 
Study Design and 
sampling 
Number of  
patients 
Intervention Compara-
tor 
Characteristics of  
participants and fol-
low -up 
Psychological  
outcomes and 
measures 
Howard 
and 
Dupont, 
2014 
(145) 
UK 
RCT 
 
Recruited from 10 
GP practices and in-
vited to participate. 
Computer block ran-
domisation. 
222 total 
112 CBT 
110 Con-
trol 
CBT Breath-
lessness man-
ual with two 
telephone 
booster ses-
sions plus 
Relaxation CD 
British 
Lung 
Founda-
tion infor-
mation 
booklets. 
Mean age – 72.2 
52% Females 
FEV1/FVC ratio 
 
Anxiety (HADS) 
Depression (HADS) 
HRQOL (CRQ-5R) 
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Jiang 
and He, 
2012 
(138) 
China 
RCT 
Recruited from hos-
pital outpatients. 
 
 
99 Total: 
 
50 CBT 
49 Con-
trol 
CBT uncer-
tainty manage-
ment using  
Self-Help Man-
ual and audio 
CD. Weekly tel-
ephone calls 
for 4 weeks 
then monthly 
calls for 10 
months 
Usual 
Care 
Mean age 65 
63% Males 
 
 
Anxiety (SSAI and 
STAI) 
Depression (HADS) 
QOL (SF-36) 
Lamer’s 
et al, 
2010 
(144) 
Holland 
RCT (anxiety was 
secondary outcome) 
 
Recruited from 89 
general practices 
 
Computerised Block 
randomisation 
187 Total: 
 
96 CBT in-
terven-
tion (only 
71 pa-
tients re-
ceived in-
terven-
tion). 
  
91 usual 
care 
Minimal Psy-
chological In-
tervention 
(MPI)  
2-10 individu-
alised visits 
over 3 months 
 
Nurse adminis-
tered with psy-
chiatric/GP 
support 
Usual 
care 
Mean age 71 years 
60% Males 
No details of lung 
function given  
Mild- moderate 
depression (anxi-
ety not stated) 
Follow up varied - 
1 week, 3 and 9 
months after in-
tervention 
Control group – 6 
weeks 
Anxiety (SCL) 
Depression (BDI) 
HRQOL (SGRQ) 
Liver-
more et 
all, 2010 
(101) 
Australia 
RCT 
Recruited from out-
patient clinics (con-
secutive patients 
who met criteria) or 
in-patients invited 
to participate.  Pa-
tients volunteered 
for the study. 
Excel computer 
package was used to 
generate a random 
sequence of num-
bers. 
41 total: 
21 CBT 
20 usual 
care 
4 individual-
ised  hour long  
sessions of CBT 
following PR 
 
Administered 
by psycholo-
gist. 
 
Patient manual 
used. 
Routine 
care fol-
lowing  
PR 
Mean age 73.2 
56% Females 
FEV1/FVC ratio 
<70% 
FEV1 <60% 
Moderate – severe 
COPD 
 
Follow up at 6, 12 
and 18 months 
Anxiety (HADS) 
Depression (HADS) 
Panic attacks and 
panic disorder 
(ADIS-IV) 
HRQOL (SGRQ) 
Illness specific cat-
astrophic cogni-
tions (IPBQ) 
Howard 
et al, 
2010 
(145) 
UK 
Interventional con-
trol study 
48 total 4 weekly 2 
hours Group 
with a carer 
(average 6 par-
ticipants per 
group) CBT 
sessions.  Pa-
tients received 
a handbook 
and relaxation 
tape. 
A 6 week tele-
phone follow-
Patients 
were own 
controls 
(from ret-
rospec-
tive data) 
Mean age 71 
60% males 
54% were married 
85% ex-smokers 
Average pack 39 
pack years 
Mean FEV1 % was 
33% 
No record of 
FEV1/FVC ratio 
33% have long 
term oxygen  
Therapy (LTOT) 
Anxiety (HADS) 
HRQOL (SGRQ) 
Hospital admis-
sions 
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up was under-
taken. 
Follow up 4 weeks 
and 10 weeks 
Hynnine
n et al, 
2010 
(142) 
Norway 
RCT 
 
Recruitment from 
outpatient pulmo-
nary clinic and by 
newspaper advert 
 
Randomisation by 
matched pairs (ac-
cording to their 
FEV1 predicted), 
one participant was 
randomly assigned 
to CBT. 
51 total: 
 
25 CBT 
26 stand-
ard care 
7 weekly 2 
hour group 
session at uni-
versity outpa-
tient clinic 5 
patients on av-
erage). 
Phone follow-
up.  
 
 
Administered 
by Masters-
level psychol-
ogy student. 
Standard 
care with 
5-10 mi-
nute tele-
phone 
contact 
every 2 
weeks. 
Mean age 61 
51% female 
FEV1/FVC ratio 
<70% 
FEV1 % predicted 
<80% 
Mean education 
years 12.1 
25% current smok-
ers 
Follow up 2 and 8 
months from 
baseline. 
Anxiety (BAI) 
Depression (BDI-II) 
HRQOL (SGRQ) 
Sleep Quality 
(PSQI) 
Cully et 
al, 2010  
(143) 
USA 
Open trial 
 
CHF and COPD pa-
tients 
recruited from elec-
tronic medical rec-
ords (10 COPD, 6 
CHF and 7 both) 
23 CBT 
 
6 x 50 minute 
sessions of CBT 
(ACCESS). 2 
face to face 
sessions fol-
lowed by 4 
core modules 
either face to 
face or tele-
phone. 
Administered 
by 5 providers 
advanced psy-
chology train-
ees) 
No com-
parison 
Mean age 
100% male 
 
Follow up at 8 
weeks and 3 
month 
Anxiety (STAI-
Trait) 
Depression (BDI-II) 
HRQOL (CRQ) 
Heslop 
et al, 
2009 
(146) 
UK 
Pre-Post observa-
tional study.   
 
Recruited from hos-
pital out-patients 
clinic. 
10 CBT CBT 2-6 indi-
vidual sessions 
depending on 
need. 
No com-
parator 
Mean age 
80% severe COPD 
10% Moderate 
10% Mild 
Anxiety (HADS-A) 
Depression (HADS-
D) 
Hospital Admis-
sions 
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Kunik et 
al, 2008 
(148) 
USA 
 
RCT (single blind) 
Recruited from vet-
erans hospital and 
advertising 
238 total: 
120 edu-
cation 
118 CBT 
CBT 8 x 1 
hourly sessions 
per week 
 
Delivered by 
psychological 
interns and 
post-doctoral 
fellows 
Group 
COPD ed-
ucation 
8 sessions 
(1 hour) 
 
Delivered 
by psy-
chological 
interns 
and post-
doctoral 
fellows 
Mean age 66.3 
96.2% males 
81% Caucasian 
FEV1/FVC ratio 
<70% 
FEV1 <70% 
Moderate anxiety 
or depression 
Follow-up 4,8 and 
12 months 
48% attrition rate 
Anxiety (BAI) 
Depression (BDI) 
HRQOL (CRQ) 
QOL (SF-36) 
De Go-
doy et 
al, 2003 
(147) 
Brazil 
RCT (single blind) 
Consecutive pa-
tients attending out-
patients referred for 
PR 
30 total: 
14 PR and 
psycho-
therapy 
 
16 PR 
only 
12 week PR  
programme: 
24 sessions of 
physical exer-
cise, physio-
therapy; 12  
psychological 
sessions *does 
not state if 
group or indi-
vidual sessions 
(Cognitive & 
logotherapy) 
and 3 educa-
tional sessions. 
 
Delivered by 
psychologist 
12 week 
PR pro-
gramme: 
24 ses-
sions of 
physical 
exercise, 
physio-
therapy & 
3 educa-
tional ses-
sions only 
 
 
 
Mean age 60.33 
73% Male 
FEV1/FVC ratio not 
stated 
Mild-moderate 
anxiety and de-
pression 
 
 
 
Follow-up 3 
months 
Anxiety (BAI) 
Depression (BDI) 
HRQOL (SGRQ) 
Kunik et 
al, 2001 
(149) 
USA 
RCT (single blind) 
Recruited from vet-
erans hospital and 
advertising 
48 total: 
24 CBT 
29 educa-
tion 
Single 2 hour 
Group  CBT (6-
10) 
6 weekly 
phone call 
Delivered gero-
psychiatrist 
Group Ed-
ucation 
and 6 
weekly 
phone 
calls 
 
Delivered 
by intern-
ist 
Mean age 71.3 
83% male 
90% Caucasian 
FEV1/FVC <70% 
Mild anxiety and 
depression 
Follow-up 3 
months 
Anxiety (BAI) 
Depression (GDS) 
QOL (SF-36) 
Abbreviations: Anxiety Disorder Interview Schedule (ADIS-IV), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Chronic Res-
piratory Questionnaire (CRQ), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), Illness Specific Catastrophic 
Cognitions (IPBQ), Pittsburgh Sleep Quality Index (PSQI), Pulmonary Rehabilitation, Symptom Checklist (SCL), Short-Form 36 (SF-36) ST 
Georges Respiratory Questionnaire (SGRQ), Short State Anxiety Inventory (SSAI), State Trait Anxiety Inventory (STAI). 
3.2.4 Relevant Systematic Reviews 
In 2002 the first systematic review of the efficacy of psychological treatment to reduce anxi-
ety and panic in patients with COPD was published (129).   Systematic reviews aim to iden-
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tify, evaluate and summarise the findings of all relevant studies.  However, flaws in the de-
sign of the review can introduce bias (163).   A limitation of the review by Rose et al (2002) is 
the inclusion of the term ‘pulmonary rehabilitation’ in their search strategy (129).  Pulmo-
nary rehabilitation is a very important exercise based intervention rather than a psychologi-
cal intervention.  Whilst the benefits may well affect psychological well- being, its primary 
focus is improving exercise capacity. There were many articles on the topic of pulmonary re-
habilitation which were not included in their review. In addition, several papers of psycho-
logical interventions in COPD were missed and could have been included e.g. Emery et al 
(150), Eiser (151) and Lisansky and Clough (152).  It may be that the literature search terms 
were flawed which can miss pertinent papers or the design of the review introduced bias 
(163). Rose’s review rightly concluded that there was insufficient research of sufficient qual-
ity on which to base recommendations for effective interventions for anxiety and panic in 
COPD. 
A second systematic review was conducted by Coventry  and  Gellatly in 2008 and focused 
on CBT for the treatment of mild to moderate anxiety and depression (141).   The author’s 
question was focused and the PICO format was used to identify an appropriate population, 
intervention, comparison and outcomes.  The authors state that the search terms were 
broad to capture the maximum number of studies but this paper did not include studies 
which were identified in a third review which followed in 2011.  Again this may be due to the 
search terms or criteria used.  This review identified a study by De Godoy in 2003 (147).  
However, I found two papers from the authors of the same study.  The first paper in 2003 
reported on 39 patients and the second paper in 2005 included 49 patients (147, 164). Cov-
entry included four papers in their final review and concluded that there was scant evidence 
for the use of CBT to reduce symptoms of anxiety and depression (141).  The authors sug-
gested that there was only limited evidence that CBT, when used with exercise and educa-
tion, can contribute to significant reductions in anxiety and depression in COPD patients and 
suggested there was scope for a well powered RCT to evaluate the effectiveness of CBT in a 
COPD population (141).  
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A third systematic review on the efficacy of psychologically based interventions to improve 
anxiety, depression and QOL in COPD was published in 2011 (136).   A clearly focused ques-
tion was identified in terms of population studied, intervention given and the outcomes con-
sidered.  The authors conducted extensive searches to identify appropriate research from 
1983 up to 2009.  In addition reference lists were scrutinised to identify additional studies.  
Key authors were contacted to obtain details of additional studies in an attempt to address 
publication bias.  Data were extracted using a standardised extraction sheet.  A second re-
viewer independently extracted data from 50% of included studies to ensure accuracy and 
reliability.  It is recommended that a second researcher should independently check all of 
the forms for accuracy and detail to ensure data extraction is unbiased and reliable (163).   
A final review and meta-analysis was published in 2014 (4).  As with previous reviews, the 
search was restricted to English language studies only which may result in the exclusion of 
appropriate research in other languages.  The review included papers published between 
2000 and 2013.  A clearly focused question was identified and PICO format was used to de-
termine eligibility criteria.  Study selection and data extraction was undertaken by two inde-
pendent reviewers.  A study from China was identified (138).  Four studies were included in 
the meta-analysis and the results of the review concluded that there was a small effect of 
CBT interventions. 
3.2.5 Assessment of Bias 
It is important to assess the risk of bias in all studies in a review (165). The task of assessing 
the risk of bias in studies is part of assessing the strength of a body of evidence (166).  Biases 
can result in an overestimation or underestimation of the true effect of an intervention 
(165).  The Cochrane Collaboration recommend using judgements when assessing bias and 
discourage the use of scales (165).  It is argued that common scales  emphasise reporting ra-
ther than the conduct of the research and does not cover allocation concealment, one of the 
most important potential biases in trials (165).   The outcome of bias assessment is recorded 
as low, medium or high risk (165).  The papers identified in this review were judged for risk 
of bias and the results are presented in table 15.
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Table 15 – Assessment of bias. 
 
When assessed for bias all studies were assessed as high risk and therefore the results must 
be viewed with caution.  There is a clear need to develop a RCT which address bias. 
3.2.6 Recruitment and attrition 
Recruitment was a problem in some studies.     A host of complex and inter-related factors, 
including patient, provider and health care systems, affects accessibility of medical treat-
ment (167). Patients with COPD are at high risk of poor mental health treatment and un-
deruse services for a variety of reasons including stigma, access to care, or do not recognise 
mental health needs (167).  Causes highlighted by patients in the studies identified for this 
 Random se-
quence gen-
eration 
Allocation 
concealment 
Blinding of 
outcome as-
sessment 
Losses to 
follow 
up >20% 
Adequate statisti-
cal handling of 
missing data 
ITT 
Analysis 
Howard & 
Dupont, 2014 
Low Low High Low Low Low 
Jiang & He, 
2012 
High High High Low Moderate High 
Lamer’s et al, 
2010 
Low Low High High Low Low 
Livermore et 
all, 2010 
Low Moderate Moderate High Low Low 
Howard et al, 
2010 
High High High Low Low Low 
Hynninen et al, 
2010 
Low Low High Low Low Low 
Cully et al, 
2010 
High High High Low High High 
Heslop et al, 
2009 
High High High Low Low High 
Kunik et al, 
2008 
High High High High Low Low 
De Godoy et al, 
2003 
High High High Low Low High 
Kunik et al, 
2001 
High High High Low Low High` 
Emery et al, 
1998 
Moderate High High Low Low High 
Eiser et al, 1997 
 
High High High Low Low High 
Lisansky & 
Clough, 1996 
High High High Low High High 
Gift et al, 1992 
 
Low High High High Low Low 
Rosser et al, 
1983 
Moderate High High Low High High 
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review included lack of transportation (142), patients believing they are not anxious or de-
pressed, being too busy or feeling fatigued (142) , illness or death (144).  It is also likely that 
patients who are anxious would rather avoid anything that may increase their anxiety such 
as participating in research. Patients may also lack motivation, especially if they are de-
pressed (84).  Careful consideration must be given to engage and support patients to ensure 
adequate participate rates are achieved (142).   
3.2.7 COPD Severity 
A range of COPD severity was found across the studies.  A recommendation of one of the re-
views suggested including all severities of COPD (136).  It was noted that a number of meth-
ods were used to ascertain the severity of airways obstruction.  This ranged from spirometry 
and peak flow measurements (153), spirometry (151, 152, 154) , no measurements at all 
(144) or it is not mentioned in the paper (143).  Only five studies reported the gold standard 
FEV1/FVC ratio <70%. Two studies reported mean FEV1 (145, 154).  The main disadvantage of 
not recording the FEV1/FVC ratio is the diagnosis of COPD cannot be confirmed.  One study 
relied on general practitioner (GP) opinion for the diagnosis or verification merely being 
made based from the GP practice COPD register  (144). Relying on a diagnosis from primary 
care may result in patients without COPD being inappropriately included in studies as pri-
mary care databases have a 20% misdiagnosis of COPD (168).  
3.2.8 Age  
The ages of patients were similar in all of the studies.  The mean age ranged from 60 – 73. 
3.2.9 Setting 
The studies were undertaken in a number of different countries with a variety of healthcare 
systems (see Table 16).  It is therefore difficult to identify the impact of cultural or environ-
mental differences (4). 
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Table 16 - Summary of countries where studies were conducted. 
Country  Number of Studies  (n=16) 
United States of America 6 
Australia 1 
Holland 1 
New Zealand 1 
UK 4 
Norway 1 
China 1 
Brazil 1 
 
3.2.10 Psychological Morbidity 
You would expect studies investigating the effectiveness of an intervention to reduce symp-
toms of anxiety or depression to include psychological morbidity as a necessary entry criteria 
(unless it is a preventative study).  The level of psychological morbidity within studies identi-
fied in this review varied.   Some studies did not report baseline psychological morbidity at 
all. This is important data which should be clearly documented.  Table 17 outlines which 
studies included symptoms of anxiety as an inclusion criteria. 
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Table 17 – Studies with anxiety in inclusion criteria. 
Study Anxiety Symptoms in inclusion criteria 
Howard & Dupont, 2014 (145) No 
Jiang & e, 2012 (138) No 
Hynninen, 2010 (142)  No 
Cully, 2010 (143) Yes – STAI-S or STAI-T >39 
Lamers, 2010 (144) No 
Howard, 2010 (145) No 
Livermore, 2010 (101) No – preventative study.  Excluded patients with panic disorder. 
Heslop, 2009 (146) Yes – HADS-Anxiety score ≥8 
De Godoy, 2003 (147) No 
Kunik, 2008 (148) Yes – BAI >16 
Kunik, 2001 (149) No 
Emery, 1998 (150) No 
Eiser, 1997 (151) Yes – HADS-Anxiety score ≥8 
Lisansky & Clough, 1996 (152) No 
Gift et al, 1992 (153) No 
Rosser, 1983 (154) No 
    
3.2.11 Study design  
RCTs are the gold standard study design for evaluation of health care interventions (169).  
Randomisation is key to ensure the intervention and control groups do not differ and biased 
results can be minimised (169).  Ten of the studies were RCTs.   The remainder were non-
randomised experimental designs which have been shown to be prone to bias (169).   How-
ever, as there is a lack of high quality RCT’s all papers have been included in this review.   
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3.2.12 Power Analysis 
A significant problem with a number of studies on CBT in COPD was the low sample sizes and 
lack of power calculation.  From the 16 studies only five reported a power calculation. Two 
studies failed to recruit sufficient patients suggested in the power calculation which is a sig-
nificant weakness (101, 142).   
3.2.13 Outcome Measures  
A major problem with the studies was that numerous outcome measures were used to eval-
uate the efficacy of the interventions.  It is therefore difficult to compare the outcomes of 
the studies.  For anxiety several measures were used: Visual Analogue Scale, Spielberger 
Anxiety Inventory, Kellner’s Symptom Questionnaire, Symptom Check List, Beck Anxiety In-
ventory and the HADS-Anxiety questionnaire.   The authors of one study acknowledged that 
the measures were defective and yielded such variable results that it is difficult to draw any 
conclusions from their small sample (170). The most common measure used to assess symp-
toms of anxiety was the HADS-Anxiety subscale and this questionnaire was used in five stud-
ies.  The HADS has fewer items than the other measures which reduces patient burden, has 
been extensively validated in medical out-patient settings and validated in COPD patients.  
Similarly QOL was measured by generic measures in some studies and HRQOL measures in 
others including the CRQ, SF36, SGRQ, IPBQ, MRCQ and SIP.  The most common measures 
used were the CRQ and the SGRQ. 
3.2.14 Blinding 
Blinding is recommended to minimise bias (165).  Double blinding ensures that preconceived 
views of subjects and clinicians cannot systematically bias the assessment of outcomes 
(171).  Due to the nature of the interventions used in the papers included in this review, it is 
difficult to blind patients to the intervention they received.    In De Godoy’s paper it is sug-
gested that ‘both groups were blinded in relation to activities of the other group’ (page 155).  
It is difficult to comprehend how patients could give informed consent if they were not 
aware of the activities entailed in each group.   Some studies tried to minimise bias and data 
collection was undertaken by individuals blinded to the group assignment. 
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3.2.15 Type of Interventions 
Interventions to change behaviour are typically complex, involving many interacting compo-
nents (172).  The CONSORT statement for randomised trials of ‘non-pharmacological’ inter-
ventions recommends precise specification of trial processes, including specific detail of the 
delivery of interventions and description of the different components of the interventions 
(173).  Studies describe interventions in protocols and publications in different ways but may 
mean the same thing (e.g. self-monitoring may be labelled daily diaries or behavioural coun-
selling may involve educating patients, providing feedback, self-monitoring and reinforce-
ment) (174).  This may lead to uncertainty and confusion  (174).     The CONSORT Guidelines 
provide an excellent structure for reporting RCTs.  However, it is argued that behavioural sci-
entists should provide additional information in published reports (175).  The following infor-
mation has been proposed: 
a) The content or elements of the intervention 
b) The characteristics of those delivering the intervention 
c) The characteristics of the recipients 
d) The setting 
e) The mode of delivery (e.g. face to face) 
f) The intensity (e.g. contact time) and  duration (number of sessions) 
g) Checks on adherence to delivery protocols 
The studies identified in this review were assessed for the above categories and a summary 
can be found in table 18. 
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Table 18 – Description of interventions used in studies. 
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y 
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nd
 d
u-
ra
tio
n 
Ad
he
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e 
to
 d
e-
liv
er
y 
pr
ot
oc
ol
s 
Howard 
and 
Dupont 
2014 
(139) 
 
Psychologists Yes Home Self-Help Manual 
with two 30 min 
booster sessions 
by phone 
Patients were encourage to use 
manual for 1 hour daily  during 
5 week programme 
Not stated 
Jiang & 
He, 2012 
(138) 
 
Nurses (no fur-
ther infor-
mation given) 
Yes Home Self-Help Manual 
and audio CD 
Weekly telephone calls (35 
minutes) for 4 weeks then 
monthly calls for 10 months 
Not docu-
mented 
Lamer’s 
et al,  
2010 
(144) 
 
Nurses Yes Home One to One ses-
sions 
Maximum of ten visits over 
three months. 1 hour each visit. 
(Range 2-10 hours.  Mean 4 vis-
its). 
 
Checklists 
were used 
to check 
adherence 
to protocol 
Liver-
more et 
all, 2010 
(101) 
 
Psychologists Yes Hospital 
out-pa-
tient De-
partment 
One to One ses-
sions 
1 hour sessions over 4 weeks.  4 
hours in total. 
Not stated 
Howard 
et al, 
2010 
(145) 
 
Psychologists 
(although this is 
not explicit in 
the paper) 
Yes Hospital 
out-pa-
tients De-
partment 
Group sessions 
plus handbook 
and relaxation 
tape. 
Telephone call at 
5 weeks 
2 hour weekly sessions over 4 
weeks.  8 hours in total. 
Not stated 
Hynninen 
et al, 
2010 
(142) 
 
Two masters 
level Psychology 
students 
Yes University 
Out-pa-
tient clinic 
Group sessions 1 hour weekly sessions over 7 
weeks  
Sessions 
were 
video-
taped for 
adherence 
and com-
petence  
Cully et 
al, 2010 
(143) 
Five psychology 
interns, post-
doctoral fel-
lows, pre-doc-
toral interns. 
Yes Large 
Medical 
Centre 
One to one ses-
sions plus 3 
booster tele-
phone or one to 
one sessions  
 50 minute sessions (6 in total) 
plus 3 booster telephone or one 
to one sessions of 10-15 
minutes.  5-6 hours. 
Yes 
Heslop et 
al, 2009 
(146) 
Respiratory 
Nurse 
Yes Hospital 
Out-pa-
tients De-
partment 
or home 
visit 
One to one ses-
sions 
 30 minute sessions.  Every two 
weeks.  Number of sessions 
ranged  2-13 (mean 4) 
No 
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Kunik et 
al, 2008 
(148) 
 
Psychology in-
terns and post-
doctoral fellows 
Yes Large 
Medical 
Centre 
Group sessions 8 hourly sessions held weekly Yes 
De Go-
doy et al, 
2003 
(147) 
 
Not stated Yes Hospital 
out-pa-
tients de-
partment 
? One to one ses-
sions 
12 hourly sessions held weekly  Not stated 
Kunik et 
al, 2001 
(149) 
 
Gero-psychia-
trist 
Yes Hospital 
out-pa-
tients de-
partment 
Group sessions Single 2 hour session Not stated 
Emery et 
al, 1998 
(150) 
 
Psychologist Yes Hospital 
out-pa-
tients 
Group sessions 1 hour weekly sessions over 10 
weeks (in addition to PR).  10 
hours in total. 
Not stated 
Eiser et 
al, 1997 
(151) 
 
Psychiatrist Yes Hospital 
out-pa-
tients de-
partment 
Group sessions  90 minute sessions at weekly 
intervals. Total number 6. 
Not stated 
Lisansky 
and 
Clough, 
1996  
(152) 
 
Psychiatrist & 
nurse 
Yes Hospital 
out-pa-
tients de-
partment 
Group sessions 8 weekly sessions.  No further 
information given. 
Not stated 
Gift et al, 
1992 
(176) 
 
Pre-recorded 
tape 
Yes Physician’s 
office 
Individual ses-
sions 
4 weekly sessions for 20 
minutes. 
Not appli-
cable 
Rosser et 
al, 1983 
(154) 
Psychoanalyst Yes Hospital 
Out-pa-
tients 
?One to one (not 
clear from paper) 
45 minute sessions over 2 
months. 
8 sessions in total. 
Yes 
 
A major challenge with complex interventions is identifying the effective components within 
them.   Some of the papers in this review were difficult to read and identify what the inter-
vention involved, who undertook the intervention and what the intensity and duration of 
the sessions were.  This makes replication and implementation of the most effective inter-
ventions difficult (174).  A number of interventions were used including group and individual 
CBT, CBT based education, taped progressive muscle relaxation and individual analytical 
therapy.  It has been suggested that group CBT may not be appropriate for patients with 
more severe disability and/or psychological distress (142).  Whilst group therapy may be 
more cost effective, it may not be acceptable to patients and lessens individualised goal set-
ting opportunities (142).  Key components of the interventions used in previous research 
were clearly presented in some studies (139, 144, 145, 146, 148, 149).  Hynninen et al (2010) 
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provided a very comprehensive table of techniques used, the aim of the technique and an 
example to aid the reader (142).  Table 19 summarises the main cognitive and behavioural 
change techniques used across all studies based on the Taxonomy of behavioural techniques 
(174). 
Table 19 - Taxonomy of techniques used in studies. 
 
Older studies tended to use less techniques (or report less).  Almost all of the studies re-
ported using shaping knowledge or psychoeducation, relaxation and cognitive therapy. 
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Howard & Dupont, 2014 √ √ √ √ √ √ √ √ √ √   
Jiang and He, 2012     √ √    √   
Lamer’s et al, 2010  √ √ √  √   √    
Livermore et all, 2010    √  √ √ √ √    
Howard et al, 2010    √ √ √  √ √    
Hynninen et al, 2010    √ √ √ √     √ 
Cully et al, 2010    √ √ √ √  √    
Heslop et al, 2009 √ √ √ √ √ √ √ √ √ √   
Kunik et al, 2008   √ √ √ √ √  √  √  
De Godoy et al, 2003      √       
Kunik et al, 2001    √ √ √ √    √  
Emery et al, 1998    √ √ √       
Eiser et al, 1997    √ √ √       
Lisansky and Clough, 1996   √   √     √  
Gift et al, 1992     √        
Rosser et al, 1983 
 
           √ 
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3.2.16 Delivery of the intervention   
In previous research a variety of professionals delivered the CBT intervention.  This ranged 
from nurses, psychology students, psychoanalysts, internist, psychiatrist, psychologist and 
post-doctoral fellows. One study involved a number of professionals including a nurse, psy-
chologist, physiotherapist and occupational therapist.  Each profession will have varying lev-
els of training and expertise in psychological care.  No studies have established if CBT deliv-
ered by respiratory nurses reduces anxiety, depression and healthcare utilisation/ hospital 
admissions.   
3.3 Recommendations for future research 
A number of methodological weaknesses of current research has been proposed and need 
to be addressed in future research including: 
x Small sample sizes and underpowered studies  (4, 129, 141)  
x Failure to measure or report lung function to ensure only COPD patients recruited 
(129). 
x A need to include patients with all COPD disease severity (141, 136). 
x More rigorous inclusion and exclusion criteria for clinical samples (129)  
x Short duration of studies (129). 
x Lack of standardisation of outcome measures   (4, 129).  Rose et al (2002) suggest the 
use of the HADS (129). 
x The need to use theories of the relationship between dyspnoea and anxiety to de-
velop the most appropriate treatment including interventions for panic (129). 
x Heterogeneity of interventions (4). 
x Identify suitable settings for the intervention including primary care, community set-
tings and even home visits (141). 
x Interventions should target QOL and evaluate their efficacy (136). 
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x There may be alternative methods of using CBT such as telephone or computerised 
CBT models (141). 
x Lack of blinding in assessment of treatment outcomes (129). 
x Finally, there is a need to for a well-developed RCT to investigate the use of CBT for 
patients with COPD (141). 
3.4 Summary 
There are a growing number of studies evaluating the efficacy of psychological interventions 
to improve the psychological well-being of patients with COPD. Most of the studies published in 
the last twenty years have used CBT.   In total 16 studies were included in this review incorpo-
rating research involving 612 patients.   However, despite the valuable contributions of prior 
research, a number of methodological limitations leave the role of CBT in question.  Most 
studies of CBT in COPD patients include very small numbers of patients from a variety of dif-
ferent health care settings with a variety of health care professionals undertaking the CBT.  
Mixed results were found in these studies.  It is noteworthy that studies that have been con-
ducted more recently are of a higher standard.  However, it is difficult to interpret and com-
bine the results as the studies are so different in terms of design, setting, focus, interven-
tions and outcome measures.  There is some evidence that psychological interventions im-
pact on anxiety and depression but further research is needed.  What is not clear is if CBT is 
effective in the COPD population where complex physical health symptoms compound 
symptoms of anxiety and depression or what the best model is to support patients.    
In a comprehensive systematic review, Baraniak and Sheffield (2011) concluded that there is 
some evidence that psychological interventions such as cognitive behavioural therapy im-
pact on anxiety (136).  However, a meta-analysis revealed a small effect for anxiety only.  
Previous reviews have highlighted that there is a need for high-quality research of CBT in the 
routine management of patients with COPD (129, 136).  Future studies should develop ro-
bust methodology (4, 129, 177) be adequately powered   (4)  and  include  a clearly defined 
population  (129).  It has also been recommended that the treatment of psychological diffi-
culties in COPD should be developed from existing models of care e.g. panic (129) and  evalu-
ate health outcomes  such as QOL and cost effectiveness (136).  In addition, future studies 
should use robust outcomes measures of anxiety, depression and QOL suitable for a COPD 
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population (4, 129). However, it is of course critical to identify an intervention that is ac-
ceptable to patients (141).  The recommendations from previous researchers have been 
carefully considered to develop an appropriately robust RCT for this research.   
The following chapter provides the background of the development of the novel CBT inter-
vention used in this study.  The research methods for the study will then be presented in 
chapter 5. 
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Chapter 4 – Development of a Novel CBT Intervention for people with COPD and anxiety 
The previous chapters of this thesis have outlined the theoretical basis of using CBT for 
symptoms of anxiety and depression in patients with COPD and a summary of previous re-
search has been given.  The aim of this chapter is to describe how the complex CBT interven-
tion used in this study evolved and developed and provide a description of the CBT interven-
tion itself to enable future researchers to replicate the intervention if needed. 
4.1 Complex interventions in healthcare 
Complex interventions are increasingly being used in health care.   Conventionally complex 
interventions are described as having several interacting components (172).  Whilst it could 
be argued that few interventions are simple, there are inevitably some that are more com-
plex than others (172).   Examples of complex interventions include treatments that are not 
drugs or surgical procedures, but may have many potential ‘active ingredients’ (178).  It can 
be difficult to precisely define the ‘active ingredients’ that makes development and evalua-
tion even more difficult (178).   On a continuum, we may consider a RCT of a drug versus a 
placebo is at the simplest end of a spectrum (178) and  a comparison of psychological ther-
apy as being at the most complex end of the spectrum.   
 In 2000, the MRC published guidance for developing and evaluating RCTs for complex inter-
ventions to improve health (178).  The MRC originally proposed a sequential framework that 
might help researchers and set out objectives to be met at each stage prior to moving for-
ward to the next stage.  These stages are outlined in figure 12.    However, it was suggested 
that these stages may not be a stepwise process, but rather a flexible approach depending 
on the quality of existing evidence and nature of the intervention (172). 
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Figure 12 – The original MRC Framework for the development and evaluation of RCTs of complex 
interventions to improve health (178). 
 
 
In 2008, an update of the MRC guidance reinforced these key messages and addressed the 
limitations identified in the original document.   The MRC rightly highlight a number of di-
mensions add to the complexity of an intervention (172). These are presented in table 20. 
Table 20 – Dimensions of Complexity of CBT Interventions (172). 
The intervention itself – the content, mode of delivery, number of sessions, duration, intensity, context. 
Adaptability/flexibility– the extent to which the intervention can be modified and on what basis, for example: 
participant assessment and therapeutic progress based on clinical judgment. 
Location - clinic, home setting or other venue. 
Psychological therapist - number of therapists involved, therapist professional training, knowledge and skills, 
therapeutic relationship with patients and compliance with the treatment protocol. 
Patient – preference, physical disability and comorbidities, cognitive ability, motivation, confidence, percep-
tions of self-efficacy and compliance. 
 
Explore 
relevant theory
(pre-clinical) 
Modelling -
Identify 
components
(Phase I)
Exploratory 
trial
(Phase II)
Definitive RCT
(Phase III)
Long term 
implementation
(Phase IV)
  
 
92 
The MRC updated the framework as it had been recognised that the development of a com-
plex intervention may take a wide range of different forms, and addressed the linear frame-
work with a cyclical model (Figure 13) (172). This acknowledges the experimental approach 
that incorporates learning at each stage of development of a complex intervention. 
Figure 13 – Diagram of the revised MRC Framework for the development and evaluation of RCTs 
for complex interventions to improve health (172). 
 
 
 
4.2 Background to the development of the complex CBT intervention for this study. 
The development of the CBT model used in this study evolved over many years and was con-
ceived from work within the field of palliative care and physical health.  Dr. Kathryn Mannix, 
a Consultant in Palliative Care, pioneered the development of CBT in palliative care.  Dr. 
Mannix recognised that specialist nurses working in palliative care commonly encountered 
patients with emotional problems and frequently offered psychological support to patients 
and their families.  There was evidence that CBT was an effective psychological treatment for 
anxiety, panic and depression in physical health although no formal studies had been under-
taken within palliative care settings. Traditionally CBT was undertaken by highly trained CBT 
therapists.  However, within the palliative care setting this model was thought not be desira-
Development -
identifying evidence base, 
developing theory, modelling 
process and outcomes
Feasibility- testing procedures, 
evaulating recruitment/retention, 
determining sample size
Evaluation- assessing effectiveness, 
understanding change process, assessing 
cost-effectiveness
Implementation - dissemination, 
surveillence and monitoring, long 
term follow up
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ble or practical for very ill people with advanced or end-stage illness  on account of the lim-
ited access to this level of psychological therapist and the high level of need (179).  Indeed, 
many patients in the physical health setting have complex physical and emotional health 
needs, reduced energy reserves and possibly a limited capacity for new therapeutic relation-
ships (179).   Dr. Mannix’s novel idea was to identify if non-mental health professionals who 
worked in palliative care could be trained in ‘basic CBT skills or first aid’ (179).   
A basic introductory course in CBT skills for nurses working with palliative care patients was 
developed (179).  A RCT was designed to assess the effect of the training using a before and 
after design without any controls.   Sixteen experienced nurses, two hospice social workers 
and two palliative care occupational therapists volunteered to enter a study to evaluate the 
effectiveness of the CBT training.  The training consisted of the equivalent of nine days 
taught sessions over a twelve week period.  The course included basic theory of CBT; models 
of anxiety, depression, panic, adjustment to serious illness and training and supervision in 
relevant cognitive and behavioural techniques (179). The course involved observing tutors 
modeling CBT skills, practicing skills using role play, and all trainees completed a reflective 
diary (179).   
An integral part of the study for all participants was supervision with an experienced CBT 
trainer who was familiar with delivering CBT in a physical health setting.  Supervision was 
structured to build skills and trainers modeled CBT techniques (179).  Trainees were assigned 
to groups of four and attended for two hours fortnightly over three months.  Trainees were 
asked to supply audiotapes of interviews with patients and bring to supervision for reflection 
and comment (179).  After twelve weeks basic training half of the nurses were randomised 
to continue supervision or a control group of no ongoing CBT supervision to identify if the 
CBT skills were enhanced or diminished.  I had volunteered for the study and following the 
initial training was randomised to ongoing supervision with Dr. Chris Baker.  
The primary outcome measure for the study was the change in the trainee’s level of compe-
tency in the application of CBT techniques over time.  Audiotapes of actual clinical sessions 
with patients were assessed using a ten-item scale called the Cognitive First Aid Rating Scale 
(CFARS) which had been developed by the research team specifically to assess CBT skills of 
non-mental health practitioners (179) (Appendix 2).  In addition all trainees participated in a 
  
 
94 
structured clinical interview detailing their experiences of learning CBT and their use of CBT 
skills.  The results of the study demonstrated that the brief, focused training in CBT tech-
niques supported by supervision, produces a significant improvement in the ability of pallia-
tive care professionals to recognise emotional distress, select appropriate CBT techniques,   
enable  patients to gain insight, change their behaviour and regain control (179).   A further 
RCT was published in 2009 which also demonstrated a significant impact on common mental 
disorders in patients with advanced cancer (180). 
In cancer services it was identified that patients’ psychological symptoms were not recog-
nised and this resulted in patients not being offered access to the services they needed 
(179).   Respiratory patients face the same problem as many health care professionals lack 
appropriate assessment skills and may underestimate the benefits of psychological support.  
Health and social care professionals offering day-to-day care are in a position to provide gen-
eral psychological support to patients and carers and can play a key role in psychological as-
sessment, prevention and amelioration of distress (132).  I identified that there was a strong 
argument to develop awareness of psychological needs and skills in delivering psychological 
care into the field of respiratory medicine considering the psychological burden encountered 
by patients.   
My initial idea to deliver CBT to COPD patients with symptoms of anxiety and depression 
first developed in 2001 during my participation in the study for palliative care professionals. 
The aim of CBT for patients with COPD was to address psychological needs and to compli-
ment medical management.  My experience suggested that CBT might be effective in ad-
dressing breathlessness, dysfunctional breathing, related anxiety, reduced activity levels and 
avoidance of activities (that induce breathlessness and lead to deconditioning) and break the 
panic cycle. Evidenced based CBT models for depression and anxiety were drawn upon to 
develop a treatment for patients with COPD (92). 
I continued to apply my basic CBT skills and applied to complete a post graduate diploma in 
CBT at the Newcastle Regional CBT Centre and Durham University.  Most of the professionals 
training at diploma level were from a mental health background including psychiatrists, men-
tal health nurses and social workers.  Very few professionals from the physical health back-
ground applied for training at diploma level and I was the only professional from a physical 
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health background to undertake the course in 2003. Reflecting on the impact of my therapy 
work enabled me to identify the potential benefits of this approach for people with COPD.  A 
key stage in the revised MRC framework for complex interventions is identifying the evi-
dence base to develop the model to be used.  As part of the course I completed a disserta-
tion on the use of CBT for patients with respiratory disease, looked at the literature relating 
to psychological distress in COPD and the rationale for using CBT skills and techniques for 
anxiety, panic and depression. It was clear at the time that there was limited research on the 
effects of CBT with COPD patients and there were no studies with respiratory nurses deliver-
ing the intervention.   
4.3 CBT Competencies 
Developing, piloting, evaluating and implementing a complex intervention can be a lengthy 
process (172).  During my training as CBT therapist I was assessed through academic assign-
ments and practical assessments to ensure I had achieved the necessary competencies. It is 
essential that individuals have the right skills to deliver CBT to a good and coherent standard 
(134). It took several years to consolidate my knowledge and skills. However, this experience 
enabled me to develop and refine a model of CBT that could be used for patients with COPD 
as suggested in the new MRC Framework.     
Within the NHS a number of professionals may deliver psychological therapies and their 
training will vary considerably.  In 2007, a report was published by the Department of Health 
identifying competences that are needed to deliver good-quality CBT, rather than simply re-
lying on job titles to indicate proficiency (134).  The evidence to support the competencies 
was  identified by a group of leading experts in the field drawing on descriptions given in 
clinical controlled trials (which usually use ‘manuals’  describing the treatment model and 
associated techniques) (134).  They suggested a  range of competencies that a therapist 
should have in order to adhere to evidence based models of treatment delivery  to achieve 
the best outcomes for the patient (134). Figure 14 shows the key therapeutic competences 
identified in 2007 (134).  
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Figure 14- Competency Framework for CBT skills  (134). 
 
Generic competences such as building a therapeutic alliance, knowledge, assessment skills 
and ability to use supervision are applicable to all forms of psychological therapy (134).   CBT 
needs to be undertaken by knowledgeable healthcare professionals who understand mental 
health problems, are able to elicit and understand the patient’s history (or story), identify 
suitable interventions to be effective in their treatment and understand the rationale for us-
ing them.  However, I would argue that it is crucial to understand the role of physical health 
problems on psychological well-being.  The patient’s physical health will almost certainly be 
relevant to the patients presenting problems.  Key competencies identified by the MRC in-
clude the ability to explain and demonstrate the rationale for CBT to the patient, structuring 
therapy sessions appropriately, the use of problem solving skills,  agreeing goals for interven-
tions, and using measures to guide therapy and monitor outcome (134). 
A vital role of any therapeutic intervention is the ability to build a good therapist-patient re-
lationship by relating to patients in a warm, encouraging and accepting manner.    One might 
expect that due to the nature of the work, most health care professionals within the heath 
care setting have some therapeutic skills in psychological and emotional care.    However, it 
is clear that some people do not have a natural ability to develop therapeutic relationships 
sufficiently to deal with emotional distress.  A common way of coping with distressed pa-
tients is to offer ‘a cup of tea’ to diffuse the situation. This may be a kind gesture but may 
Generic 
competences
Basic CBT 
competences
Specific CBT 
tecniques
Problem-specific 
competences
Metacompetences
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not address the patient’s difficulties.  Undertaking CBT with physically ill patients is challeng-
ing in that patients may not understand the link between physical and psychological symp-
toms, may not be able to sit or concentrate for a traditional mental health-style one hour  
consultation and may not be able to attend a clinic for treatment.   
As time progressed I gained a good insight into specific mental health problems experienced 
by patients with COPD and consolidated my competencies in generic therapeutic and CBT 
skills in line with the MRC Framework.  Specific CBT techniques were used and were evalu-
ated well by patients.  According to the MRC Competency Framework ‘meta-competencies’ 
involve reaching the stage where you develop abstract knowledge, incorporating theory and 
practice and can skillfully adapt therapy to the individual needs of the patient (172).   With 
limited time and resources I adapted CBT therapy to suit the needs of patients presenting 
with COPD within the constraints of my working environment.  Sessions were shorter than 
traditional therapy but remained structured.  Having a structure for therapy is advantageous 
for busy clinics when time is limited.    It is argued that the structured nature of CBT is often 
misunderstood and is not merely  a set of techniques, delivered in a didactic manner by a di-
rective therapist (134). If CBT were implemented in this manner it is highly unlikely it would 
be successful (134).  A fundamental characteristic of CBT is to work collaboratively with the 
patient. Within my clinical setting patients are not used to such structured sessions, deter-
mining an agenda or indeed being actively involved in the session so care was taken to de-
velop a model that they would be acceptable to patients.   
There are a number of competency frameworks and there is no consensus about the meth-
ods of developing these frameworks (181).  Roth and Pilling (2007) appropriately 
acknowledge that the combination of knowledge, skills and attitude defines competency and 
without the ability to integrate these areas, practice is likely to be poor (134).    Having said 
that, on the whole, the structure of the competency model proposed by the Department of 
Health is excellent, is applicable to anyone who delivers CBT and is not too prescriptive that 
it is set in stone.   
4.4 Identifying appropriate CBT techniques for patients with COPD 
When developing an intervention it is important to have a coherent theoretical basis for the 
intervention, be clear about what you are aiming for and how you will bring about that 
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change (172).  Key theoretical models were used to identify appropriate CBT techniques as 
the CBT therapy evolved for patients with COPD.  Addressing symptoms of anxiety requires 
specific techniques depending on the severity and complexity of the patient’s difficulties 
(125).  Techniques commonly used for anxiety include those that help the patient identify 
and modify unhelpful thoughts or emotions which can trigger the ‘fight or flight response’, 
and tackle unhelpful behaviours (such as avoidance or safety behaviours).  Techniques used 
for COPD patients who were troubled with symptoms of depression predominantly included 
behavioural activation.   
As I developed my own competencies and model I began to think about other staff develop-
ing their CBT skills.  Developing competencies in specific CBT techniques, ensuring fidelity to 
treatment and enabling replication of therapy involves identifying and carefully describing 
the techniques used. The CONSORT statement for RCTs of non-pharmacological interven-
tions recommends including a ‘description of the different components of the intervention’ 
(178).    Mitchie et al (2013) would argue that the absence of standardised definition of be-
havioural techniques is likely to lead to duplication of effort and undermines the potential to 
accumulate evidence across reviews (174).  Common CBT techniques that I have found help-
ful during my own training, supervision and reflection on CBT practice with patients with 
COPD patients, as well as in training and supervising others can be found in table 21.   
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Table 21- Key Components of techniques used in the COPD CBT Intervention 
Component tech-
niques 
Aim Examples 
Education /increasing 
awareness 
Increase awareness about COPD, anxiety, panic 
and depression. 
Help patient understand the link between physi-
cal and psychological symptoms. 
Explaining how anxiety can exacer-
bate breathlessness and the link be-
tween frightening thoughts, role of 
adrenaline and identifying vicious cy-
cles that can develop. 
Cognitive therapy  Identifying, challenge and reconsidering unhelp-
ful thinking and behaviour and identify more 
helpful ways of thinking or behaving. 
Identifying patients own unhelpful 
thoughts about their breathing which 
may lead to panic e.g. I’m going to 
die. 
Goal setting Set or agree goals important to the patient.  
Goals would be reviewed, modified to smaller or 
new goals set if needed. 
Agree a goal such as practice a tech-
nique to manage breathless or an ac-
tivity each day that may help patient 
feel a sense of achievement.  Goals 
would be reviewed and further 
adapted. 
Graded tasks and Be-
havioural Activation 
Reduce avoidance and increase levels of activity 
especially activities which provide a sense of 
achievement or pleasure, increase confidence 
and help improve mood. 
Patients complete a simple activity di-
ary and rate activities for achievement 
or pleasure. Patients are encouraged 
to break tasks down into small man-
ageable bite size activities and pace 
themselves. 
Breathing Control Instruction (written, verbal and practical) of 
techniques that might help control breathing 
more effectively. 
Instruction (written, verbal and practi-
cal) of breathing exercises.  This may 
involve a demonstration. 
Relaxation/mindful-
ness 
Help the patient to learn to relax and cope with 
their physical symptoms.  Techniques can reduce 
tension and help develop coping skills. 
Practicing progressive muscle relaxa-
tion or mindfulness techniques espe-
cially when feeling breathless or anx-
ious. 
Distraction To help shift attention away from breathing to 
an alternative focus for attention to avoid trig-
gers for panic. 
Patient to focus on something e.g. 
count backwards from a hundred in 
seven’s, to take mind off breathing 
when they have exerted themselves. 
Comparing outcomes Help patient identify and compare the ad-
vantages and disadvantages of their thinking or 
behaviour. 
Patients discuss the advantages and 
disadvantages of avoiding exertion in 
case they become breathless. 
Biofeedback Providing feedback about physiological meas-
urements as part of a behavioural change strat-
egy. 
Breathing tests would be discussed 
and expectations of what might be 
achieved given their level of lung 
function. 
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Re-attribution Identify perceived cause of an experience or be-
haviour and suggesting alternative explanations. 
Acknowledging that COPD causes 
breathlessness but exploring how the 
patient thinks anxiety may affect 
breathing and how techniques for 
anxiety can help. 
Positive self-talk Positive self- talk (aloud or silently) for encour-
agement or reassurance. 
Patient may tell themselves their 
breathing will settle down when they 
use distraction and breathing control. 
Problem solving Learning to analyse situations and identify strat-
egies to overcome difficulties or any barriers. 
Identify ways to achieve one of their 
goals e.g. organising a wheelchair may 
help patients achieve their goal of go-
ing out more. 
Fear-based exposure Replace avoidance with graded exposure to situ-
ations or activities which are associated with 
anxiety. 
If a patient has avoided going out of 
the house they may agree to walk to 
the garden gate and then increase the 
distance gradually. 
Behavioural Experi-
ments 
To test hypotheses about a particular belief or 
behaviour. 
A patient may be believe they will not 
be able to walk to the garden gate.  
An experiment could be developed to 
try it and test out their hypothesis. 
 
Written information can also be provided during CBT sessions as an adjunct to therapy to re-
inforce discussions.  Written self-help leaflets have come to be seen both as psychological 
interventions in their own right and also as an adjunct to therapist-delivered care.  Such in-
terventions have been referred to as ‘psychoeducation’ or ‘bibliotherapy’ (182).  Psychoedu-
cation is a more general approach involving the provision of therapeutic information, which 
could include written materials, support and advice.  Providing unsupported written materi-
als is bibliotherapy (182).    
4.5 Field testing  
Having identified the key components of CBT for patients with COPD and competencies for 
delivery of this in a Chest Clinic setting, the next stage was to test or evaluate the therapy 
(172).  It is also important to adequately pilot the intervention so field testing was under-
taken (172).    Modelling a complex intervention prior to a full scale evaluation can provide 
important information about the design of both the intervention and the evaluation of it 
(172).  
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Once I had qualified as a CBT therapist I developed a CBT clinic dedicated to respiratory pa-
tients and began field testing this approach.   At the Chest Clinic at the RVI I introduced rou-
tine screening for symptoms of anxiety and depression using the HADS questionnaire. The 
majority of patients referred to the CBT Clinic had a diagnosis of COPD but a minority had 
other respiratory conditions such as interstitial lung disease (ILD), lung cancer, bronchiecta-
sis, tuberculosis and asthma. At the time I had no intention of developing the CBT interven-
tion to conduct a RCT or undertaking a PhD. However, I had developed a good theoretical 
understanding of how CBT could be adapted for patients with COPD.     According to the 
MRC it is key to understand what changes are expected and how change is to be achieved 
when a novel treatment package is being developed (172). As time progressed I began to 
standardise the therapy which again is recommended before a complex intervention such as 
CBT can be evaluated and is expected to have a worthwhile effect (172).  
With encouragement from Dr. Baker I completed a case series involving ten patients with 
COPD who had symptoms of anxiety or depression.  Hospital admissions were noted before 
and after CBT.  Although this was a very small sample, the results demonstrated clinical and 
statistical improvements in anxiety and depression scores and a statistically significant re-
duction in hospital admissions following CBT (183).  This encouraging pilot study led to me to 
refine the treatment as I gained experience.   
Following a teaching session for medical students I was approached by a fourth year student 
(Tom Foley) who expressed an interest in CBT in COPD and he arranged to work in the Chest 
Clinic for an elective placement.  The student completed a small non-randomised retrospec-
tive controlled study of 42 patients: 21 who had completed CBT were matched with 21 his-
torical matched controls.  The same techniques were used for managing anxiety and depres-
sion as the case series.  The study design was not ideal but the results again suggested that 
CBT significantly reduced anxiety and depression and also had a significant reduction on hos-
pital admissions.  The average number of COPD related admissions in the six months before 
CBT treatment was 1.48 compared with 0.42 after treatment. This suggested that treatment 
may influence hospital admissions, which had not been demonstrated previously.  The re-
sults were published (183) and the medical student has since qualified and is now specialis-
ing in psychiatry. 
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4.6 Development of the CBT Lung Manual 
My training, supervision, experience and CBT treatment outcome evaluation lead me to de-
velop a CBT guide for working with patients with respiratory illness (Appendix 3 – CD pro-
vided). Manuals are commonly written to guide CBT therapy for particular psychological 
problems. In essence a manual is basically a package of techniques, to use for a particular 
problem.  What is not known is which components in manuals actually help patients, and by 
exactly what process (134).  Manuals are similar to guidelines and clinicians can use their 
clinical judgement to decide which elements of an intervention to include and which to ig-
nore depending on the patients individual needs.  However, a criticism of the ‘manual ap-
proach’ is that it does not do justice to the complexity and individuality of the patient (184).  
Furthermore, rigorous adherence to a manual may discourage clinical judgement, innovation 
and adaption to the individual patient’s needs (184).  With this in mind, the Lung Manual 
was developed to provide a framework of CBT techniques to support nurses delivering this 
complex intervention in this study.  The manual provides a structure of key components but 
also allows flexibility depending on patient’s individual needs.   An advantage of producing a 
manual is to aid the standardisation of the CBT intervention and clarification of the compe-
tencies required to effectively and safely deliver it.  This is critical to address issues of clinical 
governance and ensure safe practice.  
4.7 CBT Foundation Training Course 
After I completed my CBT training I observed there were very few courses in CBT foundation 
skills for health care professionals working in the physical health setting.  Building on from 
the original training I had completed, I decided to develop a training course to help other 
nurses working in the general physical health setting to learn how to undertake CBT for res-
piratory patients.  Dr. Sanjay Rao (Consultant Psychiatrist) was working at Newcastle upon 
Tyne Hospitals and also provided supervision and support during CBT training.  We devel-
oped a foundation CBT program.  The training programme was built upon the four tier 
model of professional psychological assessment and support recommended for cancer pa-
tients, with an emphasis for the training level one and two.   The primary aim of the course 
was to help health care professionals working in the physical health setting develop a basic 
understanding of CBT and develop CBT skills and techniques that could be used in their daily 
work.  The course would not enable staff to be ‘qualified CBT therapists’ but would provide 
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additional skills to enable them to deal more effectively with emotional distress in their clini-
cal setting.  Dr. Rao left Newcastle Hospital Trust in 2005 and Consultant Clinical Psychologist 
Dr. Christine Baker volunteered to take over.  As the course evolved and improved we de-
cided to consolidate the course into three days.    The content of the course is presented in 
table 22.  
Table 22 – Content of Basic CBT Foundation Course. 
Day 1 Day 2  Day 3 
Course aims Revision Feedback from homework 
Basic introduction to CBT Feedback from homework Case presentations (from participants) 
Using CBT in physical health setting Goal setting What next 
Anxiety Cognitive techniques Evaluation 
Panic Behavioural techniques  
Depression Case study  
Screening for anxiety and depression 
symptoms 
Practice  
Formulation of patients difficulties Summary  
Socratic Questioning and guided dis-
covery 
Homework  
Unhelpful thinking   
Practice   
Homework   
 
This training has been delivered, evaluated and refined over 12 years and provides founda-
tion level 2 CBT training for qualified and experienced health care professionals, developing 
the understanding of the CBT approach and an introduction to the techniques outlined 
above.   A workbook was also developed to encourage participants of the training course to 
continue to practice CBT skills once the course had been completed (Appendix 4).  The aim 
of the booklet was to learn CBT techniques and practice on themselves which would hope-
fully consolidate some of the techniques used during their training.    
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4.8 Clinical Supervision 
Throughout my training I had clinical supervision.  This is expected for any sort of psychologi-
cal treatment.  Clinical supervision within the context of CBT has two aims.  The first is to im-
prove outcomes for patients and the second is to improve the performance of practitioners 
(134).  Without effective supervision and clinical governance procedures, there remains the 
potential for a minority of practitioners to provide ineffective therapy (135).  Supervision 
provides an excellent means to reflect on practice, be open to constructive criticism, develop 
knowledge and skills further and identify any gaps in competence which supervision reveals 
(134).  Without supervision CBT skills are likely to diminish (179).  Clinical supervision helped 
me develop a better understanding of ‘what’ I was doing and ‘why’ in addition to reflecting 
on individual cases.  
An integral part of undertaking CBT for this study was to participate in clinical supervision 
with Dr. Christine Baker.  Dr. Baker works within the physical health setting and is a very ex-
perienced supervisor, providing supervision for post graduate and Masters students under-
taking CBT training.  Monthly supervision sessions for one hour are scheduled as standard 
practice within the Chest Clinic.  Supervision is structured to build skills and to model CBT 
skills.  Video-taped sessions are used to reflect on the nurses skills and provide support for 
further skill development.   
4.9 Evaluation of competency and internal validity of the treatment 
The effectiveness of individual practitioners and their routine clinical outcomes vary consid-
erably (135).  To reduce the amount of therapist variance, clinicians and researchers provide 
concrete treatment manuals in which the principles and techniques of the therapy are de-
tailed with varying degrees of specificity (185).  However, merely reading manuals is not suf-
ficient to ensure that therapists do conduct treatment according to the manual (185).  Usu-
ally therapists are given rigorous training, and their performance is assessed by supervisors 
using adherence and competence scales (186).  Adherence is the degree to which a particu-
lar treatment has been delivered, whereas competence involves the quality of the particular 
treatment provided (185).   
For the purpose of this study, I planned to address the effectiveness of CBT delivered by 
clinic nurses trained in CBT and drawing on The Lung Manual.  It was not the intention to 
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achieve the level of competency expected from highly experienced mental health practition-
ers such as those involved in delivery of IAPT.  As previous studies within the physical health 
setting, the aim were to enable the nurses to apply ‘CBT first aid’ to patients who may be 
distressed (179).  Permission was obtained to use the CFARS to assess the nurses’ compe-
tency providing CBT.  It was therefore envisaged to record a random selection of clinical ses-
sions and use the CFARS to rate the skills of the nurses conducting the CBT.  Clinical sessions 
using CBT are commonly video recorded at regular intervals and used to assess competency 
of CBT skills.  The benefits of recording actual sessions is invaluable for clinical supervision 
and enables practitioners and supervisors to assess skills and integrity to treatment manuals.  
This was an important part of the intervention for this trial and the results are presented in 
chapter 6.   
4.10 Summary 
 The overall aim of this chapter was to provide an insight into the background of the devel-
opment of the CBT intervention used in this study.   A number of people were key to the de-
velopment of the CBT intervention.  Experienced clinicians and cognitive therapists such as 
Dr. Kath Mannix, Dr. Sanjay Rao and Dr. Christine Baker working in the physical health set-
ting have supported me in the development of this CBT intervention.  I have followed the 
steps recommended in the revised MRC Framework for the development and evaluation of 
complex intervention by naturally progressing through each stage.  Over the years the CBT 
intervention has been refined to the point where a substantial evaluation was possible. Field 
work was invaluable to evaluate and finalise the intervention so it could be used in this 
study.   
The addition of the training course, The Lung Manual and the CBT workbook evolved to sup-
port health care professionals working in respiratory disease develop their skills and exper-
tise when dealing with emotional distress.   An eclectic model has been specially developed 
for patients with respiratory conditions from the stepped care approaches of psychological 
care used within cancer care and IAPT.  This study is the first to identify if a brief CBT inter-
vention developed and delivered by respiratory nurses can reduce symptoms of anxiety and 
depression and improve patient’s QOL. Details of the CBT intervention have been described 
to provide future researchers sufficient information to replicate this research.  The next 
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chapter describes the research methods used for this study.  The research methods, aims 
and objectives, hypothesis and outcomes are outlined followed by details of the study.   
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Chapter 5 – Research Methods 
5.1 Introduction 
The methodology used for this research has been peer reviewed and funded by the National 
Institute for Clinical Research (NIHR) as part of a clinical academic fellowship.  The NIHR is 
committed to funding studies if they are likely to improve patient care.   
5.2 Research methodology    
The most common research methodology used in medical sciences is quantitative research 
methods such as RCTs.  Quantitative researchers use scientific techniques that are likely to 
produce quantified, and if possible, generalisable conclusions (187).     It is well recognised 
that some research designs are more powerful than others in their ability to answer research 
questions on the effectiveness of interventions (188).  Within quantitative methods, RCTs 
are considered the ‘gold standard’ methodology for evaluation of health care interventions 
in terms of being the most scientifically rigorous method of hypothesis testing and evaluat-
ing the effectiveness of interventions (188, 189) .  RCTs aim to determine whether a cause 
and effect relationship exists between treatment and outcomes (171).   
As highlighted in the literature review RCTs can lack methodological rigor.  It is therefore im-
portant that RCTs should be appropriately designed, conducted and reported (190).  A 
properly designed study optimises the chances of accurately estimating the effectiveness of 
treatment avoiding potential sources of bias and  controlling for confounding variables (189).  
If a trial is conducted correctly the results should be sufficiently precise and allow application 
in clinical practice (191).  A RCT was used for this research as the efficacy of CBT could only 
properly be assessed by comparing it against an appropriate control group.   
5.3 Study Design  
This research was carefully planned over many months to maximise the opportunity to de-
velop a useful and credible study.    At the initial stages of preparing an application to the 
NIHR I consulted the local NIHR North East Research Design Service (RDS) to gain advice on 
the most appropriate study design.  The RDS support researchers to develop and submit high 
quality applied health and social care studies for national peer-reviewed funding programs.  I 
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also met with my potential supervisory team on a number of occasions to discuss study de-
sign options. Previous studies of CBT in COPD have included control groups with ‘standard 
care’, group education, waiting list controls, weekly laboratory visits and even sitting quietly 
in a room for the same amount of time (as opposed to interventions such as progressive 
muscle relaxation).   
Following discussions it was clear that several options were possible. One option considered 
was to have a treatment group of CBT compared with a control group receiving ‘standard 
care’.  Standard care in other respiratory departments across the UK did not include address-
ing psychological symptoms. Therefore standard care would be a control of ‘no interven-
tion’.  However at the time of developing the research proposal, standard care within the 
Trust was to provide self-help CBT leaflets or individual CBT depending on the patient’s pref-
erence in accordance with NICE guidance on psychological symptoms.  It was deemed to be 
unethical to conduct a trial with care below the prevailing ‘standard practice’.  As CBT is a 
proven treatment for anxiety recommended by the National Institute of Clinical excellence, 
it would also be poor practice to deny this established treatment from the control group.    
It was also expected that patients with COPD are likely to deteriorate physically during the 
trial so offering an active control intervention which could potentially help reduce symptoms 
of anxiety was considered important.  A prospective randomised parallel controlled trial was 
therefore designed with two arms. One arm was respiratory nurse led CBT with an active 
control arm of self-help leaflets.  At the start of the study it was not known if the interven-
tions were equivalent of if one was superior to the other.   Participants in the self-help leaf-
lets were made aware of the potential to have CBT at the end of the trial should this inter-
vention be better than the self-help leaflets.  No other studies have used a design with these 
interventions.  The study design flowchart can be found below in figure 15.  
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Figure 15 – Flowchart of the study design and follow up time points. 
                                              
5.4 Aim of the study 
The aim of the study was to assess the effectiveness of CBT delivered by respiratory nurses 
compared to an active control of self-help leaflets.  
5.5 Objectives 
The objectives of this study were to address the impact, feasibility and efficacy of teaching 
CBT skills to non-mental health professionals (such as respiratory nurses), to treat anxiety 
and depression in a clinical population of COPD patients.  This is particularly important as 
there is a national shortage of therapists.  In reality, the most realistic cost effective and 
pragmatic model to be able to provide rapidly scalable psychological care for patients with 
COPD may well be trained respiratory nurses.  Respiratory nurses are front line staff who 
work with high volumes of COPD patients and are ideally placed to assess patients’ physical 
and psychological needs.  Having respiratory problems can be life threatening so having dual 
physical and psychological skills would be invaluable assessing patients’ symptoms and de-
fining if they needed physical therapies or psychological support (or both).    
5.6 Hypothesis 
The hypothesis was that CBT delivered by respiratory nurses in addition to self-help leaflets 
was superior to providing self- help CBT leaflets alone. 
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5.7 Primary outcome  
Whilst CBT is an evidence based intervention for the treatment of psychological problems 
there is no research into the effects of an individual CBT based intervention on hospital ad-
missions in this patient group.  This study builds upon and extends prior work of Lamer’s et 
al (2010) that applied a psychological intervention in Dutch primary care COPD patients with 
depression (144). The study extends clinical observations from Newcastle Respiratory Clinics 
that anxious patients with COPD appear to be admitted most frequently and this may prove 
a key target sub-group to study for healthcare utilisation and cost effectiveness studies.  The 
findings will hopefully inform future clinical care, services and research.  
I discussed the possibility of having two primary outcomes (anxiety and depression) within 
my supervisory team.  As a single primary outcome and a small number of secondary out-
comes are the most straightforward for statistical analysis it was agreed that anxiety would 
be the primary outcome. The primary objective was to identify if CBT delivered in a stand-
ardised manner by respiratory nurses reduced anxiety in patients with COPD. This would be 
measured by a fall in group mean HADS-Anxiety score of 1.5 points at 3 months post-therapy 
compared to standard care of self-help CBT leaflets. As discussed in chapter 2, this value has 
been deemed an appropriate MCID (122).  
5.8 Secondary Outcomes:- 
 Five secondary objectives were developed:- 
A. To identify if CBT delivered by respiratory nurses reduced anxiety at six and 12 
months compared to standard care (self-help leaflets). 
B. To investigate if CBT delivered by respiratory nurses reduce depression as measured 
by the HADS-Depression Scale at three, six and 12 months compared to standard 
care (self-help leaflets). 
C. To investigate if CBT delivered by respiratory nurses improves patient QOL at three, 
six and 12 months as measured by a reduction in COPD Assessment Tool (CAT) (192) 
and EuroQol 5 Dimension questionnaire (EQ5D) utility scores. 
D. To identify if CBT delivered by respiratory nurses reduces hospital admissions in the 
12 months following randomisation (compared to 12 months pre-randomisation). 
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E. To ascertain if CBT is more effectively delivered by respiratory nurses with advanced 
CBT training (post -graduate diploma) compared to foundation level training (three 
day short course). 
For the purpose of this PhD only the results from the primary and secondary outcome data 
for the three month follow up point will be presented. 
5.9 Patient and Public Involvement 
It was important to involve patients and relatives when developing the study design.  A face 
to face meeting was organised with COPD patients, carers and the regional manager of the 
British Lung Foundation (BLF) prior to applying for funding from the NIHR for this research. 
Representatives from the BLF were useful to understand their standpoint or priorities as a 
charity representing people with lung conditions from a national perspective.  The regional 
manager for the Northern and Yorkshire Region (Mrs. Bev Wears) was approached and 
agreed to be involved in the research. For practical reasons the meeting was held at the RVI 
Hospital in an area easily accessible for wheelchair patients and refreshments were pro-
vided.  The aim of the meeting was to explain the rational for the research in the first in-
stance, present a draft research proposal and discuss the relevance of the research to pa-
tients and family.  It was also important to assess if the research matched the views and 
ideas from a personal perspective of patients with COPD and their family members.  Care 
was taken to keep the discussions simple and understandable by using ‘plain english’ and 
avoiding unnecessary jargon.   
An important consideration when involving the public is any ethical implications (193).  Dis-
cussing the psychological implications of an illness such as COPD may be upsetting so care 
was also taken to present psychological difficulties within COPD in a sensitive and supportive 
manner.  Patients were encouraged to offer their personal experience of having COPD and 
comment on the research proposal.  A crucial element of PPI is that the involvement of peo-
ple who use services can lead to research that is more relevant to their needs and hence is 
more likely to encourage people to take part (193).   
One of the suggestions from the meeting highlighted the importance of providing assistance 
with transport (e.g. providing taxis) or providing home visits for housebound patients espe-
cially as car parking is particularly difficult and expensive at the RVI site.  The groups views 
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on the proposed questionnaires were sought to ensure the use of the HADS (Appendix 1, 
COPD CAT (Appendix 5) and EQ5D (Appendix 6) would not over burden patients who may be 
physically unwell. 
5.10 Institution 
Newcastle upon Tyne NHS Hospitals Foundation Trust was the main institution undertaking 
this study.  The Trust provides secondary and tertiary services at two main hospital sites.  
The Royal Victoria Infirmary (RVI) is situated in the West of the city, and has been providing 
healthcare to communities in the North East for over 250 years (194).  The Freeman Hospital 
is situation in the North of the city.   The majority of respiratory services offered by the Free-
man Hospital are elective and specialist services such as lung transplantation, pulmonary hy-
pertension, bronchiectasis and sleep disorders.  Approximately 30% of patients attending 
Newcastle upon Tyne NHS Hospital Foundation Trust are patients from outside Tyne and 
Wear. Patients attend the Trust from surrounding areas including Northumberland, Gates-
head, South Tyneside, North Tyneside, Sunderland and Cumbria (194).    
A number of in-patient and out-patient Chest Clinics are available at both hospital sites.  
Each site has a dedicated Respiratory Consultant lead for COPD Dr. Burns is the lead consult-
ant at the RVI site and Dr. De Soyza is the lead consultant at the Freeman site.  Most but not 
necessarily all COPD patients attend these consultants specialist COPD clinics.  Initially two 
study sites within The Newcastle Upon Tyne Hospitals NHS Foundation Trust were used: 
x The Chest Clinic at the Royal Victoria Infirmary Hospital. 
x The Respiratory outpatient clinic at the Freeman Hospital. 
Two further study sites were added towards the end of the study after gaining ethical ap-
proval to increase recruitment.  These included: 
x South Tyneside District General Hospital. 
x Queen Elizabeth Hospital, Gateshead. 
Only two patients were recruited from South Tyneside and Gateshead Hospitals. 
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5.11 Study Population  
The ideal study sample represents the total population from which the sample is drawn 
(195).  Sampling simply means studying a proportion of the population rather than the 
whole population which can be expensive and time consuming (195).  Quantitative studies 
usually use sampling techniques based on probability theory.  Probability sampling involves 
attempts to minimise sampling error in that they give the highest chance of the sample be-
ing representative of the total population (195).  For this study it was important to recruit a 
sample representative to the COPD population in secondary care.  The population of interest 
was all patients attending secondary care out-patient departments with a confirmed diagno-
sis of COPD (mild, moderate, severe or very severe as defined by NICE, 2010) with a HADS-
Anxiety score ≥8.  Attempts were made to include all patients with COPD attending Chest 
Clinics to ensure they had an equal chance of being recruited into the study to minimise the 
risk of bias and random sampling was used. However, like all probability samples no sample 
can ever be totally represent the population (195).   
To capture as many COPD patients as possible I attended respiratory department meetings 
at the Royal Victoria Infirmary and Freeman Hospital to disseminate information about the 
trial at the outset and gain their assistance in setting up an appropriate method of recruit-
ment for both sites that was convenient to their service.  Dr. De Soyza is the lead consultant 
for COPD at the Freeman Hospital and ensured all COPD patients attending his clinics were 
screened and offered information about the study. Similarly Dr. Burns is the COPD lead at 
the Royal Victoria Infirmary and the majority of recruitment from the RVI site was from his 
clinic.  
5.12 Governance 
5.12.1 Ethics  
The Department of Health requires that research involving patients is reviewed inde-
pendently to ensure it meets ethical standards (196).  An appointment was made to attend 
the Sunderland Ethics committee on 21/02/2011.   A favourable opinion was granted (Refer-
ence 11/NE/0025). 
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5.12.2 Research and Development Approval 
Within NHS organisations Research and Development Departments facilitate the local man-
agement of all research within that organisation (197).  An application was made for ap-
proval to undertake the study within Newcastle upon Tyne Hospitals Foundation Trust.  Ap-
proval was granted (Reference 5473). 
5.12.3 Caldicott 
Information governance is a key process to consider when conducting research. Patient in-
formation is an exceptionally valuable resource for researchers, with great potential to im-
prove healthcare, both for individuals and populations (198). However, every patient should 
feel confident that personal and health information is held safely and securely.   Information 
governance ensures necessary safeguards are in place for the appropriate use of patient in-
formation which would be collected during the study.  Caldicott approval was requested and 
obtained (Reference 1527). All personal data were held on a database at the RVI site.  For 
purposes of data analysis, only completely anonymised data sets were sent to Newcastle 
University via email.  This included data relating to gender, age, ethnic group, lung function, 
smoking status, education, MRC dyspnoea scores, hospital anxiety and depression scores, 
medication and body mass index (BMI). 
 5.12.4 NIHR Clinical Research Network Portfolio 
The NIHR Clinical Research Network (CRN) is a government funded organisation.  The aim of 
the NIHR CRN is to support late phase clinical trials and other well-designed studies (199). 
The NIHR CRN Portfolio is part of the UK Clinical Research Network Portfolio, which com-
prises the network portfolios for England, Northern Ireland, Scotland and Wales.  These four 
portfolios are held on a single information system: the UKCRN Portfolio Database (200). As 
this study was funded by the NIHR Clinical Academic Training Fellowship and the NHS agreed 
to meet the support costs for the study it was eligible to be  entered on the NIHR CRN Port-
folio (Reference CRN Study ID: 10519). 
5.12.5 Trial registration 
The ISRCTN registry was launched in 2000 in response to the growing body of opinion in fa-
vour of prospective registration of randomised controlled trials (RCTs) (201). The registry 
  
 
115 
website states that the scope of the registry has widened beyond RCTs to include any study 
designed to assess the efficacy of health interventions in a human population (201). The reg-
istry is recognised by WHO and International Committee of Medical Journal Editors (ICMJE) 
and accepts all clinical research studies (whether proposed, ongoing or completed), provid-
ing content validation and the unique identification number necessary for publication (201). 
All study records in the database are freely accessible and searchable.  ISRCTN supports 
transparency in clinical research, helps reduce selective reporting of results and ensures an 
unbiased and complete evidence base (201).   This includes both observational and interven-
tional trials (201).  This study was registered with International Standard of RCT Number 
(ISRCTN reference 55206395). 
5.12.6 Trial Protocol and amendements  
A trial protocol was developed at the start of the study to describe the objectives, design, 
methodology, statistical considerations and organisation of the clinical trial (197).   During 
this study the recruitment rate was significantly lower than for respiratory pharmaceutical 
clinical trials in Newcastle and was slower than anticipated.  This will be discussed further in 
chapter 7. Advice was sought from the Trial Steering Committee (TSC) (see section 5.12.7) 
and it was agreed to open recruitment to two local hospitals in an attempt to achieve the re-
quired sample size. The trial protocol was amended accordingly to recruit from local hospi-
tals in Gateshead and South Tyneside Hospitals.   A trial amendment application was made 
and favourable ethical approval was obtained.  The protocol was published in 2013. 
5.12.7 Trial Steering Committee 
TSCs provide the overall supervision of clinical trials (203) and to monitor the progress and 
conduct of the research and advise on scientific credibility (204).  Their role is to monitor the 
progress and conduct of the study and advise on scientific credibility (203).  It is recom-
mended that at least two people who have experience of using services are involved in a TSC 
(193).  A patient, carer and BLF representative were invited and agreed to assist with the 
management of the research by joining the TSC.  In this trial specific funding for patient 
travel was in place to avoid any financial or logistic barriers to participation.  A list of mem-
bers can be found in table 23. Those involved in the TSC were not participants of the trial as 
this can be compromising for the participant and research team (193). 
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Table 23 - Members of the COPD CBT CARE Trial Steering Committee. 
Name Position 
Dr. Graham Burns (Chair) Consultant Respiratory Physician 
Mrs. Violet Knowles Carer Representative 
Mrs. Pamela McGregor Patient Representative and carer representative 
Mrs. Bev Wears 
British Lung Foundation Manager Northern and Yorkshire Re-
gion 
Mrs. Susan Leach Research Nurse (Mental Health Clinical Network) 
Dr. Anthony De Soyza Senior Lecturer and Consultant Respiratory Physician 
Dr. Chris Baker Consultant Psychologist 
Dr. Debbie Carrick-Sen Head of Nursing and Midwifery Research 
Dr. Nick Steen Principle Research Associate (Institute of Health and Society) 
Professor Elaine McColl Director NIHR Newcastle Clinical Trials Service 
 
The TSC for this study met on 13 occasions throughout the study.   
5.12.8 Good Clinical Practice (GCP) 
NIHR CRN GCP training was completed locally as this is a key requirement for anyone in-
volved in the conduct of clinical research is Good Clinical Practice (GCP).  GCP is the ethical 
and practical standard to which all clinical research is conducted (205).   
5.13 Study Duration  
The duration of the study was 12 months from randomisation. The rationale was to identify 
if CBT was effective and if the effect was sustained up to 12 months post randomisation.  
5.14 Sample Size and Power Analysis 
For scientific and ethical reasons, the sample size for a trial needs to be planned carefully 
with a balance between clinical and statistical considerations (189).  The power of a study is 
its ability or sensitivity to detect a statistical difference when one actually exists.  The best 
way to reduce the possibility of overlooking a finding (type II error) is to conduct a power 
analysis to determine the number of subjects needed to detect a clinically important differ-
ence when one exists (206). Calculating sample sizes can help to take into account variability 
in individual level outcomes (172).  Elements of the sample size calculation include: 
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x The estimated outcomes in each group (which implies the clinically important target 
difference between the intervention groups). 
x The α (type I) error level. 
x The statistical power or the β (type II) error level and 
x For continuous outcomes, the standard deviation of the measurements (207). 
The sample size for this study was calculated by Dr. Nick Steen a senior statistician from 
Newcastle University Medical Statistics and affiliated with the NIHR North East-Research De-
sign Service (RDS). The COPD patient group is complex. It was anticipated that patients 
would experience disease progression.  It was estimated that up to 10% patients may die 
within 3 months of commencement of the study and up to 30% may die during the 12 month 
follow up. We anticipated a 30% approach decline rate and 20% data collection attrition.  
Taking into account expected mortality and data attrition we initially estimated that 312 pa-
tients would be required to be consented for the study. Complete outcome data on 224 pa-
tients (112 patients per group) was therefore required.  This would give 80% power at 95% 
significance to detect a standardised difference of 0.375 (equivalent to a change in HADS-
Anxiety of at least 1.5 when SD 4) assuming a type 1 error rate of 5%.  The intended mean 
difference was in line with prior estimates of clinical significance 1.32-1.5 (122).   
5.15 Eligibility criteria for participants  
Research studies should have strict criteria for including and excluding patients to reduce the 
risk of bias and the possibility of preferentially admitting subjects who may help to support a 
hypothesis and prove a point (206).  Eligibility criteria for this study were chosen based on 
recommendation from previous research and agreed by the supervisory team who had ex-
tensive expertise in COPD, psychological interventions and research methods.  The inclusion 
criteria and exclusion criteria are outlined in 5.13.1 and 5.13.2. 
5.15.1 Inclusion Criteria  
x Patient with a confirmed diagnosis of COPD FEV1 ratio <70%.  
x All disease severity will be eligible including mild to moderate (FEV1 >50% predicted) 
and severe to very severe (<50% predicted). 
x Patients with symptoms of anxiety as defined by HADS-Anxiety scores ≥8.  
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x Willing to participate in the study and provide written informed consent. 
x Agreed to have CBT treatment session video recorded if randomly selected for valida-
tion. 
x Agreed to attend a minimum of 2 and maximum of 6 CBT sessions. 
 
5.15.2 Exclusion Criteria  
x Patients with HADS-Anxiety score <8 (within normal range). 
x Patients with known psychiatric history such as psychosis. 
x Patients receiving psychological talk therapy including CBT treatment. 
x Patients with cognitive impairment (e.g. dementia). 
x Patients involved in any other clinical trial. 
5.16 Screening of participants 
Potential patients were identified through routine clinic outpatient appointments by their 
treating physician or nurse from 22nd of August 2011 to 28th of October 2014.  Spirometry 
and psychological screening using the Hospital Anxiety and Depression Scale is routinely 
completed for all patients at each clinic visit.  All patients with a HAD-anxiety score   ≥8 who 
fulfilled the entry criteria were given a participant information leaflet by the health profes-
sional providing direct care in the respiratory clinics (Appendix 7).  Patients were encouraged 
to take the patient information leaflet to read and discuss with their family or friends prior 
to any contact regarding consent.  The patient information leaflet contained contact details 
if they needed more information or if they had any questions about the research.  In addi-
tion the clinical staff asked the patient if they consented to being contacted within two to 
seven days following the clinic appointment.  The patients contact details were written onto 
the HADS Questionnaire if consent was given.   All of the HAD questionnaires were collected 
from respiratory clinics.  If the patient agreed to being contacted they were approached by 
telephone or in writing. 
5.17 Screening Log 
A log of all patients who were screened was maintained and held securely in a password pro-
tected file at the Royal Victoria Infirmary site on a Microsoft Excel Database.  The screening 
log contained the following details:-  
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x Hospital number 
x HADS anxiety score 
x HADS depression scores  
x Outcome of screening (e.g. recruited, declined, HADS-anxiety <8). 
 
5.18 Recruitment procedures 
Patients were given a minimum of 24 hours to consider taking part in the study.  All patients 
who had agreed were contacted by telephone. Any questions the patients had were an-
swered and further information provided if needed.  All patients interested in participating 
in the study were then offered a home visit or hospital out-patient appointment to gain con-
sent. 
5.18.1 Consent 
Informed consent is at the heart of all research (196).  Written informed consent was ob-
tained once the patient agreed to proceed with the study (Appendix 8). The original signed 
consent form was retained in the Investigator Site File.  Every patient was provided with a 
copy of the patient information leaflet and consent for their records.    The GP and hospital 
consultant were notified of the patient’s participation in the study and which group they had 
been allocated (See Appendix 9).  
5.18.2 Recruitment  
It was originally anticipated that 312 patients would be required for this research.  Over the 
course of the study the recruitment rate was much slower than anticipated but the dropout 
rate was less than expected.  It was agreed by the TSC to stop recruiting once 112 patients in 
each treatment arm had completed three month follow up. 
5.18.3 Recruitment database 
Data management is extremely important.  In this current study an appropriate database 
was integral to the research from the onset. 
5.18.4 Clinic Posters 
Following ethical approval posters were displayed in clinics at the Royal Victoria Infirmary 
and Freeman Hospital to increase awareness of the research in the area and further contact 
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details provided if patients would like further information.  Very few enquiries were made as 
a result of the posters. 
5.19 Randomisation of patients  
Randomisation refers to the process of assigning participants to study groups at random.  
Randomisation has several important features.  Firstly, it allows each participant having an 
equal probability of being assigned to any given group (188). Randomisation  eliminates se-
lection bias and balances possible known and unknown confounding factors in order to cre-
ate a control group that is as similar as possible to the treatment group (188). Without ran-
domisation treatment comparisons may be prejudiced (189).  To ensure all patients had an 
equal chance of being randomised to either group and avoid selection bias a computerised 
randomisation program was used in conjunction with Newcastle University.  Equal randomi-
sation was used as in standard parallel group trials power is maximized by using 1:1 alloca-
tion ratio. 
 Whilst randomisation may help remove selection bias, it does not always guarantee that the 
groups will be similar with regard to important patient characteristics (208).  One way of try-
ing to ensure that the groups are well matched is to identify important prognostic factors 
and use stratification during the randomisation process (188). For this study patients were 
stratified at randomisation by disease severity namely FEV1 >50% predicted (mild to moder-
ate COPD) and <50% predicted (severe to very severe) and age to control for these potential 
confounding variables.   Patients were informed that their initials, date of birth and severity 
of COPD would be entered into a web-based system, which returned the allocation status.  
Wherever possible patients were present during the randomisation procedure for further 
transparency and ensure patients understood how their treatment had been allocated.   
5.20 Allocation Concealment  
Successful randomisation in practice depends on two interrelated aspects (189).  Firstly, ade-
quate generation of an unpredictable allocation sequence and secondly, concealment of that 
sequence until assignment occurs (189).  Allocation concealment is a technique that is used 
to help prevent selection bias by concealing the allocation sequence from those assigning 
participants to intervention groups.  The technique prevents researchers from consciously or 
unconsciously influencing which participants are assigned to a given intervention group 
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(188).  Ideally, RCTs should be double-blind (i.e. patient and staff responsible for the trial are 
blinded to the treatment allocation until the study is completed) if appropriate (171).  It was 
not possible for participants or the nurses involved in this study to be blinded to their inter-
vention. Patients knew at the outset which group they had been allocated to once they had 
been randomised. However, to reduce interviewer bias nurses involved in the outcome data 
collection were blinded to the allocated intervention.  Finally, the data analysis was validated 
by a statistician who was blinded to the intervention. 
5.21 Data Collection 
Demographic and clinical data was collected at baseline (see Table 24).   To minimise incon-
venience to patients and optimise data collection data was collected at the patient's pre-
ferred location.   This was either in the patient's home or a taxi was provided to transport 
the patient to the hospital if this was preferred by the patient.   It was agreed to collect data 
two weeks before or after the required follow up date from randomisation.  The rationale 
for this was to allow data to be collected for patients who may be unwell and unable to com-
plete the questionnaires, on holiday or for those who were difficult to contact.  Data was col-
lected at three, six and 12 months using validated and non-validated questionnaires.  Data 
collection forms were developed for three month, six month and 12 month endpoints to rec-
ord primary data (Appendix 10). Data collected were then entered onto the database.  All 
data entered was double checked by a trials data manager.  The dataset was checked visu-
ally for errors e.g. obvious errors, outliers or values out of expected range which can distort 
the results during data analysis.  Any errors identified were corrected. 
  
  
 
122 
 
Table 24 - Baseline Data Collection Template. 
Data Baseline Time point 1-  
Three months 
Time point 2- 
Six months 
Time point 3- 
12 Months 
Demographic Data √    
Gender √    
Age √    
Smoking Status and pack years √    
Ethnic Group √    
Marital Status √    
Education √    
Inhaler Technique √    
Spirometry and oxygen saturations √    
MRC Dyspnoea Score √    
Comorbidities √    
BMI √    
Medication √    
Health care utilisation  √ √ √ √ 
Participation in pulmonary rehabilitation  √ √ √ √ 
HADS/CAT/EQ-5D √ √ √ √ 
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5.22 Study Interventions   
 All patients received standard medical care which included:   
x Normal Chest Clinic visits with recording of weight, smoking status, spirometry, oxy-
gen saturation levels and inhaler technique monitoring. 
x Standard screening for symptoms of anxiety and depression using the HADS ques-
tionnaire at each clinic visit. 
x Attending pulmonary rehabilitation. 
Patients also received either CBT or self-help leaflets depending on their treatment alloca-
tion. 
5.22.1 Group 1 – Self-Help CBT Leaflets 
Patients randomised to the self-help leaflets were provided with unsupported written infor-
mation on anxiety and depression (if needed) (209, 210) and the Self-Help Toolkit (211).  Pa-
tients were advised to work through the leaflets and contact their primary care team should 
further help be required. As this was a pragmatic trial it was accepted that treatment in pri-
mary care may include psychotherapy, counselling, antidepressants and/or anxiolytics or in-
deed no treatment at all.  Information on primary care directed interventions was recorded 
at each study follow up visit.  
5.22.2 Group 2 - CBT Arm (CBT based treatment with a respiratory nurse). 
Patients randomised to the CBT arm of the trial were provided with the same self-help leaf-
lets provided in group one but received individualised CBT on a one to one basis.  The CBT 
intervention involved the standardised CBT based programme described in chapter four. The 
ability to standardise interventions is a cornerstone of RCTs (212).  For this study a manual-
ised treatment protocol (The Lung Manual) was developed and used in an attempt to stand-
ardise the CBT treatment as much as possible and to ensure the CBT based treatment could 
be replicated.    An initial assessment was undertaken at the patient’s first visit. The CBT 
nurse therapist assessed the patient’s current difficulties to develop an individualised treat-
ment plan at the first session. A standardised format was used (see Table 25). 
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Table 25 - Patient Assessment at Initial CBT Visit. 
Medical History 
Medication 
Allergies 
Social History 
Presenting Problem/Difficulties 
HADS Score 
Formulation using ‘Hot Cross Bun Model’ (see appendix 4 page 225) 
Goals 
Change Techniques 
Negotiate Homework 
Patient feedback and review of session 
Arrange follow up 
 
An individualised treatment plan would be developed depending on the patients presenting 
problem.  Key techniques outlined in table 20 were drawn upon. The techniques were based 
on the those recommended in NICE Guidelines (125). The purpose of the techniques were to 
aid the development of coping strategies, help the patient learn effective ways to respond 
appropriately to symptoms and reduce avoidance behaviours that maintain anxiety and low 
mood.   
Delivery of CBT 
The CBT was delivered by four respiratory nurses.  Two nurses were trained CBT therapists 
after completing a Post Graduate Diploma in CBT.  One nurse was an experienced therapist 
and had been qualified 10 years.  The second nurse had been qualified in CBT for two years.   
In comparison two nurses had completed brief training in CBT basic foundation skills and 
techniques within the last two years.  All four nurses had supervision to develop their skills 
and expertise.   Unfortunately, three of the respiratory nurses left the Trust during the study.  
The provision of the intervention was continued by the most experienced CBT therapist until 
the end of the study.  The intervention was delivered in the Chest Clinic at the Royal Victoria 
Infirmary, Newcastle upon Tyne or within the patients’ home.   
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Training of Respiratory Nurses 
A half day training session was developed to familiarise the nurses involved in the study with 
the Lung Manual Treatment Programme.  A presentation was given explaining the manual 
and how to use it.  Practical exercises were undertaken to reinforce the use of the Manual 
and ensure the nurses were confident when using it.  Mrs. Violet Knowles from the TSC also 
attended the session and gave positive feedback on her experience.   
Number and duration of CBT sessions 
Between two and six sessions of CBT therapy were offered depending on clinical need.  Ses-
sions were held every two weeks.  The first session was scheduled for 30 - 60 minutes. This 
included ten minutes for administration at the end of the session to complete notes and dic-
tate a letter for the consultant and GP when required.  Letters were sent after the second 
and final CBT session.  Subsequent follow up sessions were up to 30 minutes every two 
weeks over a three month period. 
CBT Clinical Supervision 
Psychological clinical supervision was provided to the four CBT nurse therapists on a monthly 
basis by Consultant Clinical Psychologist (Dr. Christine Baker) as per standard practice.  A 
standard template was used to record supervision sessions (See Appendix 11).  
 Quality control of manualised CBT programme 
In previous research studies attempts have been made to validate the quality of the CBT in-
tervention.  For this study data was collected to assess consistency of the CBT intervention 
delivered in the treatment arm.  Twenty two CBT sessions were video recorded to validate 
adherence to the CBT manual and the quality of the CBT intervention.   All the videos were 
assessed by a CBT therapist independent of the study delivery team using the CFARS rating 
scale.   
5.23 Outcome Measures for Anxiety and depression 
It was important to use well validated outcome measures to assess psychological symptoms 
and QOL.  As stated in chapter two a number of validated measures could have been em-
ployed to assess symptoms of psychological distress. The most common measures used in 
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previous studies are the Beck Anxiety Inventory, the Beck Depression Inventory and the Hos-
pital Anxiety and Depression Scale (117).  The HADS questionnaire has been used extensively 
in studies on the psychological management of anxiety and depression in COPD.  The HADS 
questionnaire was selected as the most appropriate outcome measure for this study for the 
following reasons: 
x To reduce the burden of completing long questionnaires for patients. 
x The HADS was recommended for future research in a systematic review (129) and al-
lowed comparability to other studies which have used the questionnaire. 
x A power calculation could be undertaken using published recommendations for the 
MCID for the HADS (122). 
x The clinical teams in the respiratory departments were already familiar with the 
HADS questionnaire and it seemed reasonable to use this for the study. 
5.24 Outcome Measures for QOL  
The patient burden of completing questionnaires was an important consideration when de-
signing the research.  Several disease specific QOL questionnaires were considered for ease 
of completion, sensitivity to change and validated in the COPD population.   Two outcome 
measures were chosen to measure QOL.  The first was the CAT Questionnaire, a newly vali-
dated disease specific health status (192). The advantage of the CAT Questionnaire is that it 
is readily available, easy to complete and interpret and practical for clinical use (213).  For 
research purposes the CAT is significantly shorter than the St Georges Respiratory Question-
naire (SGRQ) which is commonly used to assess QOL.    The CAT contains eight items with 
strong correlation between CAT and it is considerably shorter than the longer 51 item SGRQ 
which preceded it (192).  A difference or change of two or more units suggests a clinically 
significant difference or change in COPD health status  (214). The CAT test takes approxi-
mately five minutes to administer and is clearly less cumbersome for patients to complete 
than the SGRQ. 
The EuroQol 5 Dimension Questionnaire (EQ5D) was also used to assess generic QOL.  The 
EQ-5D  is a brief (five item) well utilised, self-administered, generic, QOL questionnaire, 
yielding a preference value (215). The EQ5D takes about five to ten minutes to administer 
and assists in cost effectiveness analysis of an intervention using quality adjusted life years.  
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The quality-adjusted life year (QALY) is a measure of disease burden, including the quality 
and quantity of life lived.  It is used to assess the value for money of a medical intervention.  
A cost effectiveness analysis is planned once 12 month data is collected. 
5.25 Statistical Methods 
Many RCTs aim to identify whether a treatment can reduce pre-existing levels of symptoms 
(such as anxiety) and obtain measurements at baseline and follow up   (216).  When this 
study was first planned the NIHR North East RDS based in Newcastle were consulted and Dr. 
Nick Steen formulated a brief analysis plan prior to the commencement of the study.  This 
was important as the method of data analysis should be specified in the trial protocol (216).  
Prior to analysing the data a detailed analysis plan was circulated to all supervisors for com-
ments.  For the purposes of this thesis “completer” analysis is presented for patients who 
completed 3 months follow up.  An “Intention to treat” analysis is planned for the final publi-
cation when data collection is complete. 
As stipulated in the sample size calculation, the groups were compared using independent t-
tests (the primary outcome variable being the HADS-Anxiety score at 3 months). Future anal-
yses by a statistical collaborator are underway using imputation analysis to derive the “inten-
tion to treat analysis”.  A longitudinal analysis will be undertaken on data collected at multi-
ple points in time, comparing the changes in HAD scores over time in the different trial arms 
using repeated measures analysis of variance. This will allow us to make use of all the ob-
served data for a patient even if they missed one or more time points. A Consort Diagram 
was produced. 
5.25.1 Statistical Software 
Data analyses were conducted using Minitab Version 17, Minitab Incorporated. 
5.25.2 Tests for Normality 
Many statistical procedures including student t-tests, correlation, regression, analysis of vari-
ance, namely parametric tests, are based on the assumption that the data follows a normal 
distribution (217).  The term ‘normal distribution’ assumes that the population of interest 
from which the samples are taken may not be ‘normal’ but rather the samples should be 
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compatible with the population (which they represent) (218).  Normality and other assump-
tions should be taken seriously, for when the assumptions are not correct, it is said to be im-
possible to draw accurate and reliable conclusions about the results.  Several tests can be 
undertaken to test distribution of data (217).  Visual inspection of the distribution may be 
used, although this approach is usually unreliable and does not guarantee that the distribu-
tion is normal (217).   A visual inspection can be made using dot plots (for small samples), 
histogram, stem –and-leaf-plot or normal plot.  Kolmogorov-Smirnov and Shapiro-Wilk com-
puter tests are sometimes used to assess normality more objectively.  For this study assess-
ment of normality was undertaken for continuous variables by visual inspection using histo-
grams.  An assessment was made to identify if the data was symmetrical, skewed to the right 
(positively skewed) or skewed to the left (negatively skewed). 
5.24.3 Population Description 
Descriptive statistics were used to describe characteristics of the patient population using 
means with standard deviations and percentages.   
5.24.4 Statistical Tests used for data analysis 
Statistical comparisons of  trials comparing variables at different time points can be under-
taken in several ways (216). One method is to compare the groups post treatment  (216).  Al-
ternatively a change score can be calculated by subtracting the follow up score from the 
baseline score.  Using the change score approach leads to a statement such as ‘anxiety re-
ductions were 1.5 points greater on treatment A compared to treatment B’. Using change 
scores takes into account imbalances at baseline between treatment groups (216).  How-
ever, if the average baseline scores are the same in each group the estimated treatment ef-
fect will be the same using these two approaches  (216).    Vickers and Altman highlight an 
important point,  if the treatment is effective the statistical significance of the treatment ef-
fect by the two methods described above, will depend on the correlation between the base-
line and follow up scores (216).  If the correlation is low using the change score will add vari-
ation and the follow up score is more likely to show a significant result (216).  Conversely, if 
the correlation is high using only follow up scores will lose information and the change score 
is more likely to be significant (216).  Whichever method is used should be specified in the 
trial protocol in advance (216).   
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For the primary outcome in this study the change score was  calculated for continuous nu-
merical data  to take account of chance imbalances at baseline between the treatment 
groups (216).  To calculate the change score the HADS-Anxiety scores at three months follow 
up were subtracted from baseline to identify the individual change  in scores (216). Unpaired 
student t-test were then used to analyse the data from the two groups.   Assumptions for 
paired tests include the data from the population of interest are normally distributed and 
the sample size is reasonable (219). However, as this study had a large  sample size i.e. over 
30-40, it is argued that the sampling distribution tends to be normal, regardless of the shape 
of the data hence the violation of the normality assumption should not cause major prob-
lems (217).    
Unpaired student t-tests were also used to compare secondary outcome variables for HADS-
Depression and CAT scores at three months.  Paired student t-tests were used to analyse nu-
merical data from related groups (CBT group) at baseline and three months and self-help 
leaflet group at baseline and three months.  Unpaired student t-tests were conducted to see 
if there were any differences between baseline mean HADS-Anxiety and HADs-Depression 
scores of patients who completed the study compared to those who were recruited but ei-
ther did not receive the CBT intervention or patients who did not complete the three months 
follow up period.  Non-parametric tests were used where data were not normally distrib-
uted. 
Chi-squared tests were used to compare categorical data.   Logistic regression analysis was 
undertaken to assess the impact of a number of factors to predict who would respond to 
treatment.  Several continuous variables including HADS-Anxiety scores, HADS-Depression 
scores, age, gender, CAT score, EQ-5D utility scores and FEV1 were used.  The categorical var-
iable gender was also assessed.  In the CBT group, logistic regression analysis was under-
taken and included the variables outlined above plus the nurse therapists delivering the in-
tervention.  Pearson correlation was used to explore the relationship between several varia-
bles including HADS-Anxiety, HADS-Depression, CAT, EQ-5D utility scores, Age and FEV1.   
Where applicable, tests were two tailed and significance was set at a level of 0.05. Pearson 
correlation was used to identify the strength and correlation between two variables (such as 
FEV1 and HADS-Anxiety).   
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Further analysis is planned to use analysis of covariance (ANCOVA) for data collected from 
baseline and all time points thereafter.  This method is a better approach as it addresses 
baseline imbalance because of regression to the mean (216).  In effect ANCOVA adjusts each 
patients follow up score for his or her baseline score, but has the advantage of being unaf-
fected by baseline differences (216).  An additional advantage of ANCOVA is that it generally 
has greater statistical power to detect a treatment effect than other methods (220).  In addi-
tion ANCOVA can be seen as a type of multiple regression and can be expanded to include 
additional prognostic variable such as age and diagnostic group (216). However, as with all 
analysis of continuous data, ANCOVA depends on some assumptions.  Assumptions include 
that the groups are defined by the levels of a single factor, in the population of interest, the 
variable (e.g. HADS-Anxiety score) is normally distributed in each group, the variance in the 
groups is the same and the sample size is reasonable {Petrie, 2009 #1601}.  If these assump-
tions are not achieved data transformation may be indicated (221).    
5.26 Summary  
A critical analysis of the literature has highlighted the need for a well powered and designed 
RCT to identify if CBT is effective in reducing psychological distress.  This study builds upon 
and extends previous research evaluating the efficacy of psychological interventions for anxi-
ety and depression in COPD.  This study has been carefully planned to address weaknesses 
and recommendations of previous studies.  It is unique in that it utilises respiratory nurses 
who work closely with COPD patients.  Respiratory nurses have knowledge, skills and exper-
tise in caring for patients’ physical well-being. Additional training in addressing psychological 
skills is possible. CBT is an evidence based intervention that enhances respiratory nurses’ 
skills to managing frightening symptoms of breathlessness, anxiety and depression.  The 
most appropriate method to identify if CBT undertaken by respiratory nurses is effective for 
patients with COPD is a RCT was developed to address the research questions and test the 
hypothesis.   
This chapter has detailed the research methods used for the study.  In the next chapter the 
results will be presented.  Results are broken down into the following sections: 
1. Patient screening 
2. Recruitment 
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3. Population description 
4. Anxiety (primary outcome) 
5. Depression (secondary outcome) 
6. CAT HRQOL (secondary outcome) 
7. EQ-5D Generic QOL (secondary outcome) 
8. Correlation between variables at baseline 
9. Level of training to deliver intervention (secondary outcome) 
10. Patient feedback 
11. Summary 
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Chapter 6 – Results       
The results for the study will now be presented.  A Consort Diagram detailing the patient 
flow can be found below (Figure 16). 
Figure 16 – Consort Diagram of Patient Flow. 
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6.1 Patients Screened 
From June 2011 to October 2014 1518 patients were screened.   In total 620 (41%) patients 
recorded a HADS-Anxiety score <8, so were not eligible for the study.  There were 898 (59%) 
patients who were eligible with HADS-Anxiety score ≥8, of which 389 (43%) declined to par-
ticipate in the research.   Depression scores were collected from 1515 patients (data was in-
complete from three patients when the forms were collected).  Table 26 provides a summary 
of the outcome from screening patients for this study. 
Table 26- Summary of outcome from patients screened for eligibility. 
Description 
Number /(per-
cent) 
(n=1518) 
Mean HADS- 
Anxiety/(SD) 
Number /(percent) 
(n=1515) Mean HAS- 
Depression/(SD) 
 
Recruited 279 (18) 12.1 (3.1) 
 
279 (18) 9.2 (3.9) 
   
Declined 389 (26) 11.7 (3.02) 
 
388 (26) 8.7 (4.10) 
 
HADS-Anxiety <8 & 
HADS-Depression <8 620 (41) 3.9 (2.35) 
 
   
848 (56) 3.7 (2.22) 
 
Previous psychological 
problems 86 (6) 13.0 (3.2) 
 
86 6) 11.0 (4.30) 
 
‘COPD’ but FEV1/VC Ra-
tio >70 41 (3) 12.9 (3.56) 
 
41 (3) 9.7 (4.74) 
 
Unable to contact    24 (2) 11.9 (3.17) 
 
24 (2) 8.5 (4.79) 
 
Not COPD 27 (2) 11.5 (2.97) 
 
27 (2) 7.7 (3.28) 
 
In other study 4 (<1) 9.3 (0.50) 
 
4 (<1) 6 (4.76) 
 
Cognitive impair-
ment 24 (2) 13.0 (2.71) 
 
24 (2) 9.6 (4.44) 
 
Out of area 8 (<1) 10.9 (2.10) 
 
8 (<1)  9.1 (3.76) 
 
Prognosis less than 1 
year (cancer) 3 (<1) 14 (3.0) 
 
3 (<1) 10 (6.0) 
 
Requested CBT now 12 (<1) 12.6 (2.69) 
 
12 (<1) 10.3 (3.31) 
 
Died 1(<1) 13 
 
1 (<1) 10 
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The mean HADS-anxiety scores for the 1518 patients screened was 8.70 (SD 4.91).  As ex-
pected the scores were normally distributed and are shown in a histogram (Figure 17).  The 
median was 9 and IQR was 5-12. The arrow in figure 17 marks the entry criteria for this and 
previous research of CBT in COPD when the HADS Questionnaire was used.   
Figure 17 – Histogram of the distribution of HADS-Anxiety scores for 1518 patients screened for eli-
gibility for the study. 
                               
Figure 18 below shows the HADS-Depression scores for 1515 patients screened.  The distri-
bution of the scores does not appear to be normally distributed.  In this cohort, symptoms of 
depression were lower than symptoms of anxiety with the mean HADS-Depression score of 
7.0 (SD 4.55).  The median HADS-Depression score was 7 and IQR 3-10. 
Figure 18 – Histogram of the distribution of HADS-Depression scores for 1515 patients screened for 
eligibility for the study. 
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6.2 Baseline Characteristics of patients recruited 
In total, 279 patients were recruited: 139 patients were randomised to the CBT group and 
140 to the Leaflet group.   Baseline characteristics can be found in table 27. 
Table 27 – Baseline characteristics of patients recruited at baseline. 
 CBT Group (n=139) Leaflet Group (n=140) Total Patients (n=279) 
 Total /(Percent) Total /(Percent) Total /(Percent) 
Age (years) 66 67 66.5 
Gender    
Male 61 (44) 67 (48) 128  (46) 
Female 78 (56) 73 (52) 151 (54) 
Ethnic Group    
White British 139 (100) 140 (100) 279 (100) 
Educational Level    
No higher educational qualifications 
(e.g. GCSE and above) 100 (75) 103 (77) 203 (73) 
BTS Severity of airflow obstruction    
Mild 16 (11) 13 (9) 29 (10) 
Moderate 44 (32) 47 (34) 91 (33) 
Severe 50 (36) 49 (35) 99 (35) 
Very Severe 29 (21) 31 (22) 60 (22) 
MRC Breathlessness Score    
0- 2 8 (6) 12 (9) 20  (7) 
3 26 (19) 18 (13) 44 (16) 
4 39 (28)  44 (31) 83 (30) 
5 67 (48) 65 (46) 132 (47) 
Employment Status    
Employed 8 (6) 76 (4) 15 (5) 
Retired 60 (42) 56 (40) 115 (41) 
Unemployed 7 (5) 5 (4) 12 (4) 
Retired early due to ill health 65 (47) 72 (51) 137 (49) 
Married or Co-habiting 68 (49) 63 (45) 132 (47) 
Current smoker 39 (28) 40 (29) 79 (28) 
Mean pack years 46 49 47 
BMI (kg/M2) 26 27 
 
26.5 
Abbreviations: BMI -Body Mass Index, GCSE -General Certificate of Education, MRC- Medical Research Council. 
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There were no significant differences for any demographic or clinical parameters at baseline.                      
6.2.1 Age 
The mean age for all patients was 66 (range 41 to 88).  There was no difference between the 
two groups (p=0.40, 95% CI -3.31 – 1.34).   There were 157 (56%) of patients over 65 years of 
age and 61 (22%) of patients over 75 years.   Prior observations have suggested that anxiety 
may be more commonly associated with certain age groups.   Pearson product-moment cor-
relation was performed to identify if there was a relationship between the severities of anxi-
ety (as measured by the HADS-Anxiety scale) in the recruited population and age.  Figure 19 
shows a scatterplot of the correlation between HADS-Anxiety scores and age at baseline. 
Figure 19 – Scatterplot of the correlation between HADS-Anxiety scores and age at baseline. 
                              
There was a negative correlation indicating that anxiety decreases with age (-0.218, 
p=<0.001).  Pearson product-moment correlation was also performed to identify if there was 
a relationship between HADS-Depression and age.  Figure 20 shows the relationship be-
tween HADS-Depression scores and age at baseline. 
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Figure 20 – Scatterplot of the correlation between HADS-Depression scores and age at baseline. 
                           
The results indicate that depression decreases with age (-0.32, p=<0.001). 
6.2.2 Gender 
From the 279 patients recruited 151 patients (54%) were female and 128 (46 %) male.   
There was no difference between the groups regarding gender at baseline.   
6.2.3 Ethnicity 
All of the patients recruited were white British. From the patients screened there was only 
one patient from an ethnic minority group, who politely declined to participate in the study.   
There are no statistics on the prevalence of COPD in ethnic groups in the North East.  The 
low numbers of patients screened from ethnic groups other than white British may be unu-
sual to other areas in the country.  
6.2.4 Smoking Status 
Patients had a significant smoking history of 47 pack years.  From the patients recruited 79 
(28%) patients continued to smoke.   
6.2.5 Severity of Obstruction 
As expected for a secondary care population 159 (57%) patients recruited had severe to very 
severe COPD.  The severity of COPD for patients recruited into the study is shown below in 
table 28 using NICE Criteria (10). 
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Table 28 – Breakdown of severity of obstruction at baseline using NICE Criteria (n=279). 
Severity of Obstruction All patients n=279/(percent) CBT n=139 / (percent) Leaflets n=140 /(percent) 
Mild 29 (10) 16 (11) 13 (9) 
Moderate 91 (33) 44 (32) 47 (34) 
Severe 99 (35) 50 (36) 49 (35) 
Very Severe 60 (22) 29 (21) 31 (22) 
 
Pearson product-moment correlation was used to identify if there was a correlation be-
tween FEV1 and HADS-Anxiety.  Figure 22 shows a scatterplot of HADS-Anxiety scores and 
FEV1 at baseline of study entry.   
Figure 22 – Scatterplot of the correlation between HADS-Anxiety scores and FEV1 at baseline 
(n=279). 
                       
Unlike previous studies there was no correlation between HADS-Anxiety scores at baseline 
and actual  FEV1 recorded at baseline when analysed using Pearson Product-Moment Corre-
lation (-0.009, p=0.89), or HADS-Anxiety scores and FEV1 percentage predicted (0.06, 
p=0.32).  Similarly, Pearson product-moment correlation was used to identify if there was a 
correlation between FEV1 and HADS-Depression (Figure 23).  
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 Figure 23 – Scatterplot of the correlation between HADS-Depression scores and FEV1 at baseline 
(n=279).        
                         
The results indicate that there was no correlation between HADS-Depression scores and ac-
tual FEV1 recorded at baseline when analysed using Pearson Product-Moment Correlation 
(0.01, p=0.82), or HADS-Depression scores and FEV1 percentage predicted (-0.11, p=0.07).   
6.2.6 Medical Research Council (MRC) Breathlessness scores 
In total 259  (92%) recruited reported  MRC scores of  3 or above indicating significant disa-
bility associated with breathlessness affecting QOL with  132 (47%) reporting MRC 5. A sum-
mary of the scores can be found in table 29. 
Table 29- MRC Breathlessness scores of patients recruited at baseline (n=279). 
MRC Dyspnoea 
Score CBT Group n=139 /(percent) Leaflets n=140 /(Percent) Total n=279 /(percent) 
0-unable to answer 0 1 (<1) 1 (<1) 
1 0 0 0 
2 8 (6) 11 (8) 19 (6) 
3 25 (18) 19 (14) 44 (16) 
4 39 (28) 44 (31) 83 (30) 
5 67 (48) 65 (47) 132 (48) 
Median/mean 
MRC 4 4 4 
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6.2.7 Marital Status 
Just under half of patients were married or co-habiting. There was no significant difference 
between the mean HADS-Anxiety  or HADS-Depression scores for patients who were married 
or co-habiting compared to those who were not (Anxiety p=0.55 95% CI -0.951- 0.505; De-
pression p=0.11 95% CI -1.654 – 0.158).   
6.2.8 Mortality 
From 279 patients recruited only six patients died before reaching the primary endpoint at 
three months.  Two patients died in the CBT group and four patients from the Leaflet group.  
Table 30 provides information on the cause of death for each patient. 
Table 30 – Summary of cause of death for CBT and Leaflet groups (n=6) 
 CBT Group   
Patient Cause of Death Age Expected 
1 Infective exacerbation of COPD and bronchiectasis 84 Yes 
2 VF Cardiac Arrest 59 Yes 
    
 Leaflet Group   
1 Pneumonia/cor pulmonale/renal failure 82 Yes 
2 Pneumonia/Chronic lymph 76 Yes 
3 Pneumonia/Severe COPD/Type 2 respiratory failure 60 Yes 
4 Pneumonia 67 Yes 
 
6.2.9 Educational Status 
The majority of patients recruited in this study did not have any formal educational qualifica-
tions.  In total 203 (73%) patients did not have any educational qualifications. Only six (2%) 
patients had qualifications at A-level or above. 
6.2.10 Employment Status 
Very few patients were employed with only 15 (5%) stating they were working.   From the 
279 patients recruited, 137 (49%) stated they had to retire early due to ill health.  Out of the 
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patients who retired early 49 (36%) were under the age of 60 with 13 (9.5 %) of these pa-
tients under the age of 50.  A breakdown of employment status can be found in table 31. 
 Table 31- Employment status of patients recruited at baseline (n=279). 
Occupational Group 
CBT Group n=139 
Number /(percent) 
Leaflet Group n=140 
Number /(percent) 
Total n=279  
Number/(percent) 
Employed 9 (7) 6 (4) 15 (5.4) 
Retired 58 (42) 57 (40) 115 (41.2) 
Unemployed 7 (5) 5 (4) 12 (4.3) 
Retired early due to ill 
health 65 (47) 73 (52) 137 (49.1) 
 
6.2.11 BMI 
BMI ranged from 15 - 55. The mean BMI scores for 278 patients was 26 (27 in CBT group and 
26.5 in Leaflet group).  In total, 45 (16%) of patients had a BMI scores ranging from 15 to 20 
which is a poor prognostic indicator (222) (223).  A histogram of BMI scores from all patients 
recruited can be found in figure 24 and was normally distributed. 
Figure 24 – Histogram of the distribution of BMI scores for patients recruited (n=279). 
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6.2.12 Pulmonary Rehabilitation (PR) 
At the point of entry only a third of patients had completed PR despite the fact that PR is a 
key treatment for patients with COPD.  A breakdown of rehabilitation can be found in table 
32. In total, 102 patients had not completed PR.  It is likely that PR had been offered but this 
could not be confirmed.  A number of patients (56 patients) had been referred for PR.  Dur-
ing the study, 23 patients completed pulmonary rehabilitation (13 from the CBT group and 
10 from the leaflet group).  By the end of the 12 months study period only 120 patients 
(43%) had completed pulmonary rehabilitation.    The other 33 (59 %) patients who had been 
referred either declined, dropped out or the re-habilitation team were unable to contact 
them.   
Table 32-Breakdown of participation in pulmonary rehabilitation at baseline (n=279) 
  Number/ (percent) CBT Group           Number/ (percent) Leaflet Group     Total/ (percent) 
Completed at baseline 46 (33)    51 (36)    97 (35) 
No   54 (39)    48 (34)    102 (36) 
Declined  9 (7)    5 (4)    14 (5) 
Dropped out  3 (2)    5 (4)    8 (3) 
Unable to contact 0    2 (1)    2 (1) 
Referred  27 (19)    29 (21)    56 (20) 
 
6.2.13 Respiratory Medication 
At baseline patients were asked to report respiratory medication used. The results are pro-
vided in table 33. 
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Table 33- Self-reported respiratory medication used by patients at baseline (n=279) 
Self-Report  Respiratory Medication 
CBT Group (n-139)-   
Number/ (percent) 
Leaflet Group  
(n=140) 
Number / (percent) 
Total (n=279) 
Number / (percent) 
Short acting beta agonists 138 (99) 139 (99) 277 (99) 
Short acting anticholinergics 1 (1) 2 (1) 3 (1) 
Long acting beta agonists 2 (1) 1 (1) 3 (1) 
Long acting anticholinergics 128 (93) 132 (94) 187 (67) 
Corticosteroids/Long acting beta ago-
nists 133 (96) 134 (96) 267 (96) 
Mucolytics 55 (40) 59 (42) 114 (41) 
Nebulised short acting bronchodilators 18 (13) 21 (15) 39 (14) 
Diuretics 36 (26) 39 (28) 75 (27) 
Prepacks (steroids/antibiotics) 48 (35) 53 (38) 101 (36) 
Oxygen ( short burst) 4 (3) 2 (1) 6 (2) 
Oxygen  (Long term oxygen therapy) 15 (11) 9 (6) 24 (9) 
Oxygen  (Ambulatory oxygen) 2 (1) 4 (3) 6 (2) 
 
6.2.14 Medication for anxiety and depression 
Self-reported data was also collected on the use of pharmacological therapy for anxiety and 
depression. The results are provided in table 34. In this study 35% of patients reported re-
ceiving treatment for depression which is slightly higher than the 30% quoted in a recent sys-
tematic review (4). 
Table 34– Self-reported medication used for anxiety and depression at baseline (n=279) 
Self-Report Psychiatric Medication 
CBT Group  (N=139)  
Number / (percent) 
Leaflet Group  
(n=140) 
Number/(percent) Total / (percent) 
Anti-depressants 52 (37) 47 (34) 99 (35) 
Anxiolytics 14 (10) 6 (4) 20 (7) 
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6.3 Outcome of CBT group following randomisation 
 In the CBT group, 11 (8%) patients did not receive the allocated treatment (Table 35).  Data 
collection was missed for one patient at three months. 
Table 35 – Summary of randomised patients who did not receive CBT intervention. 
Number of patients Reason 
3 Dropped out (reasons stated: two patients withdrew consent; one patient’s husband was ill). 
2 Withdrawn (incorrectly completed HADS.  Scores <8 on re-screen so were not eligible). 
2 Withdrawn due to unrecognised cognitive impairment. 
2 Withdrawn due to psychiatric problems which clinical team were not aware of. 
1 Diagnosis changed from COPD to asthma. 
1 Lost to follow up.  Did not respond to telephone calls or letter to organise CBT.  This was re-ported to GP and hospital consultant. 
 
In total 129 patients received the allocated intervention.  At three months, 13 (10%) patients 
discontinued the intervention.  The reasons for discontinuing the CBT intervention can be 
found in table 36.    
Table 36 – Summary of patients who discontinued CBT intervention (n=13). 
Number of patients  Reason 
2  Died. 
4  Lost to follow up but known to be still alive 
5  Withdrew consent (reasons stated: ill health, too busy, ‘could not be bothered’ and 
‘not her cup of tea’). 
2  Found to be ineligible; one patient had psychiatric problems which clinical team were not aware of and another had cognitive impairment. 
 
Patients from both groups who did not complete the three month follow up are not included 
in the ‘per-protocol’ analysis.  Data collection was missed for one patient in the CBT group at 
three months. 
6.4 Outcome of Leaflet group following randomisation 
In the leaflet group, all of the randomised patients received the allocated intervention (140 
in total).  At three months, 18 (13%) patients discontinued the intervention (see Table 37). 
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Data collection was missed for one patient in the leaflet group at three months (which was 
the same as the CBT group). 
 
Table 37 – Summary of patients who discontinued Leaflet intervention. 
Number of patients Reason 
4 Died. 
6 Lost to follow up. 
7 Dropped out (reasons stated: social problems, too busy, ill health, three pa-tients requested CBT). 
1 Withdrawn as clinician requested CBT for patients who was in palliative phases of COPD. 
 
Across both treatment arms six (2%) patients died before the three months follow up time 
point which was lower than the 10% at 3 months and 15% over the year anticipated at the 
start of the study.  Data attrition was 15% overall which was lower than the anticipated 20% 
at the start of the study.   
6.5 Comparison of patients completing study to 3 months (completers) and patients who did 
not (non-completers). 
When the non-completers were grouped irrespective of treatment allocation there were no 
difference between those who completed the three month follow up compared to patients 
who did not for the following: age, FEV1, HADS-Anxiety, HADS-Depression, CAT or EQ-5D util-
ity scores (Table 38).  
Table 38 – Comparison of variables between patients completing three month follow up and those 
who did not. 
Variable 
Completers (number= 
236) 
Non-Completers (num-
ber=43)   
 Mean (SD) Mean (SD) p-value 95% CI 
Age 66 (9.58) 65 (SD 11.5) 0.59 -2.71-4.74 
FEV1 1.33 (2.65) 1.11 (0.66) 0.27 -0.17-0.61 
HADS-Anxiety 12.1 (3.02) 12.3 (3.33) 0.68 -1.32-0.86 
HADS-Depression 9.0 (3.84) 10.3 (3.79) 0.05 -2.51-0.01 
CAT 28.3 (6.36) 29.3 (5.33) 0.27 -2.84-0.81 
EQ-5D Utility 0.41 (0.27) 0.38 (0.29) 0.48 -0.06-0.13 
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6.6 Anxiety 
The HADS-Anxiety scores ranged from eight (which was the minimum entry criteria) to 21 for 
the 279 patients recruited.  The distribution of HADS-Anxiety scores would be expected to be 
normally distributed in the general population.  However, in this study the distribution of the 
scores were skewed as the entry criteria into the study was ≥8 using HADS-Anxiety scale (fig-
ure 25).      
Figure 25– Histogram of the distribution of HADS-Anxiety Scores for patients recruited at baseline. 
                             
The mean HADS-Anxiety score for 279 patients was 12.1 (SD 3.1), median 12 and IQR 9 – 14.  
Mann-Whitney Test was used to analyse the data.  There was no difference between the 
groups for HADS-Anxiety scores at baseline using Mann-Whitney Test (Table 39).   
Table 39 – Comparison of HADS-Anxiety scores for CBT and Leaflet groups at baseline (n=279). 
 
CBT Group (n=139) 
Median     
Baseline 
Leaflet Group (n=140) 
Median     
Baseline p-value (95% CI) 
HADS-Anxiety Score 12.0  12.0  0.55 (-0.000-1.000) 
 
6.6.1 HADS-Anxiety Scores at three months  
 The primary outcome for this study was a change in group mean HADS-Anxiety scores at 
three months.  A clinically meaningful reduction is defined as ≥1.5 points on the HADS-Anxi-
ety scale (122).     In total 236 patients completed the primary endpoint of three months 
(85% completion rate).  Data was normally distributed (Figure 26).  The HADS-Anxiety scores 
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ranged from 0 -20 at three months.  The mean HADS-Anxiety score was 9.5 (SD 4.5), median 
9 and IQR 6-13.   
Figure 26 – Histogram of distribution of HADS-Anxiety scores for patients completing three 
months. 
                   
Of the 236 patients completing the primary endpoint, 132 (56%) improved over ≥1.5 on the 
HADS-Anxiety scale (termed responders).  Logistic regression analysis was performed on all 
patients completing the primary outcome at three months.  The aim was to assess the im-
pact of a number of factors to predict who would respond to either CBT or Leaflets (≥1.5 on 
the HADS-Anxiety scale).  Baseline continuous variables assessed included age, HADS-Anxi-
ety, HADS-Depression, CAT and EQ-5D utility scores at baseline.  Categorical variables in-
cluded gender.  Three variables made a unique contribution to the model (responding ≥1.5 
on HADS-Anxiety scale).  The strongest predictor was a HADS-Anxiety score at baseline with 
an odds ratio of 1.20 (p= 0.001 95% CI 1.07 – 1.34).  The second strongest was age with an 
odds ratio of 1.04 (p=0.005 95% CI 1.01 – 1.08).  The third strongest was the CAT score at 
baseline with an odds ratio of 0.94 (p=0.008 95% CI 0.89 – 0.98). 
6.6.2 HADS-Anxiety Scores for patients in the CBT group at three months. 
In the CBT arm the HADS-Anxiety scores ranged from 0 – 20.  The mean HADS-Anxiety score 
reduced from 12.3 (SD 3.19) at baseline to 8.9 (SD 4.50), at three months (Table 40).  The 
group mean change was 3.40 (SD 4.2; 95% CI 2.62 – 4.17 p=<0.001) reaching the suggested 
MCID of 1.5 (122).   
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Table 40 – Change in mean HADS-Anxiety scores for patients in the CBT group at baseline and three 
months. 
 
CBT Group (n=115) CBT Group (n=115) p-value  (95% CI) 
 
Mean    (SD)  
                  Baseline 
Mean    (SD)  
Three months  
     
HADS-Anxiety Score 12.3 (3.19) 8.9 (4.50) <0.001 2.62-4.17 
 
The interval plot in figure 27 shows mean change in HADS-Anxiety scores for the CBT group 
at baseline and three months. 
Figure 27- Interval plot of the mean HADS-Anxiety scores for the CBT groups at baseline and three 
months.   
 
                          
The results indicate there is a statistically and clinically significant improvement in mean 
HADS-Anxiety score at the three month primary end point in the CBT group. 
6.6.3 Comparison of responders compared to non-responders in CBT group. 
From the 115 patients, 69 (60%) patients achieved a decrease of ≥1.5 in HADS-Anxiety scores 
(responders) reaching the MCID for their individual scores suggested by Puhan (122) com-
pared to  46 (40%) who did not (non-responders).  Patients who achieved a fall of HADS-Anx-
iety scores by ≥1.5 in the CBT group were compared with those patients who did not re-
spond (Table 41).   
  
Three monthsBaseline
13
12
11
10
9
8
HA
DS
-A
nx
iet
y S
co
re
s
95% CI for the Mean
Individual standard deviations were used to calculate the intervals.
Mean  HADS-Anxiety scores in CBT group at baseline and three months.
p=<0.001 
  
 
149 
Table 41 – Comparison of baseline data in responder patients in CBT group compared to those who 
did not. (Responder was defined as a fall in MCID ≥1.5 on HADS-Anxiety Scale). 
 
Variable Responders (n=69 ) Non-responders  (n=46)   
 Mean (SD) Mean (SD) p-value 95% CI 
Age  68.1 (8.54) 62 (10.9) 0.002 2.33 – 9.91 
FEV1 1.15 (0.60) 1.29 (0.52) 0.19 -0.351 – 0.07 
HADS-Anxiety 12.5 (2.94) 12.0 (3.42) 0.42 -0.73 – 1.73 
HADS-Depression 8.64 (3.75) 10.0 (4.28) 0.08 -2.91 – 0.18 
CAT 27.0 (6.53) 29.11 (6.27) 0.09 -4.52 – 0.30 
EQ-5D Utility 0.48 (0.27) 0.35 (0.28) 0.02 0.02 – 0.23 
 
There was a significant difference between responders and non-responders for age and EQ-
5D utility scores. This suggests older patients and those with better QOL (as measure by the 
EQ-5D utility scores) responded better than younger patients reporting poorer QOL. 
6.6.4 HADS-Anxiety for patients in the Leaflet group at three months. 
The HADS-Anxiety scores in the leaflet group ranged from 0-19.  The mean HADS-Anxiety 
score reduced from 12.0 (SD 2.93) at baseline to 10.1 (SD 4.44) (Table 42).     
Table 42 – Mean HADS-Anxiety scores for patients in the Leaflet group at baseline and three 
months. 
 Leaflet Group (n=121)  Leaflet Group (n=121) p-value  (95% CI) 
 
Mean    (SD)  
Baseline 
 Mean    (SD)  
Three months  
      
HADS-Anxiety Score 12.0 (2.93)  10.1 (4.44) <0.001 1.19 - 2.55 
 
An interval plot of the mean HADS-Anxiety scores for the Leaflet group at baseline and three 
months is presented in figure 28. 
  
 
150 
 Figure 28 – interval plot of mean HADS-Anxiety scores for Leaflet group at baseline and three 
months. 
 
                         
The group mean change from baseline to three months was 1.9 (SD 3.8) 95% CI 1.19 – 2.55 
p=<0.001 reaching the suggested MCID of ≥1.5 (122). 
6.6.5 HADS-Anxiety Scores comparison of mean change between the CBT and Leaflet 
groups at three months. 
The group mean change in HADS-Anxiety scores was significantly greater in the CBT group 
compared to the leaflet group (mean difference = 1.52; CI 0.50 – 2.55; p=0.004) (Table 43) 
and reached the suggested MCID between the groups of ≥1.5.   
Table 43 – Mean change in HADS-Anxiety scores in CBT and Leaflet groups at three months 
(n=236). 
 
CBT Group 
(n=115) 
Leaflet Group  
(n= 121) p-value  (95% CI) 
 Mean    (SD) Mean    (SD)   
     
HADS-Anxiety Score 3.4 (4.2) 1.9 (3.8) 0.004 0.50 - 2.55 
 
Figure 29 shows an interval plot of the mean in HADS-Anxiety scores for the CBT and Leaflet 
groups at baseline and three months.   
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Figure 29– Interval plot of mean HADS-Anxiety scores for CBT and Leaflet groups at baseline and 
three months. 
                      
                                         
In total 132 (56%) of patients achieved an improvement in HADS-Anxiety scores at three 
months reaching the MCID of ≥1.5.  In the CBT group 69 (60%) patients improved compared 
to 63 (52%) in the leaflet group with no significant difference between the groups (Chi-
squared statistic 1.50; p=0.22). 
6.6.6 Comparison of responders and non-responders for HADS-Anxiety in Leaflet group  
Of the 121 patients, 63 (52%) patients achieved a decrease of >1.5 in HADS-Anxiety scores 
reaching the MCID for their individual scores.  There was no difference in any variable be-
tween those patients who achieved a fall of HADS-Anxiety scores by ≥1.5 in the Leaflet group 
compared with those patients who did not respond (Table 44).  
  
P=0.004 
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Table 44 – Comparison of patients with a HADS-Anxiety score reducing by MCID ≥1.5 in Leaflet 
group to those who do not. 
 
Variable Responders (n= 63) Non-responders  (n=58)                
 Mean (SD) Mean (SD) p-value 95% CI 
Age  68.2 (8.36) 66.2 0.22 -1.25 – 5.32 
FEV1 1.15 (0.5) 1.13 (0.58) 0.85 -0.17 – 0.21 
HADS-Anxiety 12.1 (3.13) 11.8 (2.64) 0.63 -0.79 – 1.29 
HADS-Depression 8.90 (3.69) 9.16 (3.42) 0.70 - 1.53 – 1.03 
CAT 29.1 (6.20) 28.1 (6.26) 0.35 - 1.18 – 3.31 
EQ-5D Utility 0.40 (0.30) 0.40 (0.31) 0.75 -0.12 – 0.10 
 
Gender 
From the 279 patients recruited 151 patients (54%) were female and 128 (46 %) male.   
There was no difference between the groups regarding gender at baseline.   
Males 
In the CBT arm the group mean HADS-Anxiety scores for male patients was 12.0 (SD 2.86), 
range 8-20 at baseline and this reduced to 8.9 (SD 4.18) range 1-19 at three months.  The 
mean difference change was 3.04 (SD 4.16), 95% CI 1.89 – 4.18 p= <0.001 at three months 
compared to baseline.  The mean change reached the suggested minimal clinical importance 
difference (MCID) ≥1.5 (122).  The mean HADS-Anxiety score for patients in the leaflet group 
reduced from 12.2 (SD 3.09) range 8-20 at baseline to 9.89 (SD 4.24) range 1-17 at three 
months. The mean change was 2.13 (SD 3.58),   95% CI 1.17 – 3.08 p= <0.001 at three 
months compared to baseline.   The mean change also reached the suggested MCID of ≥1.5 
(122).   Unpaired student t-tests were used to compare the group mean change in HADS-
Anxiety scores between the two groups at three months.  The results can be seen in table 
45.  There was no significant difference between the CBT and Leaflet groups for males. 
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Table 45 - Mean change in males HADS-Anxiety scores between CBT and Leaflet groups at three 
months (n=109). 
  
CBT Group (n=53) 
Males 
Leaflet  Group 
(n=56)   
  
Mean  (SD) 
Three months 
Mean    (SD) 
Three months p-value  (95% CI) 
      
HADS-Anxiety  3.04 (4.16) 2.13 (3.58) 0.22 -2.39 – 0.57 
 
Females 
In the CBT arm the group mean HADS-Anxiety scores for female patients was 12.6 (SD 3.40), 
range 8 to 21 at baseline.  The mean HADS-Anxiety scores reduced to 8.8 (SD 4.79) range 0-
20 at three months. The mean difference change was 3.69 (SD 4.24) 95% CI 2.62 – 4.77 p= 
<0.001 at three months compared to baseline, reaching the suggested MCID of ≥1.5 (122).  
In the leaflet arm the group mean HADS-Anxiety score was 11.7 (SD 2.80), range from 8-20 
at baseline.  The mean HADS-Anxiety reduced from 11.7 (SD 2.8) to 10.2 (SD 4.63) range 0-19 
at three months.  The mean difference change was 1.65 (SD 3.97), 95% CI 0.66 – 2.63 
p=0.001.  Unpaired student t-tests were used to compare the group mean change in HADS-
Anxiety scores between the two groups at three months.  The results can be seen in table 
46. 
Table 46 - Mean change in females HADS-Anxiety scores in the CBT and Leaflet groups at three 
months (n=127) 
  CBT Group (n=62) females Leaflet  Group (n=65)   
  Mean  (SD) at 3  months Mean    (SD) at 3 months p-value  (95% CI) 
      
HADS-Anxiety  3.69  (4.24) 1.65  (3.97) 0.006 0.60 – 3.49 
 
The interval plot presented in figure 21 shows the mean change in HADS-Anxiety scores for females 
in the CBT and Leaflet groups at three months. 
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Figure 21- Interval plot of mean change in HADS-Anxiety scores for females in the CBT and Leaflet 
groups at three months.  
                                    
In contrast to the male patients, the mean change in the HADS-Anxiety scores in the CBT 
group for females was significantly better than the leaflet group as shown in figure 21 above. 
 
6.7 Depression  
Baseline HADS-Depression scores ranged from zero to 20 for 279 patients recruited.  The 
HADS-Depression scores were normally distributed (Figure 30).  The mean score was 9.2 (SD 
3.9), median 9 and IQR 7-20.   
Figure 30 – Histogram of the distribution of HADS-Depression scores for patients recruited at base-
line (n=279). 
                                           
There was no difference between the groups for HADS-Depression scores at baseline (Table 
47).  Two thirds of patients recruited 186 (67%) reported symptoms of depression with a 
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HADS-Depression score ≥8.  A total of 24 (9%) patients reported significant symptoms of de-
pression with HADS-Depressions scores ≥ 15.  
Table 47- HADS-Depression scores at baseline between CBT and Leaflet groups at baseline (n=279). 
 CBT Group (n=139) Leaflet Group (n= 140)  
 
Mean    (SD) 
Baseline 
Mean    (SD) 
Three months p-value (95% CI) 
HADS-Depression Score 9.42 (4.01) 8.98 (3.68) 0.34 (-0.470 - 1.347) 
     
6.7.1 HADS-Depression Scores for patients at three months. 
A secondary outcome measure for this study was a reduction in group mean HADS-Depres-
sion scores at three months.  This was defined by a clinically meaningful reduction in group 
mean of ≥1.5 points on the HADS-depression scale at three months.  Data collected at three 
months was normally distributed (Figure 31).   
Figure 31– Histogram of the distribution of HADS-Depression scores for patients recruited at three 
months (n=279). 
 
                                  
Logistic regression analysis was performed on all patients (236 patients in total) to assess the 
impact of a number of factors on the likelihood that they would respond ≥1.5 on the HADS-
Depression scale (responders).  Baseline continuous variables assessed included baseline 
age, HADS-Anxiety score, HADS-Depression score, CAT and EQ-5D utility scores.  Categorical 
variables included gender only.  Only two variables made a unique contribution to the 
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model.  The strongest predictor was HADS-Depression at baseline with an odds ratio of 1.22 
(p= <0.001 95% CI 1.12 – 1.32).  The second predictor was age with an odds ratio of 1.06 
(p=<0.001 95% CI 1.03 – 1.09).  This analysis was repeated in those patients whose HADS-De-
pression scores were ≥8 at baseline i.e. a significantly raised HADS-Depression at inclusion 
but had improved ≥1.5 on the HADS-Depression scale. Logistic regression analysis was per-
formed on 108 patients to assess the impact of a number of factors on the likelihood that 
they would respond ≥1.5 on the HADS-Depression scale (responders).  Baseline continuous 
variables assessed included baseline age, HADS-Anxiety score, HADS-Depression score, CAT 
and EQ-5D utility scores.  Only one variable made a unique contribution to the model.  The 
only predictor was HADS-Depression at baseline with an odds ratio of 1.46 (p= <0.001, 95% 
CI 1.22 – 1.74).  
6.7.2 HADS-Depression Scores for patients in the CBT group at three months. 
The mean HADS-Depression scores for the CBT group were compared at baseline and three 
months. The data presented is restricted to those with complete data sets. In the CBT group 
the mean HADS-Depression score reduced from 9.18 (SD 4.1) at baseline to 6.99 (SD 4.44) at 
three months (Table 48).  The mean difference change was 2.2   (SD 3.62) 95% CI 1.53 – 2.87 
p=<0.001 reaching the suggested MCID of ≥1.5 (122).  
Table 48 – Mean HADS-Depression scores for patients in CBT group from baseline to three months 
(n=115).   
 CBT Group (n=115) CBT Group (n=115) p-value  (95% CI) 
 
Mean    (SD)  
Baseline 
Mean    (SD)  
Three months  
     
HADS-Depression Score 9.18 (4.01) 6.99  (4.44) <0.001 1.53 - 2.87 
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Figure 32 shows an interval plot of the mean HADS-Depression scores for the CBT group 
from baseline to three months. 
Figure 32– Mean HADS-Depression scores for CBT group at baseline and three months (n=115). 
                                 
The results indicate the CBT group achieved a statistically and clinically significant improve-
ment in symptoms of depression from baseline to three months.                       
6.7.3 Comparison of responders and non-responders in CBT group 
From the 115 patients, 60 (52%) patients achieved a decrease of ≥1.5 in HADS-Depression 
scores (responders) reaching the MCID for their individual scores suggested by Puhan (122) 
compared to  55 (48 %) who did not (non-responders).  Patients who achieved a fall of HADS-
Depression scores by ≥1.5 in the CBT group mean change scores were compared with those 
patients who did not respond (Table 49).   
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Table 49 – Comparison of patients with HADS-Depression scores reducing by MCID ≥1.5 in CBT 
group compared to those who did not (n-115). 
 
Variable Responders (n=60 ) Non-responders  (n=55)   
 Mean (SD) Mean (SD) p-value 95% CI 
Age 67.1 (8.60) 64.1 (11.1) 0.11 -0.66 – 6.74 
FEV1 1.17 (0.60) 1.24 (0.55) 0.51 -0.28 - 0.14 
HADS-Anxiety 12.7 (3.06) 11.8 (3.18) 0.12 -0.24 – 2.07 
HADS-Depression 10.2 (3.58) 8.09 (4.20) 0.005 0.64 – 3.54 
CAT 28.5 (6.39) 27.1 (6.56) 0.24 -0.95 – 3.84 
EQ-5D Utility 0.37 (0.30) 0.49 (0.25) 0.02 -0.23 - -0.02 
 
The results indicate that patients who responded had a higher mean HADS-Depression score 
at baseline compared to those who did not respond.  This finding is interesting as it has been 
suggested that patients with low scores at baseline generally improve more than those with 
high scores (216). 
6.7.4 HADS-Depression scores for patients in the Leaflet group at three months. 
In the Leaflet group the mean HADS-Depression score reduced from 8.84 (SD 3.68) at base-
line to 7.76 (SD 4.14) at three months (Table 50).  The mean difference change was 1.07 (SD 
3.55) 95% CI 0.44 – 1.71 p=<0.001 which did not reach the suggested MCID of ≥1.5 (122).  Of 
the 121 patients with complete data, 50 (41%) patients achieved a decrease of >1.5 in HADS-
Anxiety scores. 
Table 50– Mean HADS-Depression scores in Leaflet group at baseline and three months (n=121). 
 Leaflet Group (n=121) 
Leaflet Group at three months 
(n=121) p-value  (95% CI) 
 
Mean    (SD) 
Baseline 
Mean    (SD) 
Three months  
     
HADS-Depression 
Score 8.84 (3.68) 7.76 (4.14) <0.001 
0.44 – 
1.71 
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An interval plot of the HADS-Depression scores for patients in the Leaflet group at baseline 
and three months is presented in figure 33.    
Figure 33 - Interval plot of mean HADS-Depression scores for patients in Leaflet group at baseline 
and three months (n=121). 
 
                             
Whilst the results are statistically significant between baseline and three months for Leaflet 
group, the mean change in HADS-Depression scores failed to reach the MCID of   ≥1.5 (122). 
6.7.5 HADS-Depression Scores comparison of mean change between the CBT and Leaflet 
groups at three months. 
The mean HADS-Depression scores for the two groups were compared at three months. The 
data presented is restricted to those with complete date sets. The reported MCID of HADS 
score is an improvement (fall) in scores >1.5.  In the CBT group the mean reduction in HADS-
Depression scores was 2.20 and the leaflet group was 1.07 (see Table 51).  The CBT arm was 
statistically significantly better than the leaflet arm (p=0.02) this did not reach the MCID 
when compared across intervention arms (mean difference 1.13).   
Table 51 – Mean change in HADS-Depression scores between CBT and Leaflet groups at three 
months (n=236). 
 
 CBT Group (n=115) Leaflet Group (n=121) p-value  (95% CI) 
 
Mean    (SD)  
Baseline 
Mean    (SD)  
Three  months  
     
HADS-Depression Score 2.20 (3.62) 1.07 (3.55) 0.02 0.21 - 2.05 
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The mean change in HADS-Depression scores from baseline and three months for both 
groups can be seen in figure 34. 
Figure 34 – Interval Plot of mean HADS-Depression Scores for CBT and Leaflet groups at baseline 
and three months. 
                             
6.7.6 Comparison of response by MCID of ≥1.5 for HADS-Depression scores in Leaflet group. 
From the 121 patients, 50 (41%) patients achieved a decrease of ≥1.5 in HADS-Depression 
scores (responders) reaching the MCID for their individual scores suggested by Puhan (122) 
compared to 71 (59 %) who did not (non-responders).  Patients who achieved a fall of HADS-
Depression scores by ≥1.5 in the Leaflet group were compared with those patients who did 
not respond (Table 52).   
Table 52 – Comparison of patients with HADS-Depression score reducing MCID ≥1.5 in Leaflet 
group compared to those who did not (n=121). 
 
Variable Responders (n=50 ) Non-responders  (n=71)   
 Mean (SD) Mean (SD) p-value 95% CI 
Age 68.8 (9.01) 66.2 (9.02) 0.12 -0.65 – 5.94 
FEV1 1.09 (0.47) 1.15 (0.56)) 0.53 -0.246– 0.13 
HADS-Anxiety 12.0 (2.96) 11.9 (2.87) 0.86 -0.98 – 1.16 
HADS-Depression 9.94 (3.63) 8.06 (3.53) 0.005 0.57 – 3.20 
CAT 28.3 (7.54) 29.0 (5.17) 0.60 -3.10 – 1.80 
EQ-5D Utility 0.39 (0.36) 0.41 (0.27) 0.68 -0.14 – 0.10 
 
P=<0.001 
p=<0.001 
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6.8 CAT QOL 
A secondary outcome measure for this study was an improvement in HRQOL as measured by 
the CAT Questionnaire.   
6.8.1 CAT QOL Scores for 279 patients recruited at baseline 
The baseline CAT scores ranged from 7 to 40.  The distribution of the CAT scores were not 
normally distributed. The CAT scores appears slightly skewed towards higher scores indicat-
ing significant impact on HRQOL, reflecting a symptomatic secondary care COPD cohort (Fig-
ure 35). The mean score was 28.4 (SD 6.22), the median 30 and IQR 25-40.    In total 253 
(91%) of patients had a CAT score over 20 suggesting this COPD population had a significant 
burden of symptoms. 
Figure 35 – Histogram of the distribution of CAT Scores for patients recruited at baseline (n=279). 
                                
                                                    
Table 53 shows the CAT scores from all patients recruited at baseline.  The high scores ob-
served suggest significant burden of symptoms affecting HRQOL. 
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Table 53 –Median CAT scores from patients in CBT and Leaflet groups at baseline (n=279). 
 CBT Group (n=139) Leaflet Group (n= 140) 
 
 Median Median p-value (95% CI) 
CAT  29 30 0.55 (-2.000-1.000 
 
The results show that there was no difference between the groups for the CAT score at base-
line using Mann-Whitney Test. 
6.8.2 CAT results at three months. 
Complete CAT score data were collected at 3 months for 229 patients (111 from CBT group 
and 118 from the leaflet group).  Data was normally distributed (Figure 36).   
Figure 36 – Histogram of the distribution of CAT Scores from patients at three months (n=229). 
                    
The mean CAT score was 25.8, range six to 40, median 27, IQR 21-31.  From the group, 120 
(52%) patients achieved an improvement in CAT scores reaching the previously reported 
MCID of >2 for their individual scores (214).               
6.8.3 CAT results for the CBT group at three months. 
In the CBT group the mean CAT score reduced from 27.7 (SD 6.56)   at baseline to 25.0 (SD 
7.65) at three months (Table 54).  The mean difference change was 2.7 (SD 6.36); 95% CI 
1.49 – 3.88 p=<0.001. The mean change reached the suggested MCID of 2 points (214).  60 
(54%) patients achieved an improvement >2. 
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Table 54- Mean CAT scores from patients in CBT group at baseline and three months (n=111).        
  CBT Group (n=111) CBT Group (111)   
  
Mean    (SD) 
Baseline 
Mean    (SD) 
Three months p-value  (95% CI) 
      
CAT (Health Status)  27.7 (SD 6.56) 25.0 (SD 7.65) <0.001 1.49 - 3.88 
      
6.8.4 CAT Scores for patients in the Leaflet group at three months. 
In the Leaflet group the mean CAT score reduced from 28.7 at baseline to 26.6 at three 
months (see Table 55).  The mean difference change was 2.06 (SD 5.30), 95% CI 1.09 – 3.04 
p=<0.001. This mean change also reached the suggested MCID of 2 points.   Of the 118 pa-
tients with complete data, 60 (51%)   patients achieved an improvement >2. 
Table 55– Mean CAT Scores for patients in the Leaflet group at baseline and three months (n=118). 
  
Leaflet Group 
(n=118) Leaflet Group (118)   
  
Mean    (SD) 
Baseline 
Mean    (SD) 
Three months p-value  (95% CI) 
      
CAT (Health Status)  28.7 (SD 6.28) 26.6 (6.72) <0.001 1.09 - 3.04 
 
6.8.5 CAT Scores comparison of mean change between the CBT and Leaflet groups at three 
months. 
Mean change in CAT scores from baseline were 2.68 (SD 6.36) for the CBT group and 2.06 
(SD 5.34) for the Leaflet group.  There were no statistical differences between the two 
groups (Table 56).  In total 120 (52%) of patients achieved the recommended minimal im-
provement of ≥2 or more on the CAT scale  (214). 
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Table 56 – Mean change in CAT Scores between CBT and Leaflet groups at three months (n=229). 
 
 CBT Group (n=111) Leaflet Group (n=118 )  
 Mean    (SD) Mean    (SD) p-value (95% CI) 
     
CAT (Health Status) 2.68 (6.36) 2.06 (5.34) 0.43 -0.91 – 2.16 
 
The mean CAT scores for the two intervention groups were compared at 3 months. The data 
presented is restricted to those with complete date sets (completer analysis). The reported 
MCID of the CAT score is an improvement (fall) in scores >2. The fall seen in the CBT group 
was not significantly different to the leaflet arm (2.68 vs 2.06, p=0.20) (see figure 37).   
Figure 37– Interval Plot of mean change in CAT Scores between the CBT and Leaflet groups three 
months. 
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However, there was a clinical improvement from baseline CAT scores in both intervention 
arms as per reported MCID (214). 
6.9 EQ-5D QOL 
A secondary outcome for this study was an improvement in QOL as measured by the EQ-5D 
Questionnaire.   
6.9.1 EQ-5D QOL Scores for 279 patients recruited at baseline 
The baseline EQ-5D utility scores for 279 patients ranged from -0.29 (feeling worse than 
death) to 1.0 (perfect health).  The distribution of the EQ-5D utility scores were not normally 
distributed (Figure 38). At baseline the median score was 0.52 and IQR -0.29 – 1.0.  
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Figure 38 – Histogram of the distribution of EQ-5D utility scores at baseline (n=279). 
                                   
There was no difference between the groups for EQ-5D utility scores at baseline using paired 
student t-test (Table 57).    At baseline 122 (44%) of patients rated their overall health less 
than 50%.  Furthermore, 37 (13%) patients reported a negative value utility score represent-
ing a health state equivalent to ‘worse than death’ suggesting a significant impact on QOL.  
Table 57 – EQ-5D utility Scores for CBT and Leaflet groups at baseline (n=279). 
  CBT Group (n=139) Leaflet Group (n=140)  
  Mean  Mean p-value  (95% CI) 
      
EQ-5D Utility Score  0.41 (SD 0.29) 0.41 (SD 0.30) 0.95 -0.072—0.067 
 
The reported symptom burden at baseline was high.  From the EQ-5D domains, 268 (97%) 
patients reported problems performing their usual activities.  In total, 234 (84%) patients re-
ported problems with mobility, 231 (83%) reported symptoms anxiety and/or depression 
and 206 (74%) reported pain/discomfort. 
6.9.2 EQ-5D utility Scores for all patients at three months. 
At three months data was collected on 228 patients (111 from CBT group; 117 leaflet group).  
The EQ-5D utility scores ranged from   -0.35 to 1.0 at three months.  The median score was 
0.59 and IQR 0.19 -1.0.   Data was not normally distributed in this cohort (Figure 39).  Due to 
the sample size, parametric tests were used as advised by the statistician. 
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Figure 39 – Histogram of distribution of EQ-5D utility scores for all patients at three months 
(n=228). 
                                    
6.9.3 EQ-5D utility scores in the CBT group at three months. 
At three months complete data was available for 111 patients in the CBT group.     The mean 
EQ-5D utility score improved from 0.43 (SD 0.28) to 0.51 (SD 0.34) reaching the MCID of 
≥0.08 (224). Results are presented in table 58.   
Table 58 – EQ-5D utility scores in CBT group at baseline and three months (n=111). 
  CBT Group (n=111) CBT Group (n=111)   
  
Mean 
Baseline 
Mean 
Three months p-value  (95% CI) 
      
EQ-5D Utility Score  0.43 (0.28) 0.51 (0.34) 0.007 -0.11 - -0.02 
 
Figure 40 shows an interval plot of the mean change in EQ-5D utility scores from the CBT 
group at baseline and three months.   
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Figure 40 – Interval plot of EQ-5D utility scores for CBT group at baseline and three months. 
                          
The QOL measured by EQ-5D utility scores improved significantly from baseline to three 
months in the CBT group. 
6.9.4 EQ-5D utility scores in the Leaflet group at three months. 
At three months complete data was available for 117 patients in the Leaflet group.  The 
group mean EQ-5D utility scores in the Leaflet group at three months of 0.42 was unchanged 
at three months.  Results are presented in table 59.  The Leaflet group did not reach statisti-
cal significance or reach the MCID of 0.08 (224).   
Table 59 - Mean change in EQ-5D utility scores in Leaflet group at baseline and three months 
(n=117). 
  Leaflet Group  (n=1117) Leaflet  Group (n=117)   
  
Mean 
Baseline 
Mean 
Three months p-value  (95% CI) 
      
EQ-5D Utility Score  0.42 (0.30) 0..42 (0.34) 0.09 -0.06 – 0.05 
 
Figure 41 shows an interval plot of the mean change in EQ-5D utility scores from the Leaflet 
group from baseline and three months. 
  
3 MonthsBaseline
0.60
0.55
0.50
0.45
0.40
0.35
M
ea
n 
EQ
-5
D 
Ut
ili
ty
 S
co
re
s
95% CI for the Mean
Individual standard deviations were used to calculate the intervals.
 EQ-5D Utility scores in CBT Group  at  baseline and three months
p=0.007 
  
 
168 
Figure 41 – Interval plot of EQ-5D utility scores for the Leaflet group at baseline and three months. 
                               
The leaflet group did not reach statistical significance or reach the MCID of  ≥0.08 (224). 
6.9.5 EQ-5D utility scores comparison of mean change between the groups at three 
months. 
The mean change in the CBT group was -0.08 in CBT group and -0.003 in the leaflet group 
(Table 60).   
Table 60 – Mean change in EQ-5D utility scores between CBT and Leaflet groups at three months 
(n=228). 
  CBT Group (n=111) Leaflet  Group (n= 117)  
  Mean    (SD) Mean    (SD) p-value  (95% CI) 
      
EQ-5D Utility Score  -0.08 (0.31) -0.003 (0.31) 0.06 -0.16- 0.00 
 
Figure 42 shows an interval plot of the mean change in EQ-5D utility scores from the CBT 
group compared to the Leaflet group at baseline and three months.   
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Figure 42 – Interval Plot of mean change in EQ-5D utility scores for CBT and Leaflet groups at three 
months. 
                                   
The group mean change in EQ-5D utility scores did not reach statistical or clinical significance 
between the two groups at three months.        
6.10 Correlation between psychological and QOL variables 
Pearson product-moment correlation was used to explore the relationship among psycho-
logical variables and QOL.  A summary of the results is presented in table 61. 
Table 61 – Relationship between outcome measures at baseline. 
Variables Pearson Correlation P Value 
HADS-Anxiety and HADS-Depression 0.475 <0.001 
HADS-Anxiety and CAT 0.30 <0.001 
HADS-Anxiety and EQ-5D utility -0.28 <0.001 
HADS-Depression and CAT 0.427 <0.001 
HADS-Depression and EQ-5D utility -0.40 <0.001 
CAT and EQ-5D utility 0.42 <0.001 
 
The results show there was a correlation between the variables tested.  These will be now be 
presented. 
6.10.1 Correlation between HADS-Anxiety and HADS-Depression Scores at baseline 
There was a positive correlation between symptoms of anxiety and depression at baseline 
(0.475, p=<0.001) (figure 43).   
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Figure 43 – Scatterplot of correlation between HADS-Anxiety and HADS-Depression scores at base-
line. 
                               
The results indicate that symptoms of depression as measured by the HADS scale increase 
with symptoms of anxiety.            
6.10.2 Correlation between HADS-Anxiety and CAT at baseline. 
There was also a positive correlation between HADS-Anxiety and CAT scores at baseline 
(0.30, p=<0.001) (figure 44). 
Figure 44 – Scatterplot of correlation between HADS-Anxiety and CAT scores at baseline. 
                        
The results indicate that as increased symptoms of anxiety is associated with poorer HRQOL 
as measured by the CAT. 
6.10.3 Correlation between HADS-Anxiety and generic QOL  
There was a negative correlation between HADS-Anxiety and generic QOL as measured by 
the EQ-5D utility scores (-0.28, p= <0.001).  This is demonstrated in figure 45.   
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Figure 45- Scatterplot of correlation between HADS-Anxiety and EQ-5D utility scores at baseline. 
                    
The results indicate that as symptoms of anxiety decrease, QOL as measured by the EQ-5D 
utility score improves. 
6.10.4 Correlation between HADS-Depression and CAT at baseline. 
As seen in figure 46, there was a positive correlation between HADS-Depression scores and 
HRQOL as measured by the CAT at baseline (0.427, p=<0.001).   
Figure 46 – Scatterplot of correlation between HADS-Depression and CAT scores at baseline. 
                                    
The results indicate that increased symptoms of depression is associated with poorer HRQOL 
as measured by the CAT. 
6.10.5 Correlation between HADS-Depression and EQ-5D utility scores at baseline. 
There was a negative correlation between HADS-depression at baseline and generic QOL as 
measured by the EQ-5D utility scores at baseline (Figure 47). 
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Figure 47 – Scatterplot of correlation between HADS-Depression and EQ-5D utility scores at base-
line. 
                               
The results suggest that symptoms of depression is associated with poor generic QOL as 
measured by the EQ-5D utility scores. 
6.10.6 Correlation between CAT and EQ-5D utility scores at baseline 
There was a negative correlation between HRQOL measured by the CAT and generic QOL 
measured by the EQ-5D utility scores (0.42, p=<0.001) as seen in figure 48. 
Figure 48- Scatterplot of correlation between CAT and EQ-5D utility scores at baseline. 
                               
The results indicate that poor HRQOL measured by the CAT scores is associated with poor 
generic QOL measured by the EQ-5D utility scores. 
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6.11 Nurse Training 
From the 129 patients who received CBT, 93 patients were seen by nurses with Diploma 
level training.  A breakdown of the number of patients seen depending on CBT level of train-
ing can be seen in table 62. 
Table 62- Breakdown of number of patients seen, mean age and number of sessions delivered de-
pending on level of training. 
Training 
Number of patients/ 
(percent) Mean age Mean number of sessions 
Diploma 93 (72) 65 3.6 
Foundation 36 (28) 65 4.0 
 
6.11.1 Results from video validation 
Twenty two CBT sessions were video recorded and assessed to evaluate adherence to the 
Lung Manual and competency delivering the CBT.  The modified CFARS rating scale was 
used.  The scoring system for the ten items range from zero (poor skills and competency) to 
6 (high level of skill and competency).  Nurses with Diploma level training would be expected 
to achieve high scores to gain their qualification.  The average competency scores for the 10 
items can be seen in table 63. 
Table 63 – Average competency scores for CFARS rating scale. 
Competency Average Score (scale 0-6) 
Focus/structure 5 
Pacing 4.4 
Feedback/summaries 4.5 
Integration of CBT 4 
Collaborative relationship 4.5 
Guided discovery 4.4 
Interpersonal effectiveness 4.3 
Elicit key components 4.4 
Application of appropriate change techniques 4.2 
Closure 4.3 
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The nurses scored highly on focus/structure, therapeutic relationship and feedback/summar-
ies.  Scoring four or above is certainly an acceptable level of skills and expertise.  A summary 
of the individual scores can be found in table 64. 
Table 64 – Summary of individual scores from video validation. 
Focus/ 
Structure 
Pac-
ing 
summar-
ies 
Integra-
tion CBT  relationship 
Guided 
 discovery 
Interper-
sonal  
effect 
Elicit key  
compo-
nents  
Change  
tech-
niques 
 
Closure 
4 4.5 4.5 4.5 5 4.5 5.5 4.5 4 
 4 
4 3.5 3.5 4 4 4.5 5 4 4.5 
 4.5 
5 5 5.5 5 5.5 5 6 5 5 
 5.5 
5.5 5.5 5 5 5.5 5.5 6 5.5 6 
 5 
5 5 5 5 5 4.5 5.5 5.5 4.5 
 4 
5 5 5 5 5 5 5 5 4 
 4 
5 4 6 5 5 5 6 5 5 
 5 
5.5 5.5 5.5 6 5.5 5.5 5.5 5.5 5 
 5 
5.5 4.5 5.5 5 4.5 5.5 5.5 5.5 5.5 
 5.5 
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 5 
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 5.5 
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 3.5 
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 4.5 
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6.11.2 Effectiveness of the CBT intervention for Diploma and Foundation Level Training 
A secondary outcome for this study was to explore the effectiveness of the CBT intervention 
when delivered by nurses with post-graduate diploma and foundation level training (consist-
ing of 3.5 days training) plus clinical supervision.   Descriptive results are presented here as 
the study was not powered to conduct a comparative analysis (Table 65). 
Table 65- Summary of outcome from nurses delivering the CBT intervention. 
    Level of Training 
Number of pa-
tients/(percent) 
Mean 
HADS- 
Anxi-
ety/SD 
at baseline  
Mean HADS- 
Anxiety at 
Three months 
Mean 
Differ-
ence 
at 
three 
months 
p-value  (95% CI) 
     Diploma level  83 (72) 12.3 (3.11) 8.93 (4.36) 3.37 <0.001 2.43 - 4.34 
    Foundation level  32 (28) 12.2 (3.26) 8.8 (4.92) 3.41 <0.001 2.05 - 4.76 
 
The mean number of CBT sessions was similar between the nurses  in the diploma level 
training group ( 3.62, median 3 and IQR 2-5 for diploma level training)  compared to 
foundation level training (3.98, median 3, IQR 5). The  mean severity of  COPD, HADS-Anxiety 
scores and number of CBT sessions was not discernably different between the diploma and 
foundation level.  Given the prior definition of a MCID in HADS-Anxiety score a definition of a 
responder can be made.  If a responder to an intervention was defined as a change in HADS 
domain of ≥1.5 then an analysis of characteristics or responders to CBT treatment compared 
to those who did not respond to CBT delivered by nurses with Diploma level training.  Table 
66 shows a comparison of responders to non responders in the CBT group for diploma level 
nurses. 
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Table 66 – Comparison of responders (HADS-Anxiety scores falling by ≥1.5) and non-responders 
from Diploma Level Nurses. 
Variable Responders (n=45 ) 
Non-responders  
(n=38)   
 Mean (SD) Mean (SD)       p-value                  95% CI 
Age  68.1 (8.28) 63(11.0) 0.02 0.84 – 9.50 
FEV1 1.16 (0.68) 1.30 (0.54) 0.32 -0.40 – 0.13 
HADS-Anxiety 12.9 (2.91) 11.6 (3.22) 0.05 0.002 – 2.71 
HADS-Depression 9.29 (3.47) 10.0 (4.28) 0.88 -1.63 – 1.89 
CAT 27.4 (6.32) 29.2 (5.95) 0.20 -4.45 – 0.92 
EQ-5D Utility 0.47 (0.27) 0.39 (0.28) 0.15 -0.03 – 0.21  
 
Table 67 presents a comparison of responders to CBT treatment compared to those who did 
not for nurses with Foundation  level training. 
Table 67 – Comparison  of responders (HADS-Anxiety scores falling by HADS ≥1.5)  and non-
responders for foundation level nurses. 
Variable Responders (n=22 ) 
Non-responders  
(n10)   
 Mean (SD) Mean (SD) p-value 95% CI 
Age  68.1 (9.60) 60.1(10.0) 0.05 0.05 – 16.03 
FEV1 1.13 (0.46) 1.17 (0.46) 0.79 -0.42 – 0.32 
HADS-Anxiety 11.8  (2.94)) 13.1.(3.87) 0.35 -4.30 – 1.64 
HADS-Depression 8.0 (3.66) 11.4 (5.02) 0.08 -7.22 – 0.42 
CAT 26.1 (7.19) 8.4 (7.44) 0.43 -8.22 – 3.69 
EQ-5D Utility 0.47 (0.29) 0.24 (0.30) 0.06 -0.12 – 0.46 
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6.12 Patient Feedback 
When data was collected at three months, patients were asked if they had read the written 
information leaflets provided.  In total 30 (22%) of patients reported that they did not read 
the information provided.   Table 68 below shows patient responses regarding reading writ-
ten information provided. 
Table 68 – Patient responses on reading written information. 
 No of patients/(per-
cent) 
Number of pa-
tients/(percent) 
Number of pa-
tients/(percent) 
 Not read Part-read Answer not provided 
CBT Group 18 (14) 56 (44%) 17 (13) 
Leaflet Group 12 (9)                 49 (35) 19 (14) 
 
Patients were asked if they would like to provide feedback about their experience participat-
ing in the study.  The comments provided have been formulated into positive comments and 
negative comments. 
Positive Comments 
Leaflet helped with cutting back on smoking and changing my lifestyle to lose weight. 
Help with breathing techniques was particularly useful. 
Breathing sections helpful. Exercise part not helpful. 
Very helpful - some exercises were challenging. 
Learning about breathing control using the elephant exercise to control my breathing very helpful. 
Information was good but I find it hard to concentrate. I feel very forgetful and tired all the time. 
Found the leaflet very good - helped to deal with anxiety. 
I think the information is OK.  Will read again. 
The information was thorough, adequate good information.  Incorporating lots of information. 
Straight forward.  Use questions, take time. Excellent.  Distraction very good.  I read it weekly. 
Extremely helpful - nurse was excellent, informative. 
Read all of the leaflet - found it very helpful.  Support was very good. 
Mostly helpful, recognised I had a problem. 
Information was useful - you don’t realise that many people feel like you. 
Leaflet has given me a better understanding of my condition and a different way of dealing  
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with anxious situation, which I found helpful. 
One to one sessions were more helpful. 
Information very good.  Answered all my questions.  I regularly look at the leaflets - marvelous. 
Handy - explains thing you don't know anything about. 
Improved my knowledge and increase my understanding of how I felt. 
Enlightening. 
Helpful. 
Ideas about coping were helpful. 
Information gives you an insight into your condition. 
A little bit helpful. 
Really good. 
Quite good - found that questions were answered in a simplistic way. 
Reading booklets took me back when I had stress and anxiety when I was younger. 
Throws light on things to do.  Pretty informative - how to overcome little things and calm down. 
Helped cope better with panic attacks and manage with breathing exercises. 
Very helpful- easy to read and take in. 
Best to be worked through with someone else - without guidance I think it might be potentially  
dangerous. 
 
Most of it was concerned with what I am already doing.  I found a positive benefit from talking to 
the nurse. 
 
Relaxation helps a lot. 
Absolutely brilliant - makes a big difference to life.   
Leaflet was good for anxiety. 
Very very helpful and good.  Makes you think twice. 
Please with information.  Lots of explanation of things I didn’t understand.  Very helpful indeed.   
My son also found it helpful. 
 
Helpful with panic attacks.  Made them better.  Not as bad now. 
I have tried to do what it says in the book.  Sometimes it seems to work, sometimes it takes longer. 
I found the information helpful- explained everything I needed to know. 
I feel benefit from talking in the Chest Clinic. 
Good idea to have the study - really appreciate the opportunity.  Very good to look at the whole person. 
Found techniques helpful. 
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Panic leaflet most helpful. 
Good made me think about pacing my activities prior to carrying them out. 
Really helpful - I've have the booklets to look at again if needed. 
Supports lots of strategies which work well. 
Quite helpful- common sense. 
Helpful - showed how to control breathing.   
Good reading about using distraction. 
Brilliant study- helpful to my care.  Using booklets during a current exacerbation. 
Feel like I have improved 100%. I'm getting out and about due to the information and support. 
A lot didn’t apply to me but I found the list making very helpful – even if it is a simple task. 
It's a good thing - good to know I'm not by myself. 
Felt it was really helpful especially when experiencing night time panic attacks. 
Definitely helpful - good to talk.  Everything was excellent.  Put me at ease. 
Some information was given in the rehab class such as using distraction. 
Found information from the study extremely helpful.  I have been able to use certain strategies 
to help manage breathlessness. 
 
I learnt how to cope with panic attacks - very helpful.  Big help- helped a lot. 
Information was quite useful.  I was made aware of things I wasn’t told about to manage and  
what symptoms to look for. 
 
Certainly beneficial, positive thoughts and coping strategies, able to more readily accept my  
condition and prognosis. 
 
Very improved with the written information. 
Yes - I knew a lot about panic attacks and anxiety as I have had depression and have agoraphobia. 
Helps with breathing by using distraction. 
Useful- I keep going back to the information.  I'm getting the hang of it. It’s helpful thinking more  
of why problems occur and questioning yourself. 
 
Negative Comments 
Couldn’t see how leaflet would help. 
Panic leaflet wasn’t helpful.  I thought it apply to those who have had a stroke. 
Learning about pacing myself was more helpful than the leaflet. 
Helped at first but lost interest in it - lost interest in everything. 
I was unable to read information and someone had to go through it with me. 
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Cannot see very well so had difficulties reading information. 
Made me feel depressed. 
Fine - helpful in some ways.  Difficult getting time to read them. 
I was hoping to have CBT in the study. 
No - not useful. 
Can't remember if useful.  Feels more accepting of condition now that there is nothing he can  
do to get better and that COPD is a chronic condition. I would prefer more effective treatment  
for my physical symptoms rather than CBT. 
 
It's not made any difference. 
 
Same as I already knew. 
Haven’t had time to read them. 
I need help with reading and writing – haven’t been through it with anyone yet. 
Didn’t feel I could use the strategies - feel very anxious all of the time. 
Not helpful at all- didn’t apply to me. 
A little bit helpful.  Kept forgetting after I read things. 
It was complicated. 
 
6.13 Summary 
The findings from this study result from an exploration of data from the population screened 
and recruited for this RCT.  From 1518 patients screened, 898 (59%) reported symptoms of 
anxiety and 667 (44%) reported symptoms of depression.  A total of 279 patients were re-
cruited.  The groups were well matched at baseline.  The mean age was 66.5 so the cohort 
were relatively young (range 41 – 88).  In total 57 % of patients had severe or very severe 
COPD indicating significant lung disease.  The population as a whole had few formal educa-
tional qualifications and nearly 50% of patients had to retire early due to ill health.    The 
baseline HADS-Anxiety scores was from patients recruited was 12.1 suggesting significant 
symptoms.   From the cohort a large number of patients recruited also reported symptoms 
of depression with 186 (67%) compounding their psychological difficulties.    At baseline the 
mean HADS-Depression scores were 9.2 (SD 3.9).  Whilst the baseline scores for depression 
were lower than anxiety scores, they were still in the abnormal range.   
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The primary outcome for this study was a change in group mean HADS-Anxiety scores at 
three months.  As recommended in the literature, the clinically meaningful reduction is de-
fined as of ≥1.5 points on the HADS-Anxiety scale.       There was a significant reduction in 
HADS-anxiety scores in both groups from baseline at three months:  CBT group mean change 
3.4 (SD 4.20) p=<0.001 CI 2.62- 4.17    and leaflet group mean change 1.9 (SD 3.80) p= <0.001 
CI 1.19 - 2.55. The reduction was more marked in the CBT group with a mean change of 1.52 
p =0.004 CI 0.50 – 2.55.  There was a significant reduction in HADS-depression scores in both 
groups at three months: CBT group mean change 2.20 (SD 3.62) p=<001 CI 1.53 – 2.87 and 
leaflet group mean change 1.07 (SD 3.55) p=0.001 CI 0.44 – 1.71.  The CBT group reached the 
MCID reduction of 1.5 at three months but the leaflet group did not.   
There was a significant reduction in the group mean change in the CAT scores from baseline 
in both groups : CBT group mean change 2.68 (SD 6.36) p=< 0.001 CI 1.49 – 3.88 and leaflets  
group mean change 2.06 (SD 5.34 p=<0.001 CI 1.09 – 3.04 but no difference between the 
groups at three months (p =0.43 CI -0.161 – 0.00).  There was a significant reduction in the 
group mean change in the EQ-5D utility scores from baseline in the CBT group:  mean change 
improvement 0.08 (0.31)   p=0.007 CI -0.14 - -0.02 and leaflet group mean change -0.003 (SD 
0.31) p= 0.09 CI -0.06 – 0.05) but no difference between the groups at three months (p =0.06 
CI -0.161 – 0.00).   The CBT reached the MCID of 0.08 but the Leaflet group did not.  There 
was no correlation between FEV1 for symptoms of anxiety or depression but positive correla-
tions were found between HADS-anxiety and HADS-Depression, HADS-Anxiety and the CAT, 
HADS-Depression and CAT and the CAT and EQ-5D utility scores.  Negative correlations were 
found between HADS-Anxiety and EQ-5D utility scores and HADS-Depression and EQ-5D util-
ity scores. 
This was a pragmatic trial which included patients with all severities of COPD and ages.   This 
study has identified that symptoms of anxiety are highly prevalent in COPD patients in this 
cohort from the North East of England. Both self-help leaflets and Respiratory nurses deliv-
ered CBT based intervention significantly reduced symptoms of anxiety and depression.   The 
CBT intervention achieved clinically and significantly better reductions in HADS-Anxiety, 
HADS-Depression, CAT and EQ-5D utility scores at 3 months.   The Leaflet group achieved a 
significantly significant reduction in HADS-Anxiety and CAT scores at three months but did 
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reach the clinical or statistically important improvements in the HADS-Depression and EQ-5D 
utility scores.  Overall the CBT intervention was superior to the Leaflet intervention.   
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Chapter 7 – Discussion 
7.1 Introduction 
This thesis began with an introduction to COPD and the psychological impact of the disease.  
There seems to be an overwhelming consensus that the prevalence of anxiety and depres-
sion is a significant problem for patients with COPD but given the scale of the problem, lim-
ited attempts have been made to address symptoms of anxiety and depression in the COPD 
population.  Breathlessness has physical and psychological causes and patients have entirely 
appropriate fears about their breathing difficulties.  There is no doubt that patients may 
have a life threatening illness and may have realistic negative thoughts about dying from 
their COPD.  However, anxiety can play a massive role in fueling fears of dying when perhaps 
this is not imminent.  Patients often do not see the link between anxiety and breathlessness.  
Psychological therapies such as CBT are effective interventions for the treatment of anxiety 
and depression in the general population but there was limited evidence for the use in pa-
tients with COPD.   
Several researchers have tried to evaluate the effectiveness of treatments to manage anxi-
ety and depression in the COPD population.  A criticism of previous research is that a num-
ber of methodological problems have been identified. Firstly, a significant problem with 
studies on CBT in COPD is the low sample sizes, lack of power calculation or failing to recruit 
enough patients required.  Secondly, most studies have a serious weakness of investigating 
the use of CBT in patients who were not anxious at baseline.  Patients without symptoms of 
anxiety are unlikely to need any psychological intervention unless the study is to prevent 
symptoms developing.   
Thirdly, the possibility of bias was also highlighted.  The quality and methods of randomisa-
tion were poorly reported raising the possibility of selection bias.  As with all complex inter-
ventions it is difficult to blind participants. However, steps can be taken to minimise bias by 
ensuring outcome measures are collected by individuals blinded to the allocated treatment.  
Previous studies appear to have a high risk of bias as many of the studies did not report 
blinding for outcome measurements.   
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Another significant problem identified in the literature was the number of outcome 
measures used.  One study acknowledged the measures were defective and yielded variable 
results making it difficult to draw conclusion from the small sample (154).  Existing research 
fails to answer the important question as to the effectiveness of CBT in the COPD popula-
tion.  The conclusion of all of the studies and systematic reviews published so far recom-
mend a high quality and significantly powered randomised controlled trial.  
This research was developed to build upon the current evidence for CBT in COPD and a RCT 
was considered the most appropriate method to test the research hypothesis. The objective 
of this study was to develop an appropriately designed high quality RCT and address the im-
pact, feasibility and efficacy of teaching CBT skills to non-mental health professionals (such 
as respiratory nurses), to treat anxiety and depression in a clinical population of COPD pa-
tients. This study is the first to use respiratory nurses who have skills in respiratory disease 
and training in psychological skills such as CBT.  Respiratory nurses are at the front line car-
ing for patients with COPD and are well placed to provide holistic care for COPD patients.  
The Newcastle COPD CBT CARE Study presented in this thesis was an ambitious trial as it is 
the biggest study ever to be undertaken in COPD patients with symptoms of anxiety.  The in-
tervention used in this study has developed over many years and had been evaluated before 
embarking on this RCT. 
A large number of patients attending secondary care clinics were screened for suitability for 
the study and a considerable number reported symptoms of anxiety.  The prevalence of anx-
iety in this cohort was 59%, which is significantly higher than the prevalence of 36% quoted 
in the systematic review by Yohannes et al (225).   It had been suggested that there may be a 
dose-response relationship between illness severity and symptoms of anxiety and depres-
sion but this was not found to be the case in this study.  No relationship was found between 
lung function and psychological symptoms.  It is clear that the impact on patients’ lives from 
COPD is extensive.  From 279 patients recruited a total of 268 (96%) patients reported prob-
lems performing usual activities.  Importantly 231 (83%) reported comorbid symptoms of 
anxiety and depression and 206 (74%) reported pain or discomfort on the EQ-5D Question-
naire.  Neither of these symptoms are commonly addressed in clinical practice.    
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The results of this study have demonstrated that CBT is effective for patients with COPD.  
Clinical and statistically significant results were found for: 
x Symptoms of anxiety (HADS-Anxiety) (p=<0.001) 
x Symptoms of depression (HADS-Depression) (p=0.001) 
x Health related QOL (CAT) (p=0.001) 
x Generic QOL (EQ-5D utility scores) (p=0.007) 
Whilst this is an important result, it is also prudent to consider that 60% of patients in the 
CBT group improved >1.5 on the HADS-Anxiety Scale reaching the MCID.  Patients who re-
sponded were older (p= 0.002) and had a significantly higher score on the EQ-5D utility 
scores suggesting better QOL (p= 0.02).  The mean number of sessions of CBT required in this 
study was four confirming that this brief intervention is not only clinically effective but po-
tentially is cost effective.  Further analysis of the 12 month data is required to establish the 
cost effectiveness of the intervention.   An important finding was that no difference was 
identified between CBT delivered by nurses with diploma or foundation level training. 
Whilst the CBT intervention was superior to the self- help leaflets, the results of the study 
have shown that the self-help leaflets were also effective. Clinical and statistical significance 
was achieved for: 
x Symptoms of anxiety (HADS-Anxiety) (p=0.004) 
x Health related QOL (CAT) (p=0.001) 
 
In the leaflet group 53% of patients improved >1.5 on the HADS-Anxiety scale achieving the 
MCID quoted by Puhan (122).  
It is interesting that there was no correlation between HADS-Anxiety or Depression scores 
and lung function in this study.  Females in the CBT group improved significantly from base-
line and the results were significantly better than the Leaflet group.  One possible explana-
tion for this is that females are happy to talk about their difficulties and responded well to 
the one to one intervention. 
7.2 Trial Design 
The study design was very important to ensure this research was credible and would be use-
ful and acceptable to be used in clinical practice.  One of the key issues in the design of RCTs 
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is the choice of intervention. As a criticism of many trials is that the design is inappropriate, 
it was important to consider the options carefully.   In addition to recommendations from 
previous researchers, patients, carers, the NIHR RDS and experienced researchers were all 
consulted in the planning phase and this was time well spent.  A critical area considered in 
the design of this study was an appropriate control group. Many studies use ‘standard or 
usual care’ as the control group.  Generally, psychological screening for symptoms of anxiety 
and depression is not conducted as routine practice in respiratory clinics.  The team did not 
feel it was appropriate to offer ‘less’ than our ‘usual care’.  
For pragmatic reasons two active arms were agreed (CBT with self-help leaflets and self-help 
leaflets alone) to take into account current ‘standard care’ with the Trust. The rationale be-
hind these two arms was complex.  Firstly, it would be unethical to withhold ‘standard prac-
tice’ from patients attending Newcastle upon Tyne Hospital Trust Respiratory Clinics.  Sec-
ondly, patients are likely to deteriorate physically during the study and self-help leaflets may 
well be effective in reducing symptoms of anxiety and depression.  Another important con-
sideration was if CBT would be delivered individually or in groups. Previous research into 
psychological interventions into CBT in COPD have used either group or individual CBT.   Like 
many interventions it would be more cost effective to provide group CBT. Local experience 
within Newcastle Hospitals and patient feedback suggested patients would prefer individual 
CBT sessions.  Discussing intimate feelings about the impact of COPD can be embarrassing 
for patients.  More recently studies have used self-help manuals for patients which may also 
be a useful method of providing CBT in the future. 
It was noted that some patients dropped out of the study once they had been randomised to 
the Leaflet arm and preceded to request CBT.   In this study it is feasible that self-help leaf-
lets could be seen as inferior to patients and indeed clinicians.   One clinician requested that 
a patient in the Leaflet arm was withdrawn as the patient’s health was deteriorating and he 
requested CBT.  
7.3 Setting 
In non-pharmacological studies it is important that the description of the setting in which 
participants treatment is provided to  help readers appraise the risk for bias and the applica-
bility of the results (173).  Evidence suggests that patient outcome can be associated with 
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hospital and care providers’ volume (226).   For this study there were high volumes of pa-
tients with COPD who had symptoms of anxiety.  Non-pharmacological treatment such as 
CBT might be found to be safe and effective in an RCT performed in high-volume center’s by 
high volume care providers and this could mean that different results could be obtained in 
low volume center’s (173).   
Many patients with a diagnosis of COPD are managed within primary care rather than at-
tending secondary care clinics.  A major limitation of the recruitment strategy for this study 
is the exclusion of patients with COPD from primary care.  Including patients from primary 
care would have increased access to patients who may have less physical disability but as the 
results of this study suggest, may have significant comorbid anxiety and/or depression.  Such 
patients may be more willing to participate in a study of this kind.   
7.4 Attempts to reduce bias 
In this study every effort was made to reduce bias.  A computer generated program random-
ised the intervention and allocation concealment was maintained.  It was not possible to 
blind participants and this may introduce bias and influence the research.  However, to mini-
mise the risk of further bias the staff collecting outcome data were blinded to the treatment 
allocation.    Analysis was undertaken using data from all patients who completed follow up 
at the primary outcome for this PhD but an intention to treat analysis for the longitudinal 
follow up data once all of the data is collected is planned.  
7.5 Primary outcome measures for anxiety and depression.  
Choosing a primary endpoint is an important decision to make and should be based on the 
main objective of the study  (227).  In an excellent article on the art of choosing sound study 
endpoints, Hanson suggests that it is of particular importance that the primary endpoint can 
be measured with a valid, reliable, and responsive instrument (227).   The study team agreed 
that anxiety was a significant and frightening problem for breathless patients with COPD and 
this was chosen as the primary outcome for the study.  Careful consideration was given to 
the most appropriate outcome measure for this study.  The advantages and disadvantages of 
using each measure was discussed with the research team.  For the measurement of anxiety 
and depression Dr. Chris Baker, Consultant Clinical Psychologist was consulted.   
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The HADS questionnaire was chosen for several reasons.  Firstly, the HADS questionnaire 
had been used extensively with the Respiratory Clinics and staff were familiar with their use. 
Secondly, the HADS questionnaire had been used most in previous studies and was recom-
mended for future research.  Thirdly, the HADS questionnaire had been validated in the 
COPD populations and therefore was considered the most appropriate questionnaire to col-
lect outcome data {Dowson, 2001 #1929}.   Finally, the HADS questionnaire only has 14 
items and only takes a few minutes to complete.  This was an important consideration for 
elderly COPD patients.   However, classifying patients as being ‘anxious or depressed’ with 
the HADS questionnaire is controversial and users should be mindful that the HADS ques-
tionnaire is a screening tool and should not be used to imply a clinical diagnosis of anxiety or 
depression.  The use of self-report outcome measures has also been debated.   
7.6 Severity of Lung Function  
Most COPD studies do classify COPD entry on FEV1/FVC ratio of ≤70 but this excludes poten-
tially eligible people who may fulfil all other entry criteria.  Several patients in this study 
were identified with a diagnosis of COPD but the FEV1/FVC ratio was above 70% so were ex-
cluded.  It could be argued that the diagnosis of COPD is questionable in such patients, how-
ever, there are a minority of patients who have a well preserved FEV1/FVC ratio but have se-
vere emphysema on lung function testing.  Melek and Norris suggested that it is likely that 
some patients with more severe chronic medical  disease will become depressed or anxious 
(79).  It does seem intuitive to think that anxiety would be more prevalent in patients with 
severe lung disease.  Interestingly, in this study there was no correlation between anxiety 
and depression and lung function.  This suggests that patients may have mild airway obstruc-
tion and severe symptoms of anxiety and/or depression.  Conversely, there are some pa-
tients with severe airway obstruction who experience low symptoms of anxiety and/or de-
pression.   
7.7 Ethnic Group 
All of the patients recruited were white British. From the patients screened there was only 
one patient from an ethnic minority group and they declined to participate in the study.   
This may be unusual to other areas in the country.   As a result it might be argued that CBT 
works in a particular cultural group.  
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7.8 CBT Intervention 
CBT continues to evolve and is full of controversies (127).  CBT is one of the most extensively 
researched forms of psychotherapy extending to a wide range of psychological problems.  In-
deed, a simple search in Medline in August 2015 found 886 randomised controlled trials of 
CBT.   A comprehensive review of 16 meta-analysis of CBT was undertaken in 2006 (228).  
The review concluded that CBT is effective for anxiety and depression and there appears to 
be robust evidence that the benefits are maintained beyond the cessation of treatments and 
indeed relapse rates are half those of pharmacotherapy (228).   On the whole it is generally 
agreed that the evidence does support CBT for a number of psychological problems.  
CBT is recommended by NICE for the treatment of many psychological problems including 
anxiety, panic and depression  (125). There have been several criticisms of the NICE Guide-
lines.  Firstly, it has been suggested that NICE supports ‘the medical model’ of mental health 
which promotes diagnoses or specific disease entities (184).   As a result it is suggested that   
the guidelines ignore the ‘biopsychosocial model of mental health’ (which is well established 
in psychiatric training) (184). Instead, it is argued that repeated comparisons with drugs im-
ply a notion of a disease entity that can be corrected by the right combination of pharmaco-
logical or psychological ingredients (184).  Another pertinent point raised is the notion that 
patients studied in formal trials that inform guidelines are quite different from those seen in 
real life settings (184).  The research undertaken for this PhD was a pragmatic trial and in 
contrary to Mollon’s conclusions, patients included in this study were ‘real-life’ patients, 
many from socially deprived areas in the North East of England. 
On a positive note it has been suggested that CBT is an efficient therapy that is relatively 
easy to learn and deliver and produces good results in many instances (229).  In addition, 
CBT researchers have set standards in detailed description of their methods (“manualisa-
tion”), monitoring of adherence (e.g. video recording sessions), and tailoring treatments to 
specific disorders (229).  However, despite this, CBT has been criticised for its simplistic 
‘cookbook’ approach to therapy (127).  Whilst CBT can appear to be mechanistic, it is similar 
to the medical model of patient care.  A diagnosis is sought and treatment is given. The med-
ical model has been beneficial in one sense, it has forced psychotherapies to strive for scien-
tific credibility and conduct RCTs to establish the worth of their therapies. In contrast, it 
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could be argued that psychotherapy is essentially concerned with people, not conditions or 
disorder, and its methods arise out of an intimate relationship between two people that can-
not easily be reduced to a set of prescribed techniques (229).  
Another key component of CBT is the role of ‘unhelpful cognitions’.  It has also been ques-
tioned that CBT techniques aimed at tackling ‘negative cognitions’, such as those found in 
depression, require mindful techniques such as meditation to help patients divorce them-
selves from their emotional pain (230).  The theory behind this is that it may be helpful for 
patients to learn to tolerate and accept thoughts rather than challenging or changing nega-
tive thoughts.  As a result of this criticism, mindfulness based CBT has evolved. These claims 
could be contested as a key intervention for depression is behavioural activation rather than 
addressing cognitions.   There is also uncertainty about the long term course of psychiatric 
illness and whether CBT is effective in this area.  Problems such as depression are increas-
ingly seen as a relapsing chronic illness and without long term comparative follow up studies 
it is argued that further research into the effectiveness of all therapies is needed (229).  An 
interesting point highlighted in the literature is that unlike psychoanalytic psychotherapy 
which is a compliance neutral therapy, CBT is particularly dependent on compliance (231).  
However, many interventions rely on compliance, particularly pharmacological interven-
tions.   Indeed, an inhaler will not be effective is it is not taken.  
It is of course right and proper that patients have the best treatment.  To achieve this, It is 
vital that CBT proponents and critics work together to establish the most effective treatment 
for patients emotional distress.  As suggested by the MRC it is paramount that an emphasis 
is placed on  active ingredients which help address the patient’s needs, and  identify the 
skills needed to deliver them (229). From the literature identified in this review it is apparent 
that interventions such as CBT are complex.   Previous research has stressed the importance 
of developing a clearly defined intervention’s from existing models (e.g. panic ) and  report 
in a way that encourages replication studies (129). Whilst it could be argued that few inter-
ventions are ‘simple’ some interventions are obviously more complex than others.   
A number of dimensions add to the complexity of CBT interventions including the number 
and difficulty of behaviours required by those delivering the intervention or receiving the in-
tervention, number and variability of outcomes, number of groups or organisational levels 
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targeted by the intervention and the degree of flexibility or tailoring the intervention to the 
patient’s individual needs (172).   In addition, extra problems relate to the difficulty of stand-
ardising the design and delivery of the interventions, their sensitivity to features of the local 
context and culture. The development, evaluation and implementation of complex interven-
tions are important areas to consider and all stages are important.  Without adequate devel-
opment and piloting work, or proper consideration of the practical issues of implementation, 
weaker interventions will be developed that are harder to evaluate and  less likely to be im-
plemented  (172). 
The complex intervention used in this study was based on the theoretical underpinnings of 
CBT and guided self-help.  CBT techniques were used to specifically target breathlessness 
which may result from COPD, anxiety or panic.  The CBT treatment programme for COPD pa-
tients was developed and refined over several years.  The refinement of the treatment ena-
bled teething problems to be addressed along the way and this may have contributed to the 
positive impact of the intervention in this study.  Lack of impact of other studies may merely 
reflect teething problems rather than genuine ineffectiveness of the intervention (172). A 
key question in evaluating complex interventions such as CBT is about practical effectiveness 
(172).  Practical assessment of non-pharmacological treatments in RCTs presents special dif-
ficulties because of the complexity of the treatment  (172). It is important to provide a de-
tailed description of non-pharmacological treatments used in a study.    
This trial is one of the few trials that have provided sufficient detail of the CBT intervention 
provided.  Future studies could incorporate the Behavioural Change Taxonomy to standard-
ise the reporting of interventions in trials (174).  The CBT intervention used in this study has 
been shown to be effective.  However, what is not known is which interventions are the 
most effective.    
A question that has not been addressed in this study is if patients will require further treat-
ment.   It is conceivable that some patients will benefit from booster or repeat sessions of 
CBT, similar to pulmonary rehabilitation.  This question should be addressed in future re-
search.  Finally, maintaining the efficacy of an evidence based CBT intervention as it transfers 
from the research context into ‘routine care’ is not an easy process (186).  RCTs dedicate 
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time and resources ensuring that nurses demonstrate competence and adhere to the treat-
ment manual for which they have been trained to use (186).  This research has demon-
strated that CBT delivered by respiratory nurses is an effective and acceptable treatment.  
Due to the constraints on the NHS it may be difficult to implement in practice.  Ideally, pa-
tients should have a choice of treatments.  Some patients may prefer self-help leaflets, oth-
ers a one to one session with the nurse.  However, there may well be alternative ways of de-
livering the intervention which may be a novel way of delivering this CBT intervention and 
less resource intensive.   
Towards the end of this research £60,000 was obtained from the Academic Health Science 
Network to develop the COPD intervention used in this study as an interactive on-line ver-
sion of the CBT treatment. A focus group has been held to gain views of patients and their 
families.  The program has been built and is in the pilot phase.  It is hoped this research may 
address problems of health literacy especially for patients who are unable to read as videos 
will be presented in conjunction with written material.   
7.9 Feasibility and Acceptability. 
When this study was planned it was anticipated that 70% of patients approached who were 
eligible would be happy to participate. This was optimistic as only 43% of patients eligible 
declined to participate in the study.   However, the percentage of patients declining com-
pares favourably with studies on pulmonary rehabilitation where approximately two thirds 
of patients declined to get involved in the research (232) and other studies of CBT (148).  Re-
cruitment took a year longer than planned to ensure the number stipulated in the power cal-
culation was met.  The reasons for non-participation in this study is similar to other non-
pharmacological studies.  Mood will clearly have a role to play.  As expected, feeling anxious 
or depressed may well reduce engagement in treatment, similar to engaging in pulmonary 
rehabilitation.  
Alternatively, it may well be that the intervention was not acceptable to patients and drug 
therapy may be preferred.   This would contradict previous suggestions that patients prefer 
non-drug interventions (137).   It is also possible the stigma of mental health issues may also 
lead to non-participation.  The stigma associated with mental illness has been widely re-
searched and seen as a factor effecting engagement  (233).  In a study involving pulmonary 
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rehabilitation, reasons for non-participation included travelling, perception of benefit, com-
peting commitments or demands, past negative experiences and perception of health status 
(232). 
Identifying barriers and potential facilitators to recruitment should be a fundamental step 
when planning research (233).  It was apparent that for some patients in this study the moti-
vation for participating was their perception that it would help other patients.  This has been 
identified as a major motivating factor in participation of many studies. Furthermore, receiv-
ing feedback from a study can reinforce the perception that research can help others and 
show participants how they are contributing  to the development of knowledge in the area 
of interest (233) which is relevant or important  to them.  Significant steps were taken to en-
hance recruitment for this study including: 
x Developing an acceptable experimental design involving self-help leaflets or brief in-
tervention involving between two and six sessions of CBT. 
x Provision of transport to hospital or conducting home visits to limit costs to patients 
depending on patients’ wishes. 
x Avoiding lengthy, tedious questionnaires. 
x Avoiding lengthy consultations and working at patient’s own pace depending on their 
physical health. 
x Hopefully providing enjoyable, therapeutic contact with staff.   
x Demonstrating good interpersonal skills with patients during interactions such as be-
ing respectful, approachable, caring and compassionate.  Steps were taken to assess 
interpersonal skills with video recordings of therapy. 
x Being flexible and accommodating with participants when arranging therapy ses-
sions. 
x Ethical approval was obtained to increase study awareness with the development of 
a poster which was displayed in key locations including the Chest Clinic at the RVI and 
Freeman Hospital. 
 
What was noticeable was how patients were approached.  When patients were asked if they 
would like to participate in a study of CBT for anxiety they were more inclined to decline.   If 
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patients were asked if they would like to participate in a study that would help manage 
symptoms of breathlessness which may be exacerbated by symptoms of anxiety they were 
more likely to engage in the study.  Patients with COPD do not seem to see the link between 
anxiety and their COPD so focusing on a difficult symptom such as breathlessness may well 
improve engagement.   
A number of health care professionals could potential delivery CBT.  Prior studies show non-
psychotherapists with supervision can successfully administer interventions like CBT to emo-
tionally distressed patients; (187). In a non-RCT case series I reported clinically and statisti-
cally significant improvements in anxiety and depression scores. A statistically significant re-
duction in hospital admissions after nurse delivered CBT was also seen and the mean HADS-
Anxiety score fell from 10.6 (range 6-15) to 3.8 after CBT (1-7; p < 0.001) (187).  In an audit of 
42 patients (21 patients received nurse led CBT matched to 21 historical controls) we 
demonstrated that CBT significantly reduced anxiety (p<0.01), depression (p<0.001) and hos-
pital admissions (p <0.01) (183). 
A key benefit of using respiratory nurses is their widespread availability within NHS and the 
skills of this group of healthcare providers in providing holistic care in COPD. Notably their 
unique skill set allows them to distinguish physical and psychological aspects of symptoms.     
Respiratory nurses have knowledge, skills and expertise in caring for patients’ physical well-
being.   This model may be more acceptable to patients rather than being referred to yet an-
other healthcare professional who may have little knowledge of the complexity of COPD. It is 
reassuring that feedback from patients suggested the intervention was acceptable to them 
and indeed they would prefer to speak to the respiratory nurse involved in their care rather 
than see a mental healthcare professional who may not understand the complexities of 
COPD.  This study has demonstrated that it is possible for respiratory nurses to have addi-
tional training in addressing psychological skills. 
However, it should not be under estimated that one of the key components of successful 
treatment is attributed to the nurse’s capacity to engage and retain the patient in treatment.  
The process of engagement requires the patient and nurse to construct a therapeutic rela-
tionship or alliance (234).  Importantly, one of the most robust findings in psychological re-
search is that a good therapeutic relationship (or alliance) is the best predictor of outcome 
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(229). Therapeutic alliance broadly means the collaborative and effective relationship be-
tween a therapist and a patient (235).   It is suggested that the patient’s perception of the 
quality of the relationship is related to outcome (235).  However, there are conflicting views 
on the notion of therapeutic alliance and it has been proposed that better outcomes lead to 
the perception of better therapeutic alliance.  A further factor is that the ‘alliance’ may ther-
apeutic itself regardless of the psychological intervention (235). 
Nurses with the appropriate knowledge, skills and attitude will be an important considera-
tion when thinking about addressing patient engagement and the acceptability of the CBT 
intervention for COPD patients.   Not every nurse or indeed any other healthcare profes-
sional may have the therapeutic skills required to undertake CBT.  It is quite easy to learn the 
techniques but putting them into practice is another matter.  If the relationship is not 
formed patients are unlikely to discuss private intimate matters with someone they do not 
have a rapport with and will vote with their feet.  In this study, once patients were recruited, 
retention was excellent and patient feedback was very positive.   
As this study involved written patient materials the issue of health literacy should be consid-
ered.   Health literacy has been defined as the cognitive and social skills which determine the 
motivation and ability of individuals to gain access to, understand and use information in 
ways which promote and maintain good health (236).  Whilst this definition may be complex, 
in the context of this study health literacy would include a patient’s motivation, their ability 
to read the information provided and using the information to help reduce symptoms of 
anxiety and depression.  It is interesting that three patients provided valuable feedback that 
they were unable to read the leaflets but did not disclose this when they were enrolled into 
the study.  Only one patient admitted he could not read and I arranged for a health care as-
sistant to read the information leaflet to him.  It has been estimated that 46% of people in 
the North East do not have the literacy skills to read standard health information materials 
(236).  Poor understanding may lead to poor participation, lack of compliance with treat-
ment, low self-management and will not gain benefit from the information (236).   
It was also interesting that a few patients did not feel that the information referred to them, 
for example one patient stated: 
“The panic leaflet wasn’t helpful.  I thought it applied to those who have had a stroke” 
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It may be more appropriate to develop specific information for patients with COPD in a num-
ber of different formats such as written information or digital format such as an internet 
based program.   
7.10 Patient and Public Involvement 
Members of the public have been involved in research for many years in a number of ways 
(193).  Patient and public involvement in research means more than merely being ’subjects’ 
of the research.  Common areas of public involvement include setting the research agenda, 
research design, assisting with the management of research, interpreting and disseminating 
research. PPI involvement can start at any stage but there are certainly advantages of early 
PPI involvement.    A very important benefit of involving patients early in particular is that 
they can provide a different view of the research project from the patients’ perspective and 
can identify issues that are important to them.  I was very aware of the importance of PPI 
when developing the research proposal for this study and incorporated PPI at an early stage.  
It is understandable that it can be daunting for patients and carers to contribute to discus-
sions with health care professionals and express their views and concerns. In addition, pa-
tients with long term physical health problems such as COPD can find it hard to commit to 
attending meetings for long periods of time, may be physically unwell or may even die dur-
ing the process due to their life threatening condition.  This can be very upsetting for the 
whole TSC.  Indeed during this study the carer representative was replaced with another as 
the initial representative died unexpectedly. PPI and third sector representatives played an 
active role in the study.   I met with patient and carer representatives prior to TSC meetings 
to go through any questions they may have and brief them on the forth coming agenda.  In 
future studies I would organise specific training to ensure participants understand what is 
expected of them such as attending formal meetings.  I am aware the European Lung Foun-
dation is developing such a training package. 
During the study two events were held to inform patients and relatives about the progress of 
the study.   These were held at Freeman Hospital and in a community setting (Marie Curie 
Hospice). Attendance was in the order of 50-60 at each event and mostly attendees were 
from secondary care clinics. The trial design, aims, objectives recruitment progress was pre-
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sented and discussed with patients with COPD. It is extremely important to present the re-
sults to patients before publishing information about the research in the media (193).  The 
British Lung Foundation have published small articles about the study in their national news-
letter and a further publication of the results is planned for January 2016.  
At recruitment patients participating in the trial were informed that the results would be 
sent in a trial newsletter as soon as the results were available.  A conference has also been 
organised to present the results of the research and will be open to all patients who have 
participated in the trial. The aim of the meeting is to thank the participants, present the re-
sults personally and gain comments that might aid the interpretation of the results from a 
patients’ perspective.  Other PPI events will also be organised for local Breathe Easy Groups 
who are aware of the research and are interested in the outcome of the trial.  Feedback 
from the participants and future recipients of CBT will help in disseminating to healthcare 
professionals. Patients who use services are most likely to want to see research being imple-
mented to change practice for the better (193).  Involving organisations such as the BLF can 
be instrumental in disseminating research results and campaigning to implement results.   
It is important to evaluate the research process from a patient perspective and identifying 
what went well and what could be carried out differently if this research is expanded in the 
future.   This research was very ambitious and thus the ability to carry out in-depth qualita-
tive interviews was not considered feasible for this PhD fellowship.   In an attempt to gain 
some feedback patients were asked for their comments at three, six and twelve months 
when approached to complete the follow up questionnaires.  The feedback was positive and 
will be useful when implementing future research. Research should be conducted ‘with’ pa-
tients not just ‘to’ them (237).  PPI is an important and integral part of the research process.    
This study incorporated PPI in a number of different levels including research design and 
management.   
7.11 Limitations of this study 
A number of limitations of this study must be acknowledged.  Possible primary outcomes of 
interest for this study were a reduction in patient reported anxiety symptoms or a reduction 
in hospital admissions.  Any intervention that can reduce hospital admissions could be very 
attractive to commissioners.  Assuming an exacerbation rates of 2 per year it was estimated 
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that a sample size of 378 patients (189 per group) would allow an 80% power to detect 27% 
reduction in exacerbations. Assuming withdrawal rates as above >474 patients randomised 
(237 per arm) would be required. With a limited budget and time frame it was felt beyond 
the scope of a PhD study.  The numbers required for admission prevention and applicability 
of study findings may well inform and lead to a multicenter RCT. 
We did not undertake formal screening for memory problems or mental health problems as 
compared to some (238).  Three patients in the CBT arm were found to have mental health 
problems which were long standing but their clinical teams were not aware of this.  There 
may well be patients in leaflet group who had issues but were not identified.  Patients with 
COPD were screened for symptoms of anxiety and depression from a case finding question-
naire rather than given a diagnosis using formal assessments.  Patients did not undergo for-
mal psychiatric assessments for this study.   
As with most behavioural interventions this was an un-blinded study.  Obviously patients 
and the nurses were aware of the patient’s allocated intervention. There was no placebo 
limb and so the improvements might in part have reflected spontaneous improvements, 
changes in medication, the effects of pulmonary rehabilitation or improvements associated 
with increased familiarity with the clinical setting and staff.  Previous researchers have tried 
to address the issue of blinding participants.  In De Godoy’s paper it is suggested that ‘both 
groups were blinded in relation to activities of the other group’ (page 1155).  The paper is 
confusing as it states that both groups received education including several techniques that 
are classified as CBT techniques such as coping with illness, stress management, relaxation, 
energy saving techniques and the benefits of exercise.  There is minimal information about 
the ‘cognitive therapy’ and ‘logotherapy’ which the intervention group received.  With this in 
mind, it is difficult to comprehend how patients could give informed consent if they were 
not aware of the activities entailed in each group. 
During the study three of the nurses involved in delivering the CBT treatment gained em-
ployment elsewhere subsequently one nurse delivered  71 (55%)  of the CBT intervention.  
The use of a standardised manual-based approach and video validation should have mini-
mised the influence of individual therapists’ approaches.  As CBT is a complex individualised 
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intervention it is not possible to state which particular aspect of the Lung Manual protocol 
was most effective. 
Some patients were taking medication for anxiety (7%) and depression (35%) which may im-
pact on the results.  However, this will be similar for both groups.   Another confounding fac-
tor is the increased availability of IAPT which was introduced shortly after the launch of this 
study. However, as psychological well-being tends to be ignored for patients with COPD it is 
unlikely this will have a significant impact on the outcome. 
A further limitation of this study is the use of multiple significance testing. Whilst the pri-
mary and secondary outcomes were stated in a pre-analysis plan a priori, multiple testing 
was undertaken for sub-group analysis. As the number of comparisions increases, the risk of 
Type I error increases and incorrect inferences can be made. As the significance level of the 
test was 0.05, the test had a 5% chance of incorrectly rejecting the null hypothesis. Consider-
ation was given to reducing the significance level to 0.01 or using the conservative Bonfer-
roni's correction test which adjusts the critical level of significance for each test by dividing 
the critical level of significance by the number of tests performed. However, the Bonferroni's 
test errs on the side of non-significance and its use can inflate the type II error rate which 
will lead to a non-significant result when a difference does exist. The aim of the subgroup 
analysis was for evaluation of the CBT and leaflet groups in terms of clinical significance and 
application rather than hypothesis testing. 
Finally, ideally research needs to have external validity in that the results can be generalised 
beyond the very specific conditions which pertained to the study (239).    However, the entry 
criteria were broad but as the study was undertaken in secondary care it is not clear whether 
the findings can be generalised to primary care.  Further research is needed to test the valid-
ity of the intervention and findings in other settings 
7.12 Strengths 
This study is the largest to date of CBT in COPD.  The study was carried out within a normal 
clinical setting and demonstrated that respiratory nurses can incorporate CBT into usual clin-
ical care.  One of the strengths of this study is that it was adequately powered.  The selection 
of suitable endpoints depends on the purpose and scope of the study, available evidence 
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from previous trials, the clinical setting, the intervention of interest and anticipated treat-
ment effects  (227).    This study has addressed weaknesses of previous studies in that a 
power calculation was undertaken and the appropriate number of patients were recruited.  
In contrast to many other studies, a considerable strength of this research is the fact that pa-
tients all have anxiety at baseline.    
In addition, patients with all levels of COPD severity were included and so the study is likely 
to be representative of patients in the UK attending secondary care clinics.  Importantly, all 
patients had quality assured spirometry to ensure they fulfilled the entry criteria.  Spirome-
try was repeated in the hospital clinical physiology department if needed. Previous studies 
have accepted a diagnosis of COPD based on spirometry which may not be quality assured 
and therefore the diagnosis of COPD may be in question.  For this study only quality assured 
spirometry was accepted.   Attempts were made to minimise bias from randomisation, data 
collection and data analysis.  The outcome measures used were all standardised and previ-
ously validated.   
Treatment integrity has important considerations for drawing inferences about the efficacy 
of treatments (240).  In the past psychotherapy studies have been criticised for inadequately 
assessing treatment integrity procedures (241).   A strength of this study is that adherence to 
the CBT intervention manual was assessed as 22 session’s video recorded and assessed by an 
independent cognitive behavioural therapist using a validated rating scale.  However, ensur-
ing strict fidelity to a protocol may be inappropriate.  The intervention may work better if 
adaption to local settings is allowed (172). 
This study demonstrated that CBT approaches can be developed for COPD patients with a 
progressive illness and help manage difficult symptoms of anxiety which are intrinsically 
linked with breathlessness.    The CBT intervention used in this study was well described to 
facilitate replication. The intervention used in this research has been specified in this thesis 
and a detailed manual and training program has been developed to replicate its use.    
7.13 Interpretation 
This is the first study to demonstrate that respiratory nurses without a clinical psychology 
background can be trained to undertake CBT based intervention.   The results suggest that 
older patients treated with CBT seem to respond better than younger patients and patients 
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with a better QOL are more likely to respond.  The intervention is more effective than leaflet 
support.  Respiratory services should screen patients for symptoms of anxiety and consider 
providing CBT or at the very least the self-help leaflets used in this study. The cost-effective-
ness of the intervention is uncertain until further analysis of the data is complete.  Further 
refinement of CBT techniques should also be considered to establish the most effective ele-
ments of the intervention.  There is scope to develop alternative methods of delivering the 
intervention such as an interactive CBT digital program. 
7.14 Generalisability 
Given the wide range of COPD severity studied the findings are likely to be generalisable to 
the wider COPD population of similar ethnic origin and background. 
7.15 Dissemination of results 
The results of the study will be disseminated via publications once the 12 month data have 
been analysed.  In addition, the results will be disseminated to patients and their families in-
volved in the study and beyond. The major benefit of PPI is the ability to focus on issues im-
portant to service users.  In addition new evidence is not always implemented.  Involving pa-
tients in research dissemination not only feeds back the findings but allows patients to use 
pressure groups and other advocates to promote wider uptake of new treatments or man-
agement strategies.    PPI involvement in research dissemination not only feeds the findings 
but allows patients to use pressure groups such as the BLF and other advocates to promote 
wider uptake of new treatment or management strategies.  Importantly, another advantage 
of using national charities such as the BLF is that this may help reduce the stigma of anxiety 
in COPD and potential for treatment to help with the distressing symptoms.   It may also lead 
to higher participation in future studies e.g. Health Technology Assessment. 
7.16 Contributions to knowledge 
 This study has demonstrated that CBT is effective for COPD patients with symptoms of anxi-
ety and depression.  With adequate training and supervision, respiratory nurses can be 
trained to use CBT skills and can provide effective treatment with a brief intervention follow-
ing the Lung Manual.  The results have also shown that providing self-help leaflets is also ef-
fective in reducing symptoms of anxiety and depression but are not as effective as one to 
one CBT delivered by a respiratory nurse. 
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7.17 Policy implications 
This study suggests that simple treatment in the form of self-help leaflets and CBT delivered 
by a respiratory nurse can improve psychological well-being.  Routine screening for symp-
toms of anxiety in patients with COPD should be incorporated into standard practice.   
7.18 Summary 
It is argued that people with long term health conditions and mental health receive frag-
mented care and also may be more expensive to treat (79).  Anxiety and depression are 
common comorbidities experienced by COPD patients.  In this study of secondary care pa-
tients, symptoms of anxiety were high with 59% of patients screened reporting symptoms.  
These findings are higher than those of an earlier systematic review and meta-analysis that 
identified anxiety symptoms in 36% of patients (225).  Many patients with mild COPD as 
judged by spirometry were anxious. This raises the possibility that a significant proportion of 
primary care patients with COPD will also have un-recognised comorbid anxiety if screened 
for these symptoms.  Given this high prevalence we now show potential effective therapies 
to tackle this co-morbidity.   
Previous studies have tried to investigate the effectiveness of CBT in COPD but have failed to 
demonstrate a significant benefit.  This study is unique as it is the first to investigate the ef-
fectiveness of a brief CBT delivered by respiratory nurses who are well placed to provide 
physical and psychological support for patients.  Both CBT and self-help leaflets interventions 
were associated with a reduction in anxiety symptoms at three months that for most pa-
tients reached the MCID suggested by Puhan (122).  There was a greater improvement in 
those receiving CBT delivered by respiratory nurses. The health status of both groups also 
improved as judged by the COPD-CAT and EQ-5D utility scores but again there were greater 
improvements in the CBT intervention group.  Collectively these data indicate that comorbid 
anxiety in COPD is both common and treatable. 
It is recognised that depression is two to three times more common in patients with chronic 
physical health conditions (111) and is associated with poorer survival, longer hospitalisation 
stay, persistent smoking, increased symptom burden, and poorer physical functioning  (66).  
Two-thirds of patients in our study had symptoms of depression.   CBT is an effective treat-
ment for depression but the programme we used was not specifically designed to address 
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this.  We found improvements in depression symptoms following both CBT and leaflet inter-
vention but these were less marked than the improvements in anxiety and for most patients 
the improvement was not of a clinically significant magnitude.  CBT targeting at depression 
as well as anxiety might be worthwhile.   
Patients and clinicians often fail to recognise the psychological complications of the illness 
leading to under diagnosis.  There are also significant challenges to implementing CBT for 
physical illness including cost, the availability of trained therapists and patient reluctance to 
engage in psychological treatments   The potential benefits of actively screening for comor-
bid anxiety in clinic and having a dual skilled nurse in medical outpatient setting is that 
stigma or other barriers to accessing care may be more easily overcome thus providing more 
holistic care. 
RCT’s are the most rigorous way to evaluate the effectiveness of interventions, regardless of 
complexity.  RCT’s of complex interventions pose methodological challenges to researchers.  
There is surprisingly little consensus as to develop and evaluate complex interventions, guid-
ance is increasing with the publication of the MRC Framework  (172, 178).  Studies continue 
to emerge that suggest that over 40% of patients who are high users of healthcare resources 
have comorbid anxiety, depression or dysthymia (79).  It has been suggested that patients 
with more severe chronic medical conditions will become depressed or anxious but this has 
not been found to be the case in this study.  
As this research was funded for five years it was appropriate to conduct a RCT with 12 
month follow up.  This long term follow up will be beneficial in identifying if CBT was effec-
tive for patients with COPD and identify how long the effect was maintained.  However, the 
longitudinal results of the study will be analysed and published when available.  The cost ef-
fectiveness of this intervention will be important and 12 month data will allow a cost effec-
tiveness evaluation to be undertaken.  If hospital admissions are improved with both inter-
ventions it would be more cost-effective to provide self-help leaflets in the first instance and 
offer one to one CBT therapy for those patients who do not respond to the bibliotherapy or 
who prefer face to face treatment. 
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Chapter 8 - Recommendations for practice and future research 
 Several recommendations for practice are suggested. 
1.  Health care professionals working with patients with COPD should increase their 
awareness and understanding of the psychological impact of COPD.  Staff working 
with COPD patients should be able to recognise psychological needs, provide effec-
tive and compassionate general psychological support.   
2. Screening for symptoms of anxiety and depression is essential if appropriate treat-
ment is to be offered.   Brief screening questions could be used and if symptoms are 
identified then a HADS Questionnaire should be completed.    
3. A step-wise approach to manage symptoms of anxiety and depression should be 
adopted.   Patients should be offered a range of options including:  
a) Self-help written information (Bibliotherapy). 
b) Guided self-help with a professional trained in the use of written materials used.   
c) One to one CBT with an appropriately training professional.  Respiratory nurses are 
well placed to undertake this role with training and supervision.  Without these im-
portant elements the intervention may not be as effective.  Implementing evidence –
based therapy could be undermined if the training and supervision associated with 
this intervention are neglected.  Therapeutic alliance and empathy can influence the 
effectiveness of treatment.  Effective therapists need a sophisticated set of interper-
sonal skills to help the patients feel understood, gain their trust and react to verbal 
and non-verbal  cues especially in the initial interaction with the patient to ensure en-
gagement in the process (242). 
4. Basic CBT training should be provided to student nurses working in the physical 
health setting to develop their awareness, knowledge and skills to improve patients’ 
psychological well-being. 
5. Clinical Commissioning Groups should identify ways of integrating physical and psy-
chological well-being into care of patients with COPD. 
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8.1 Recommendations for future research 
Over the last ten to fifteen years psychological research for anxiety and depression in COPD 
has slowly developed.  This study is the largest study to date but there remain several unan-
swered questions: 
1.  A key question in evaluating complex interventions is how the intervention works 
and what are the active ingredients within the intervention that are exerting their ef-
fect (172) in the COPD population.  By addressing this question we can build on our 
understanding of causal mechanisms, design more effective interventions and apply 
them more appropriately across group and setting (172).   
2.  Future research should be undertaken to identify if the face to face brief therapy 
could be delivered to patients with COPD in novel ways such as a digital interactive 
internet program.   
3.  To maximise recruitment future studies should carefully consider the barriers and 
facilitators to participation in research on anxiety and depression.  Focusing on 
breathlessness rather than a psychological issue may be more acceptable to patients 
than a ‘psychological therapy’ and increase engagement in future research.  Ensuring 
treatment is accessible and understandable to patients is key to successful therapy.  
This will require future studies avoiding unnecessary terminology and keeping the 
treatment simple and easy to understand.  
4.  Future studies may also find it helpful to screen for cognitive impairment and ex-
clude patients who score less than 24 using an appropriate screening tool e.g.  Mini 
Mental State Examination (MMSE).   
5. The EQ-5D utility has been updated and the new version with five domains should be 
used.  Using the EQ-5D utility scores will allow a cost-benefit analysis to be under-
taken. 
6. Booster sessions of CBT may be required.  Future research could be developed to an-
swer this question. 
7. Future researchers should consider including an-depth process evaluation. 
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8.2 Conclusion 
Anxiety and depression are significant problems for patients with COPD.  There is clearly an 
opportunity to improve clinical care for patients with COPD.   Screening should be imple-
mented and patients provided with self-help leaflets or offered CBT.  The results from this 
study demonstrate feasibility, acceptability and effectiveness of CBT delivered by respiratory 
nurses for anxiety and depression in COPD.   
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Appendices 
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Appendix 1 HADS Questionnaire 
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Appendix 2 – Modified CBT Rating Scale 
 
CBT Techniques for Palliative Care Practitioners: 
Rating Scale 
 
 
 
Devised by: 
 
I-M. Blackburn, J. Scott, S. Moorey, A. Garland, K. Mannix, C. Baker, S. H. Standart, M. Ley-
land 
 
©K.Mannix 
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Scoring System: Scoring is on a 7 point scale extending from 0 where the practitioner did not adhere to that 
aspect of therapy, to 6 where there is adherence and high skills, or proficient skill in the face of difficulties. 
Item 1 – Focus / Structure 
Key features: to address adequately topics that have been agreed and set in an appropriate way.  In 
this study, practitioners are unlikely to be using cognitive therapy as a stand-alone approach, but are 
likely to be using techniques appropriately during their day to day clinical work.  Thus, the setting of a 
discreet agenda in a collaborative manner is only one example of structuring a session. 
Features that need to be considered when scoring this item are: 
x The presence of a focus to the intervention, which may be implicit (e.g. patient attending for 
a pain assessment; patient discussing breathlessness in the context of a chest clinic) or ex-
plicit and arrived at unilaterally, by practitioner or patient, or bilaterally and collaboratively. 
 
x Structure of approach, which maintains the implicit or explicit focus of the session, or agrees 
a change of focus where this becomes appropriate. 
 
x Collaborative agenda setting may not be an appropriate part of palliative care intervention, 
and the practitioner should not necessarily lose marks if this is absent. 
 
Competence      Examples  
      Level                                     NB: Score according to features not examples!  
 
  
 
 
  
  
  
0 No focus or structure. 
 
1 Inappropriate focus. 
 
2 An attempt to focus made, but strays from this. 
 
3 Appropriate at focus but not enough structure (poor adherence). 
 
4 Appropriate focus, minor difficulties evident, but structures appropriate (moder-
ate adherence). 
 
5 Appropriate focus, structure maintained and progress reviewed at the end.  Min-
imal problems. 
 
6 Highly focused and structured, or well-maintained focus and structure in the face 
of difficulties. 
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Item 2 – Pacing 
 
Notes To raters: Raters will need to consider that palliative care patients are often physically frail, 
and may tire suddenly and without much warning.  It may therefore be difficult to pace a structure 
with equal start, middle and concluding phases, and indeed a concluding phase may be very short 
(and should then be rated under item 10 appropriate closure).  The work must be paced well in rela-
tion to the patient’s needs. 
 
        Competence    Examples 
     Level  NB: Score according to features, not examples! 
  
 
  
  
  
  
  
  
  
 
0 Good pacing evident some of the time, but diffuse at times. Some problems evi-
dent. 
1 Poor time management leads to either aimless or overly rigid session. 
2 The session is too slow or too fast for the current needs or capacity of the pa-
tient. 
3 Reasonable pacing but digression or repetitions from the practitioner and/or pa-
tient leads to inefficient use of time. 
 
4 Balanced allocation of time with discrete start and middle. Concluding phase ev-
ident where clinical circumstances permit. Minor problems evident. 
 
5 Good time management skills evident. Session running smoothly. Practitioner 
working effectively in controlling the flow within the session. Minimum problems. 
 
6 Excellent time management or highly effective time management evident in the 
face of difficulties. 
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Item 3 – Chunking/Feedback/Capsule Summarising 
 
Notes to raters: The patient and practitioner’s understanding of key issues should be helped with the 
use of 2-way feedback.  This includes feeding back information as general summaries, and chunking 
of important units of information. 
 
 
 
         Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
 
0 Absence of feedback or highly inappropriate feedback. 
1 Minimal appropriate feedback. 
2 Appropriate feedback, but not given frequently enough by practitioner, with in-
sufficient attempts to elicit and offer feedback. 
 
3 Appropriate feedback given by the practitioner and elicited from patient fre-
quently, although some difficulties evident in terms of content or method of de-
livery. 
 
4 Appropriate feedback given by the practitioner and elicited from patient fre-
quently, facilitating moderate therapeutic gains. Minor problems evident (e.g. in-
consistent). 
 
5 Highly appropriate feedback given and elicited regularly, facilitating shared un-
derstanding and enabling significant progress. Minimal problems. 
 
6 Excellent use of feedback or highly effective feedback given and elicited regularly 
in the face of difficulties. 
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Item 4 – Integrating Professional Model of Care with CBT 
 
Note to raters: This item is looking at skills in incorporating concepts and skills from a CBT model into 
the professional model of everyday use by the practitioner, e.g. nursing model, social work etc. 
 
 
 
                Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
0 The absence of an appropriate integration: no bridge between the models. 
1 Inappropriate or misapplication of integration between the models leads to neutral 
impact (e.g. interferes with progress or leads to aimless application of techniques. 
 
2 Some rudimentary integration arrived at but not well linked with the goals of ther-
apy. 
 
3 Attempts to link cognitive conceptualisation with professional model but with some 
difficulties evident. Leads to appropriate interventions. 
 
4 Coherent integration with the beginnings of a cognitive conceptualisation. 
5 Coherent integration with an appropriate conceptualisation leads to therapeutic 
shifts. Minimal problems. 
 
6 Excellent integration of models with a coherent cognitive conceptualisation, which 
leads to therapeutic shifts (I.e. evidence of elegance, style or high effectiveness in 
the face of difficulties). 
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Item 5 – Collaborative Relationship 
 
Notes to raters: The patient should be encouraged to be active in the session.  There must be clear 
evidence of productive team work, with the practitioner skilfully encouraging the patient to partici-
pate fully through questioning techniques, shared problem solving and decision making, etc.  The pa-
tient should be guided by the practitioner rather than allowed to ramble in an unstructured way.  
Features which need to be considered include verbal skills, non-verbal skills and, occasionally in palli-
ative care, sharing of written summaries. 
NB: although questioning is a central feature for this item, questions designed to facilitate reflections 
and self-discovery should be scored under item 6: Guided Discovery. 
 
 
Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
  
0 The practitioner does not attempt to establish collaboration, or discourages the 
patient from being collaborative.  
1 The practitioner is too controlling, dominating or passive, discouraging collabora-
tion. 
2 Some occasional attempt at collaboration but didactic style or passivity of  
practitioner encourages passivity or other problems in the therapeutic relation-
ship. 
 
3 Teamwork evident, but some problems with collaboration e.g. not enough  
time allowed for the patient to reflect and participate actively. 
 
4 Effective teamwork is evident but inconsistent. Minor problems evident. 
5 Effective teamwork is evident throughout most of the session. Minimal problems. 
6 Excellent teamwork or highly effective teamwork in the face of difficulties. 
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Item 6 – Guided Discovery 
 
Notes to raters: In a palliative care setting, the practitioner may be helping a patient to develop a hy-
pothesis regarding their situation including attributions and meanings of physical symptoms.  Effec-
tive guided discovery will create doubt where previously there was certainty, thus providing the op-
portunity for re-evaluation and new learning to occur. 
In this context, two elements need to be considered: 
1. The style of the practitioner, which should be open and inquisitive 
2. The effective use of questioning techniques should encourage the patient to discover useful in-
formation that can be used to help the patient to gain a better level of understanding. 
 
Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
  0 No attempt at guided discovery, for example hectoring and lecturing. 
1 Little opportunity for discovery by patient. Persuasion and debate used exces-
sively. 
2 Minimal opportunity for discovery. Some use of questioning but unhelpful in  
assisting the patient to gain access to their thoughts or emotions or to make con-
nections between themes. Over use of reassurance. 
 
3 Some reflection evident. Practitioner uses primary a questioning style, which is  
following a productive line of discovery. Minimal reliance on reassurance. 
 
4 Moderate degree of discovery evident. Practitioner uses a questioning style with 
skills, and this leads to some synthesis. Minor problems evident. 
 
5 Effective reflection evident. Practitioner uses skillful questioning style, leading to 
reflection, discovery and synthesis. Minimal problems. 
 
6 Excellent guided discovery leading to a deep understanding by the patient.  
Highly effective discovery produced in the face of difficulties. 
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Item 7 – Interpersonal Effectiveness 
 
Note to raters: The assessment is how the patient is put at ease by the practitioner’s verbal and non-
verbal behaviour.  Empathy, genuineness and warmth are components of this construct. 
 
 
       Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
 
 
0 Practitioner’s manner and interventions make the patient disengage and become 
distrustful. 
1 Difficulty in showing empathy, genuineness and warmth. 
2 Practitioner’s style at times impedes their empathetic understanding of the pa-
tient’s communications. 
 
3 The practitioner is able to understand explicit meanings of patient’s communica-
tions resulting in some trust developing. 
 
4 The practitioner is able to understand the implicit as well as the explicit meanings 
of the patient’s communications, and demonstrates this in their manner. Minor 
problems evident. 
 
5 The practitioner demonstrates very good interpersonal effectiveness. Patient ap-
pears confident about being understood, which facilitates self-disclosure. Mini-
mal problems. 
 
6 Highly interpersonally effective, and even in the face of difficulties. 
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Item 8 – Eliciting Key Components of the Model 
 
Note to raters: This is a measure of the practitioner’s ability to differentiate thoughts, moods, behav-
iours and physiology.  With increasing demonstration of understanding, practitioners will be able to 
elicit these components, link them to each other and demonstrate the link clearly to the patient.  
With increasing demonstration of skill, the practitioner will lead the patient to a new understanding 
of the role of these components in their experience of their problems, selecting key components for 
further guided discovery in order to make therapeutic gains. 
Feature which need to be considered are: 
1. Eliciting components which are associated with distressing emotions 
2. Demonstrating an understanding of the link between the components 
3. Demonstrating skilfulness and breadth in the method used to elicit and link the components. 
 
 
Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
0 Practitioner fails to elicit components of the model. 
1 Inappropriate components focused on. 
2 Some components elicited but links between behaviours, cognitions, physiology 
and emotions not evident. 
 
3 Some components elicited in a component way, although some problems evi-
dent. 
4 A number of components elicited in verbal or written form leading to a new un-
derstanding of components.  Minimal problems. 
 
5 Effective eliciting of a number of appropriate components leading to a new un-
derstanding of links between components.  Minimal problems. 
 
6 Excellent work on eliciting and demonstrating components of the model of the 
patient, even in the face of difficulties. 
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Item 9 – Application of appropriate change techniques 
Note for raters: Practitioners have been trained in a number of CBT techniques.  They have been en-
couraged to take a “top down” approach, working to reduce distress and promote coping.  This sec-
tion is evaluating their skill in selecting and applying appropriate CBT techniques.  It is unlikely, even 
in later sessions that they will be working at schema level, although some opportunity to work with 
dysfunctional assumptions may present itself in some tapes. 
 
Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
 
0 Practitioner fails to use or misuses appropriate cognitive and behavioural meth-
ods. 
1  Practitioner applies either insufficient or inappropriate methods, and/or with 
limited skill or flexibility.  
2 Practitioner applies appropriate methods, but major difficulties evident. 
3 Practitioner applies appropriate intervention in a competent way although some 
problems evident. 
4  Practitioner applies an appropriate intervention with skills and flexibility, ena-
bling the patient to develop new perspectives.  Minor problems evident. 
5 Practitioner systematically applies an appropriate range of interventions in a cre-
ative, resourceful and effective manner.  Minimal problems evident. 
6 Excellent range of application or successful application of methods in the face of 
difficulties. 
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Item 10 – Appropriate Closure 
 
Note to raters: The opportunity for closure may be brief if a palliative care patient tires suddenly dur-
ing an interview.  However, palliative care practitioners ought to be familiar with this situation and 
be capable of managing a smooth if swift closure. 
The skill being assessed is the practitioner’s ability to allow the patient to leave a session with the 
feeling that the problems addressed have been dealt with in such a way that they feel contained (i.e. 
able to tolerate the distress), and/or able to deal effectively with distress in the future. 
Features of success would include obvious reduction in distress by the end of the session; new learn-
ing/understanding about their problem, or a coherent action plan. 
Competence    Examples 
     Level  NB: Score according to features, not examples! 
 
 
  
  
  
  
  
  
  
  
 
 
  
0   No attempt to use closure strategies.   
1. Abrupt termination; inappropriate closure strategies.   Patient emotionally un-
safe and unprepared for the end of the session.  No action plan. 
 
2. Minimal use of closure strategies. Patient poorly prepared; still emotionally dis-
tressed without new understanding, or no action plan.  Practitioner partially 
aware or unappreciative of patient’s distress. 
 
3. Some preparation for closure: patient is warned of imminent closure by practi-
tioner.  Some use of appropriate closure strategy but problems evident. 
 
4. Coherent use of closure strategies; attempts by practitioner to leave patient with 
reduced distress. 
 
5. Good use of closure strategies smoothly executed.  Practitioner demonstrates 
procedures to reduce patient’s distress and/or give new understanding and/or a 
plan of action. 
 
6. Excellent closure strategies used with skill, or highly effective in the fact of diffi-
culties. 
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Appendix 3 – Lung Manual (CD provided) 
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Appendix 4– CBT Foundation Workbook 
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This workbook is designed to help you develop your skills using CBT techniques by trying 
them yourself.  It contains exercises to help you practice the tasks which help patients enor-
mously and reinforces what you have learnt on the CBT course.  In CBT we use homework as 
a way of helping us learn and improve our situation. Try to work through the exercises in this 
workbook over the next four weeks to help develop your own understanding of them.    It 
may be helpful to keep a reflective diary of your progress.  Remember practice makes per-
fect.  I recommend the following textbook: 
Sage N, Sowden M, Chorlton E and Edeleanu A. (2008) CBT for Chronic Illness. A workbook 
and Toolkit Wiley Publications.   
You will be guided to read certain chapters prior to undertaking some of the exercises in this 
workbook. 
Exercise 1 – Recognising our own thinking errors. 
We know that ‘what we think affects how we feel and what we do’. We all have unhelpful 
thinking errors at some point in our lives.  We may jump to conclusions, make a crisis out of 
nothing, take things personally or discount the positive of a situation.  Unhelpful thinking can 
lead to unhealthy negative emotions such as anxiety, depression or guilt.  Understanding our 
thinking errors may help us change them.  If you can recognise unhelpful thinking you are 
more likely to correct it.  
Activity - Think about a personal or situation in your area of practice and consider if you 
have any thinking errors. (See handout to refresh your memory).   Being aware of our think-
ing style can help us challenge unhelpful thinking. 
Exercise 2 – Noticing Negative Thoughts 
Negative automatic thoughts (NATS) pop into your head without warning.  They may be un-
helpful and upsetting and are often not challenged.  NATS can also be examples of thinking 
errors.  Most people don’t notice their NATS so a thought record can be useful in making 
sense of situations. A critical step in CBT is to recognise how our thoughts affect how we 
feel.  
 
Activity - Try to think about a situation where you experienced NATS and complete the thought 
diary overleaf.   
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Thought Diary Answer        
What was the trigger?   
 
What were your negative auto-
matic thoughts? 
 
What emotion did you experi-
ence? 
 
 
 
Exercise 3 – Challenging Negative Automatic Thoughts 
Having identified NATS we need to think about how we can change them to more balanced 
thoughts. This can be undertaken in a number of ways e.g. thinking carefully about how you 
can challenge these thoughts – asking yourself what evidence there is for thinking this way. 
Does your thought fairly and accurately sum up the situation? Are you taking personal re-
sponsibility for things that are outside your control?  Are you ignoring any relevant facts?  
How might you benefit from thinking differently? 
Activity - Read chapter 15 in Sages et al text book.  Alternatively you could try to complete the chart 
overleaf.   
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Activity - Fill in as much information as possible to make sense of the situation.  Remember it is not 
the event that is important but what we think about it. 
 
Situation  
What is your automatic thought:  
Is the thought realistic or fact?  
Is your thought extreme/rigid or balanced/flexible?  
Is your thought leading to healthy feelings and be-
haviours? 
 
How are you likely to feel and act if you continue 
thinking this way? 
 
Would you encourage a friend to think in this way?  
 
What evidence can you find against my thought?  
What thought would be more helpful in order to 
feel better or do things differently? 
 
How would thinking in a more balanced/flexible 
way help you? 
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Exercise 4 – Positive Thinking 
It is easy to focus on negatives and discount information that is positive.   
 
Activity - Keep a log of everything positive for the at least 1 week and reflect on what you have 
learnt at the end of the exercise.  Use a chart like the one overleaf. 
 
Date Description 
  
  
  
  
 
Activity - What was helpful about this activity?  What made it difficult?  Did it help?  What did 
you notice about this exercise? 
 
Exercise 5 – The Hot Cross Bun 
Formulations are the basis of understanding patient’s difficulties and identifying interven-
tions that might help improve the patient’s difficulties.   
 
Activity - Complete as many ‘Hot Cross Buns’ as you can to gain develop your skills with this 
critical CBT technique.  
 
 
 
 
 
 
 
25/09/2008 Copyright - Therapy in Practice
Hot Cross Bun
Situation & Environment:
E.g. Trigger what, where, when etc.
Physical
Behaviour Thoughts
Feelings
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Exercise 5 – Problem solving 
Problems are part of everyday life.  We all have problems at some time or another. This may 
be the way you think about something (cognitive) or what you do (behaviour).  The first step 
in problem solving is defining what your problem or problems are.  From here you can priori-
tise where to start.  Next think about as many different solutions to each problem.  The next 
step is to work out which is the best solution.  Thinking about the positive and negative con-
sequences of each idea then chooses the one you think is the one that will work best. 
Activity - Read page 275 in Sages textbook.  
Activity - Think about a problem you have been facing and complete the following table.  
My Problem is: 
Possible Solution Positive Consequences Negative Consequences 
 
 
 
  
 
 
 
  
On balance, the best way to tackle this problem is: 
 
 
 
Exercise 7 – Tackling Avoidance 
We all use avoidance strategies at times.  These can actually maintain our problems or even 
make them worse e.g. avoid situations that make us anxious or put off dealing with practical 
problems and tasks that we find unpleasant, withdrawing for our usual routine or worrying a 
lot.  This exercise helps us deal with the self-defeating strategy of avoidance. Facing your 
fears and doing things you don’t want to do can be very worthwhile.   
Activity - Read page 201 in of Sages textbook.   
Activity - Think about situations or tasks you are avoiding and complete a chart like the one 
overleaf. 
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Things I am avoiding Reason for Avoidance Effects of Avoidance 
   
   
   
  
Exercise 8 – Goal setting 
Setting goals for therapy is often undertaken early. As stated in this book, the purpose of 
therapy is to help you move from your problems to achieve your goals. When thinking about 
a goal you should think about developing goals which are:- 
x Specific 
x Positive 
x Observable 
x Realistic  
x Time frame 
Activity - Read chapter 10 in Sages textbook or CBT with Older People Chapter 3.  
Activity - Think about a goal you would like to achieve using the 5 areas above. 
 
Activity - Consider how you help patients/clients to identify their goals?    What kind of goals 
would your patients set and how could they be defined? 
 
Exercise 9 – Activity Scheduling 
One of the best ways to overcome depression is to become more active and take control.  A 
useful way to do this is to increase activities you enjoy or want to achieve.  If tasks are too 
difficult it is helpful to break them down into small manageable steps.  This increases the 
chances of success.  Activity scheduling helps us get engaged in valuable activities, notice 
how they make us feel, levels of satisfaction/achievement or pleasure after completing the 
activity. 
Activity - Read page 249 from Sages textbook or CBT with Older People Chapter 5 Behavioural 
techniques pages 55-62. 
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Activity - Try activity scheduling for 1 day.  Record your activities on a simple chart such as the 
one below. 
Date and  Time Activity Rating out of 10 
   
   
   
 
Exercise 10 - Mental Distraction 
Try this technique if a patient has persistent emotional or physical distress that seems over-
whelming.  Some patients find counting backwards in 7’s from 100 helpful, looking for red 
objects in the room etc. 
Activity - Read page 272 from Sages textbook or CBT with Older People page 104 – thought 
stopping. 
 
Activity - Record how effective this strategy was.  Did it show the patient how their attention 
and thinking influenced their feelings?  Did it help the patient take control of the situation? 
Did it challenge catastrophic thoughts? 
Situation Distraction Used Outcome 
 
 
  
 
Exercise 11 - Behavioural Experiments 
Behavioural experiments are used to challenge and change unhelpful thoughts and behav-
iour.   
Activity - Read chapter 13 from Sages textbook or CBT with Older People page 79 behavioural 
experiments in cognitive restructuring. 
 
Activity - Devise a behavioural experiment:- 
x Outline an unhelpful thought or belief you wish to test out. 
x Predict what the outcome might be. 
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x Decide on your experiment – be as clear as you can about the task and how you will 
measure your results. 
x Carry out the experiment. 
x Evaluate the result (how accurate were your predictions?). 
 
Prediction Experiment Results Conclusion 
    
 
Other useful resources 
Cognitive Behavioural Therapy with Older People: Interventions for Those with and Without 
Dementia [Paperback]  
Ian Andrew James 
Publisher: Jessica Kingsley Publishers (6 Jan 2010)  
ISBN-10: 1849051003  
ISBN-13: 978-1849051002  
 
General CBT books: 
An Introduction to Cognitive Behaviour Therapy: Skills and Applications [Paperback]  
David Westbrook Publisher: SAGE Publications Ltd; Second Edition (17 Mar 2011)  
ISBN-10: 1848606877  
ISBN-13: 978-1848606876  
 
Cognitive Behavior Therapy: Basics and Beyond [Hardcover]  
Aaron T. Beck (Foreword), Judith S. Beck 
Publisher: Guilford Press; 2 edition (17 Aug 2011)  
ISBN-10: 1609185048  
ISBN-13: 978-1609185046  
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General CBT internet resources: 
www.getselfhelp.co.uk 
www.psychologytools.org 
www.sleepstation.com 
  
Summary 
x This workbook will help you develop a cognitive behavioural approach to your work.   
x In order to become more competent using CBT skills you will need to practice and read 
extensively around the subject. 
x It may be helpful to work with another colleague at a similar stage of learning if this is 
possible to support and encourage each other. 
x Find a skilled CBT practitioner (preferably in your field of work) who will act as a super-
visor or guide to some of your work.  (This is compulsory for all CBT therapists). 
x You can email therapy-in-practice for online advice if you would like further support or 
information regarding further training.1 
 
Copyright © Karen Heslop 2008.   
 
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without 
prior written permission of the copyright owner.  For queries please contact Karen Heslop on 0191-2829095. 
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Appendix 5 – CAT Questionnaire 
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Appendix 6- EQ-5D Questionnaire 
 
 
 
 
 
 
 
 
Health Questionnaire 
English version for the UK 
(Validated for Ireland) 
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By placing a tick in one box in each group below, please indicate which state-
ments best describe your own health state today. 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed   
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To help people say how good or bad a health state 
is, we have drawn a scale (rather like a thermom-
eter) on which the best state you can imagine is 
marked 100 and the worst state you can imagine 
is marked 0.   
 
We would like you to indicate on this scale how 
good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the 
box below to whichever point on the scale indi-
cates how good or bad your health state is today
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
   Worst 
    Imaginable 
0 
Best  
Imaginable 
  
 
Appendix 7 - Patient Information Booklet 
 
 
The Newcastle COPD CBT CARE Study 
Name of researchers: Karen Heslop, Dr A De Soyza, Dr D Carrick-Sen, Dr C Baker and Dr G 
Burns 
Introduction 
You are being invited to take part in a research study. This leaflet tells you what this study is about 
and what it will involve.  If anything is unclear, or if you have further questions, please feel free to ask 
the person who gave you this leaflet, or speak to a member of the research team directly on 0191 – 
2829095. 
What is the purpose of the study? 
Chronic obstructive pulmonary disease (COPD) is a common chest problem and includes chronic 
bronchitis and emphysema. Approximately 40% of patients with COPD have symptoms of anxiety.  A 
large number of patients also have depression.  Cognitive Behavioural Therapy (CBT) is a talking ther-
apy.  It has been shown to be one of the most effective treatments for anxiety and depression and is 
recommended by the National Institute of Clinical Excellence (NICE). 
Cognitive Behavioural Therapy (CBT) is a method used to explore how we think, feel and act when we 
have a physical health problem.  The benefit of CBT is that it can hopefully change the way you think 
and manage situations in a practical, problem solving way.  
In Newcastle, we did a small study in 2009 which showed that CBT helped physical symptoms such as 
breathlessness as well as psychological symptoms such as anxiety, depression and panic attacks.  
However, the number of patients involved in the study was too small to say for sure if there was a 
real difference.  This study plans to recruit 312 patients with COPD to see if CBT makes a difference. 
This study is being conducted in part towards an educational- qualification at Newcastle University. 
Why have I been chosen? 
You will have been chosen because you have COPD and were found to have symptoms of anxiety.   
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Do I have to take part? 
Absolutely not. It is entirely up to you if you wish to join the study.  Please take the leaflet home and 
talk it over with others. If you want to know more before you make your decision, either talk to the 
health care professional who gave you this leaflet, or contact a member of the research team at the 
address, e-mail or phone numbers below. The Patient Advice and Liaison Service (PALS) can be con-
tacted and aims to advise and support patients, their families and carers. This service is confidential 
and can be contacted on 0800 032 02 02.  Alternatively advice could be sought from the British Lung 
Foundation on 0191 – 2630276. 
If you do decide to take part, you will be asked to sign a consent form. You will be given a copy of this 
leaflet and the consent form to keep. You are free to withdraw at any time, and you do not have to 
explain why. If you decide not to take part, your decision will have no effect on any aspect of your 
care. 
What will happen if I do take part? 
As we do not know the best way of treating COPD patients with anxiety and depression we need to 
compare cognitive behavioural therapy (CBT) given by respiratory nurses who have been trained in 
this technique with standard care and advice you would normally have received if the study was not 
taking place. The results will help us decide which treatment is best. This leaflet will take you through 
what will happen step by step, including what each treatment would involve. 
Step One: Randomisation 
We need to make sure that the patients in each group are similar. The fairest way to do this, is to se-
lect which treatment a person gets randomly (by chance). This means neither you nor we get to 
choose which treatment you will receive. You will have a 50-50 chance of getting either treatment. 
Once you have agreed to enter the study, and have signed the consent form, a member of the re-
search team will enter your details into a computer. The computer programme will allocate you to 
one of the two groups. 
Step Two: Questionnaires 
At the start of the study, we will ask you to fill in a questionnaire which contains three sub question-
naires about your health.  The questionnaire will take you about 30 minutes to complete.  This allows 
us to take a snapshot of how you are before treatment. We will also ask you to fill in the same ques-
tionnaire at 3, 6 and 12 months after you were randomised.  
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Step Three: Treatment and follow-up 
Treatment One - CBT Group  
The CBT treatment for this study has been specially designed for nurses working with respiratory pa-
tients.  All of the nurses will be under the supervision of Dr Christine Baker who is a very experienced 
Cognitive Behavioural Therapist.  Treatment involves:- 
Attending an appointment in the outpatient clinic or at home every two weeks for a minimum of 2 
visits and maximum of 6 visits.   
These will be at the hospital or within the home if needed.   
The first appointment will last up to 1 hour.  The respiratory nurses will ensure you do not become 
overtired whilst having the CBT treatment.     
Follow up visits will last for approximately 30 minutes. 
The respiratory nurse will work with you to understand your current difficulties and develop strate-
gies to help.  These will be simple techniques, easy to learn and easy to carry out. For instance, mak-
ing small changes to your routine or daily activities can help improve your mood and respiratory 
symptoms.    
Written information on anxiety and depression will be provided to read. 
If you consent we plan to video-tape 60 sessions. This part of the study is optional. If you do not wish 
to take part in the video you can still take part in the main study. The videos will be reviewed by an 
expert CBT professional to see how the therapist delivers the CBT. The video will film the therapist’s 
face, your face will not be videoed. However it will record all that is spoken including your voice. The 
videos will be destroyed after 5 years of the end of the study. 
We welcome any written or verbal feedback you have about your experience.  
Finally at the end of the study we will access your records to see how often you have been admitted 
to hospital and what medication you are taking. 
In summary, if you take part in this study and are allocated to this group you will need to attend the 
out-patient clinic (or have a home visit) between 2 – 6 sessions.  The first session will last up to 60 
minutes and the remaining sessions will last up to 30 minutes.   
Treatment Two – Standard Care. 
If you are allocated this group you will receive standard care which involves:- 
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Written information will be provided on anxiety and depression identical to that in the CBT group.   
Your GP will be informed of the results from the anxiety and depression questionnaire, your partici-
pation in the study and the group you have been allocated to. 
We welcome any written or verbal feedback you have about your experience.  
Finally at the end of the study we will access your records to see how often you have been admitted 
to hospital and what medication you are taking. 
In summary, if you take part in this study and are allocated to this group you will be required to com-
plete four questionnaires, before allocation of the group and 3, 6 and 12 months later. We will pro-
vide a self -addressed envelope for you to ensure you are not out of pocket. 
Expenses and Payments 
Expenses will be reimbursed including car parking charges and taxi fares.  A receipt may be required. 
What do I have to do? 
If you are willing to take part in the study, then what you have to do will depend on the group you 
are allocated to (as above). All patients involved in the study will be asked to complete a question-
naire at four time points.  Both groups will receive written information on anxiety and depression. 
This information is important so filling in the questionnaires is an important part of you taking part in 
the study.  
What are the possible disadvantages of taking part in the trial? 
1.   The main possible disadvantage from CBT is that it may hit on “sore spots” in your life which can 
be upsetting.  Be assured:- 
a. You will not be forced to talk about anything that you do not want to talk about. We will stop the 
session and give you time to consider if you would like to continue. 
b. The respiratory nurses are very experienced in dealing with distress and difficulty.  They will guide 
you through dealing with this issue, under the supervision of an experienced cognitive behavioural 
therapist. 
c. If either of you feel that any area you have touched on is too much to deal with in  CBT, then you 
will, as a first step, be able to talk it over with Karen Heslop, the cognitive behavioural therapist su-
pervising the study or another member of the study team. You, your respiratory nurse and study 
team can then decide what the best course of action is. 
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No-one in our previous small study found the treatment distressing or difficult. But there are 
measures in place if you do.  
2.  The other disadvantage is that you may not get the treatment you want. Being randomised means 
not getting to choose. If it turns out, at the end of the study, that one treatment is better, we will let 
you know. If we find that CBT is the better treatment, we will offer it to you then.  
3.  We would need to inform your GP if you disclose information that may put you at risk e.g. if you 
feel so low that you feel suicidal.  Obviously we would discuss this carefully with you. 
Are there any side effects? 
Cognitive behavioural therapy is a very practical therapy, one that works on how you manage prob-
lems in the here and now – what you do about them, or what you think about them. As it is about 
making practical changes in how you manage, some people can feel a very slight and temporary 
worsening of symptoms. For instance, if you were working on dealing with a particular worry, be-
cause you are focusing on it, you might feel a little more worried about it at first. Or if you work on 
managing your breathlessness or activities differently, you might feel a little more tired at first. This is 
a normal part of changing how we deal with things, and is only a temporary stage in feeling better.  
What are the possible benefits of taking part? 
In either treatment, your anxiety (and depression if you also suffer from this) is likely to improve. The 
main evidence we have for how people feel about CBT is from our small study, and the patients who 
took part in that were very positive about it. They liked the fact that they got practical help with 
other aspects of their life besides their breathing problem. You might find this useful too. However 
the main benefit could be for future patients suffering from this condition. Should one treatment 
emerge as superior to another, this study will help us to improve treatment options. 
What happens if there is a problem? 
If you have any concerns, you should first talk to your respiratory nurse. If this is not satisfactory, or 
you do not wish to do so, you can talk to a member of the research team on the number at the end 
of this leaflet.  You may also raise your concerns with someone who is not involved in your care, the 
Patient Advice and Liaison Service (PALS) aims to advise and support patients, their families and car-
ers and provide information on NHS services. This service is confidential and can be contacted on 
0800 032 02 02. If you wish to complain formally in writing. You can do so by writing to Sir L R Fen-
wick CBT, Chief Executive,  Newcastle Upon Tyne Hospitals NHS Trust,  Freeman Hospital, High Hea-
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ton, Newcastle upon Tyne NE7 7DN.  To ensure patient safety and continual improvements any pos-
sible unsatisfactory standards noted during the conduct of the study will be investigated and where 
required reported to the relevant regulatory authorities. 
What happens when the research study stops? 
At the end of the study we will be in a position to say if one treatment is better than another. Should 
CBT be the best treatment, we will offer it to those in the standard care group. Data obtained during 
the study will be retained for 5 years. 
Will my taking part in the trial be confidential? 
Yes, all information will be confidential. Your notes for this study will be stored in a locked filing cabi-
net at the Royal Victoria Infirmary which only your respiratory nurse and the research team will have 
access to, all of whom are legally bound by codes of patient confidentiality. Any data relating to this 
trial which ends up being published will be anonymised, so no-one could identify you from it.  
Involvement of my GP and/or referring doctor 
It is standard practice for us to write to your GP and whoever referred you to the chest clinic, briefly 
describing your condition and intended care. Should you agree to enter the study, we will inform 
them of this, along with a brief description of the treatment you will be receiving.  
What if new information becomes available about the treatment? 
CBT has a very good track record of success. In the unlikely event that information arises from either 
this study or another source, to indicate a severe problem you will be informed immediately and we 
will stop the treatment. 
What will happen if I do not want to carry on with the study? 
You are free at any point to decide not to carry on with the study, and you do not need to tell us why.  
We would still like to know how you get on, and we will ask if you would still be prepared to still com-
plete the questionnaire. You are, of course, free to refuse.  Existing data already collected will be re-
tained and used in the study. 
What if I were harmed during the study? 
It is highly unlikely that any harm could come to you in this study.  It is possible that during the CBT 
treatment you may become upset.  The respiratory nurses have all received training and have exten-
sive experience caring for patients with COPD.  We would discontinue the treatment and refer you to 
your GP if needed. 
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What will happen to the results of the study?  
We will use the findings from this study to improve future treatment for your kind of condition. We 
will present our findings in academic journals and at conferences. We will also send you, at the end 
of the trial, a brief summary of our main findings. If the CBT treatment is proven to be beneficial you 
will be offered this if you received standard care.  A thesis will be written at the end of the study and 
will be retained by Newcastle University but this will not contain any personal information about you. 
Who is organising and funding the research? 
This study is funded by the National Institute of Health Research.  The research team combines re-
searchers based at University of Newcastle and in the respiratory clinical teams at the Royal Victoria 
Infirmary and Freeman Hospital. 
Who has reviewed the study? 
Sunderland Local Research Ethics Committee has reviewed and approved this study.  
What do I do now? 
A member of the research team will contact you within 2 weeks to find out if you would like to par-
ticipate in the study.  Should you agree to continue, we will make an appointment for you to sign the 
consent form. After this you will be randomised and allocated to your treatment group. 
Where can I get further information? 
You contact a member of the research team on telephone 0191 2829095 or leave a message on the 
research team mobile/ answerphone 07920547420 and we will get back to you as soon as we are 
able. You may also email the lead researcher Karen Heslop on karen.heslop@nuth.nhs.uk. 
 
Thank you for taking the time to read this leaflet. 
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Appendix 8 –Patient Consent 
The Newcastle COPD CBT CARE Study 
CONSENT FORM 
Research Team: K. Heslop, Dr A De Soyza, Dr D Carrick-Sen, Dr C Baker & Dr G Burns 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 21/02/2012 (version 1.3) 
for the above study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the study may 
be looked at by individuals from Newcastle Hospitals NHS Foundation Trust where it is relevant 
to my taking part in this research. I give permission for these individuals to have access to my 
records/data.  
 
4. I agree to my GP being informed of my involvement in the study.    
5. I agree/do not agree (delete as appropriate) to the optional video recording aspect of the study.  
6. I agree to take part in this study.   
7. I would/ would not (delete as appropriate) like to receive a summary of the study findings.  
 
 
Name of participant  Date Signature 
 
Name of person taking consent 
 
Date 
 
Signature 
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Appendix 9- GP Letter 
[Doctor] 
[Address    ] 
[Date] 
Dear [Doctor] 
Re [Patient, DOB, and Address] 
The above patient currently attends Clinic under the care of  
[Consultant].   [   Patient] has agreed to participate in The Newcastle COPD CBT CARE Study. 
The purpose of the study is to identify if CBT delivered by respiratory nurses reduces symp-
toms of anxiety in patients with COPD. We are following patients up to 12 months after ran-
domisation.  
 
 [   Patient] has been screened for anxiety and depression using the Hospital Anxiety and De-
pression Scale and scored as probable anxiety.  This patient has been randomised and allo-
cated to the [intervention or control] group.  The intervention group will undertake 2- 6 ses-
sions of CBT either in the Chest Clinic, RVI or home setting.  The control group will receive 
standard care which includes screening and written information on anxiety and depression.  
This patient is in active follow up for this study for 1 year and should not enter another inter-
ventional clinical trial during this time.  If you require further information please do not hesi-
tate to contact me on the number below. 
 
Yours sincerely 
 
Karen Heslop MSc 
Nurse Consultant Respiratory Medicine 
Tel 0191 – 2829095 
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Appendix 10 – Baseline data Collection Sheet  
Study ID Number: Telephone No: 
PIS / Consent:  Y / N                                     Postcode:             
Date of Baseline Assessment: 
First name Surname 
Hospital Number Consultant 
Gender             M  /  F DOB 
Marital Status (1 married, 2 Single, 3 divorced, 4 separated) 
Education Level    0 NVQ, 1 <GCSE, 2 GCSE, 3 A Level, 4 HNC/HND, 5 Diploma, 6 Degree: 
Occupation:                                              
HADS A: HADS D: 
CAT Score: EQ5D: 
MRC Dyspnoea Score 1-5: 
FEV1: % Pred:                        Ratio: TLCO %: O2 Sats: 
Weight                                                                                    Height   BMI 
Ethnic Group 
Pulmonary rehabilitation Y/N SCA             Pack Years 
COPD Meds:  SABA  Y/N     SAMA Y/N      LABA  Y/N      LAMA  Y/N     ICS/LABA  Y/N     
 Muco Y/N     PD4  Y/N    Nebs Y/N         Pre-pack  Y/N           Other Mediction 
Oxygen: 1 Short burst, 2 LTOT, 3 Ambulatory  4 None Inhaler Technique Checked: 
Antidepressants: Y / N    Anxiolytic: Y/N    Diuretic: Y/N   
GP Letter sent:    Y          Consultant Letter:  Y       Entered onto database: Y                 Signature: 
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Appendix 11 – CBT Supervision Record 
Date:     Attendee(s):  
 
Duration:     Venue:   
 
Format:     Individual           Facilitated Group    Peer Group 
Supervision Question(s) 
Is there anything you want to recap/discuss from last session? What would you like to discuss to develop 
your skills?  What has been difficult?  What have you researched or observed?    
 
 
Summary of key learning points (shared feedback)  
What were the main things you learned today? 
Individual reflection/action points (implications for practice development)  
For example: How will you maximise today’s learning?  What will you put into practice, research observe 
or set out before the next supervision session? 
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Appendix 12 - Publications and Presentations 
Publications and presentations completed since 2011 are presented below in table 69.   
Table 69 - List of publications since commencement of PhD. 
Title Authors Reference 
Effectiveness of cognitive behavioural 
therapy (CBT) interventions for anxiety in 
patients with chronic obstructive pulmo-
nary disease (COPD) undertaken by res-
piratory nurses: the COPD CBT CARE 
study: (ISRCTN5520695). 
K. Heslop 
J. Newton 
C. Baker 
G. Burns 
D. Carrick-Sen 
A. De Soyza 
BMC Pulmonary Medicine. 
04/11/2013 
Article URL http:www.biomedcen-
tral.com/1471-2466/13/62 
BTS Guideline on Pulmonary Rehabilita-
tion in Adults. 
CE Bolton 
EF Bevan-Smith 
J Blakey 
P Crowe 
S Elkin 
R Garrod 
NJ Greening 
K Heslop 
JH Hull 
WDC Mann 
MD Morgan 
D Proud 
CM Roberts 
L Sewell 
SJ Singh 
PP Walker 
S Walmsley 
Thorax 2013 Volume 68 Supplement 2. 
Psychological therapies for the treatment 
of anxiety disorders in chronic obstructive 
pulmonary disease (Protocol). 
ZA Usmani 
KV Carson 
K Heslop 
AJ Esterman 
A De Soyza 
BJ Smith 
The Cochrane Library  
Article URL 
http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD
010673/pdf 
Non-pharmacological treatment of anxi-
ety and depression in COPD. 
K Heslop Nurse Prescribing 2014 Volume 12 No 1 
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Are We Missing Anxiety in People with 
Chronic Obstructive Pulmonary Disease 
(COPD)? 
 
K Heslop-Marshall 
A De Soyza 
 
Annals of Depression and Anxiety 2014; 1 
(5):1023. 
Cost savings in the provision of home oxy-
gen for COPD. 
C. Irving 
M Scott 
K Heslop 
Nurse Prescribing 2015 Volume 13 No 6 p 
278-281. 
Effectiveness of self-management inter-
ventions on QOL and healthcare utilisa-
tion in people with COPD: meta- analysis 
with meta-regression. 
JJ Newham 
K Heslop-Marshall 
B Hanratty 
E Kaner 
J Presseau 
(In press – 2015) 
Validation of the DECAF score to predict 
hospital mortality in acute exacerbations 
of COPD. 
C Echevarria 
J Steer 
K Heslop-Marshall 
SC Stenton 
P Hickey 
R Hughes 
M Wijesinghe 
R Harrison 
N Steen 
A Simpson 
G Gibson 
(In press – 2015) 
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Presentations  
I have been invited to present at the following conferences. Conference presentations are listed 
in table 70.   
Table 70– Conference presentations. 
Title Organisation Date 
The Newcastle COPD CBT Study. North East Thoracic Society, Newcastle. 2012 
CBT for patients with COPD. National Respiratory Nurse Conference, Warwick. 2012 
CBT for patients with COPD. Department of Health- National NHS Innovations 
Conference, London. 
2013 
CBT for patients with COPD.   National Association of Respiratory Physiotherapists 
Conference, Leicester. 
2013 
Live National webinar on anxiety and 
depression  
British Lung Foundation, London. 2013 
CBT What it is and how it can help res-
piratory patients.   
Nottingham Respiratory Conference, Nottingham. 2013 
From CBT first aider to diploma, trainer 
and researcher.  London 
British Association of Cognitive Behavioural Thera-
pists 41st Annual Conference, London.  
2013 
Innovations in the treatment of COPD. Northern Association for Persistent Physical Symp-
toms (NAPPS), Newcastle. 
2013 
CBT- how can it help COPD Patients Improving Access to Psychological Therapies (In-
sight) Northumberland Regional Service. 
2014 
CBT in COPD Yorkshire Respiratory Nurse Conference, York. 2015 
CBT in COPD Yorkshire Thoracic Society, Leeds. 2015 
Making progress in your clinical aca-
demic career. 
NIHR conference Great North Museum, Newcastle. 
(Joint presentation) 
2015 
CBT made easy – changing lifestyle Primary Care Respiratory Society-UK, Northampton. 2015 
 
 
  
 249 
 
Poster Presentations. 
A summary of moderated poster presentation can be found in table 71. 
Table 71– Moderated Poster presentations since commencement of PhD 
Title Organisation Year 
Prevalence of anxiety and depression in 196 patients 
with chronic obstructive pulmonary disease (COPD). 
European Respiratory Society Annual Con-
gress. Vienna. 
2012 
Recruitment for psychological therapy in chronic ob-
structive pulmonary disease (COPD) Might we miss 
those who need us most. 
European Respiratory Society Annual Con-
gress. Barcelona. 
2013 
Prevalence of anxiety and patient characteristics from 
a randomised controlled trial (RCT) to identify if cogni-
tive behavioural therapy (CBT) by respiratory nurses 
reduces anxiety in COPD.   
British Thoracic Society Winter Confer-
ence. London. (Accepted for 2015). 
2015 
 
Webinar Presentation 
I was invited to present a live webinar for the British Lung Foundation to increase awareness of 
psychological issues in COPD.  This is listed in table 72. 
Table 72 – Webinar presentations. 
Title Organisation Year 
National webinar on anxiety and depression in COPD. British Lung Foundation, London. 2013 
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Awards 
The CBT service has been nominated for several awards which are listed in table 73. 
Table 73 –Award Nominations. 
Title Outcome Year 
Nursing Times Respiratory Award for CBT service. Highly commended service. 2012 
Nursing Times Respiratory Award for CBT service. Shortlisted. 2013 
Royal College of Nursing –Nursing Standard Awards.  
Respiratory Award for CBT service. 
Shortlisted. 2014 
Royal College of Nursing –Nursing Standard Awards. 
Nurse of the Year category. 
Nominated. 2014 
British Journal of Nursing –Innovation Award. 2nd Place. 2015 
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